<?xml version="1.0" encoding="UTF-8"?>
<description type="description" xml:base="/api/emi/378875770" xml:id="e78df3e0-8e43-4754-b124-f705c030ce1a" xml:lang="en">
    <p xml:id="_2ff0350029">
    </p>
    <head xml:id="_2ff0350030">TECHNICAL FIELD</head>
    <p n="0001" xml:id="_2ff0350031">This application claims the priority of the USA provisional applications 60/675,311 for which it applied to 2005/4/26 by which the whole is integrated in this specification by the reference.</p>
    <p n="0002" xml:id="_2ff0350032">This invention relates to the antibody couple|bonded with P-cadherin, and its antigen binding part.<lb>
        </lb>This invention relates also to the composition containing the methods of producing the nucleic acid molecule, P-cadherin antibody, and the antigen binding part which also code such an antibody and an antigen binding part, these antibodies, and an antigen binding part, an antibody, an antigen binding part, and the method of using a composition.</p>
    <head xml:id="_2ff0350034">DESCRIPTION OF RELATED ART</head>
    <p n="0003" xml:id="_2ff0350035">A cadherin is a super family of the trans-membrane glycoprotein which controls the cell adhesion between generation|occurrence|production and a structure|tissue homeostasis (Gumbiner, J.Cell.Biol., 148:399-404(2000);Yagi et al., Genes Dev., 14:1169-1180(2000)).<lb>
        </lb>The intracellular domain of a cadherin is interacted with cytoplasm proteins, such as a catenin and p120, and the foundation of a coupling|bonding with a cadherin and an actin cytoskeleton is formed of it.<lb>
        </lb>A cadherin has five extracellular Ca&lt;2+&gt; binding domains and the small cytosolic domain highly preserve|saved between classic cadherins.<lb>
        </lb>P-cadherin, E-cadherin, and N-cadherin is contained in the component of a classic cadherin family.<lb>
        </lb>It is thought that cell adhesion molecules, such as a cadherin, play the serious|significant role for the cell junction of a cancer cell and a transfer cell (Furukawa et al., Microscopy Res.Technique, 38(4):343-352(1997)).<lb>
        </lb>P-cadherin expression in a normal adult tissue is low, and is restrict|limited mainly to the base layer of a myoepithelial cell and the stratified epithelium (Shimoyama et al., Cancer Res., 49:2128-33(1989)).<lb>
        </lb>P-cadherin is upregulated by inflammatory bowel diseases, such as Crohn's disease and colitis (Hardy et al., Gut, 50:513-519(2002)).<lb>
        </lb>It is clear from a series of extensive proof now that abnormal P-cadherin expression is also related to the tumor of cell growth, the colon, a breast, a lung, a thyroid gland, and a uterine cervix (Gamallo, Modern Pathology, 14:650-654 (2001);, Stefansson et al., J.Clin.Oncol.,<lb>
        </lb>22 (7) :1242-1252 (2004)).<lb>
        </lb>It was reported that antigen recognition of the human P-cadherin is carried out by the NCC-CAD-299 monoclonal antibody produced with respect to the vulva epidermoid carcinoma (Shimoyama et al., Cancer Res., 49:2128-2133(1989)).<lb>
        </lb>When the adhesion|attachment and intracellular signal transduction which P-cadherin carries are adjusted, it will estimate|forecast that the proliferation and survival of the tumor cells in in vivo fall.</p>
    <head xml:id="_2ff0350046">PROBLEM TO BE SOLVED BY THE INVENTION</head>
    <p n="0004" xml:id="_2ff0350047">Therefore, when the central role considered that P-cadherin has in cell growth and advancing of a solid tumor is considered, it is desirable to produce|generate the antibody with respect to P-cadherin which can bring the patient of various cancers remedial profits.</p>
    <head xml:id="_2ff0350048">MEANS TO SOLVE THE PROBLEM</head>
    <p n="0005" xml:id="_2ff0350049">1 aspect of this invention is P-cadherin antibody or its antigen binding part, and an antibody or its antigen binding part has at least 1 among several functional characteristics described by K from the following A.</p>
    <p n="0006" xml:id="_2ff0350050">A) For example, in one Embodiment, an antibody or its antigen binding part has a large binding affinity with respect to P-cadherin (KD(P)) from E-cadherin (KD (E)).<lb>
        </lb>In one Embodiment, the antibody of this invention or its antigen binding part has 1.5 or more KD(E)/KD(P).<lb>
        </lb>In the further embodiment, the antibody of this invention or its antigen binding part has 500 or more [ 200 or more / 100 or more / 50 or more / 20 or more / 10 or more / 5 or more / 3 or more / 2 or more ] or 1000 or more KD(E)/KD(P).<lb>
        </lb>Since KD (E) value can become [ 0 ] very small, it is usually infinite to the value of KD(E)/KD(P).<lb>
        </lb>However, the upper limit of KD(E)/KD(P) can become 1x10&lt;6&gt; for the practical objective.<lb>
        </lb>Such a KD value with respect to both P-cadherin and E-cadherin can measure surface plasmon resonance, such as ELISA, RIA, a flow cytometry, BIACORE (trademark), etc. with the arbitrary techniques known by the expert.</p>
    <p n="0007" xml:id="_2ff0350056">B) At other embodiment, an antibody or its part is couple|bonded with P-cadherin by KD 1000 nM or less measured by surface plasmon resonance.<lb>
        </lb>Less than 500 nM from which an antibody or a part is measured by surface plasmon resonance in the further embodiment,<lb>
        </lb>It couple|bonds with P-cadherin by KD of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, less than 1 nM, less than 500 pM, or less than 100 pM.<lb>
        </lb>Usually, there is no minimum in the value of KD.<lb>
        </lb>However, it can be assumed for the practical objective that a minimum is about 1 pM.</p>
    <p n="0008" xml:id="_2ff0350061">C) In other embodiment, an antibody or its part has a dissociation speed|rate (Koff) with respect to P-cadherin of 0.01 or less &lt;s-1&gt; measured by surface plasmon resonance.<lb>
        </lb>For example, in specific embodiment an antibody or a part,<lb>
        </lb>Less than 0.004 less than 0.005 &lt;s-1&gt; &lt;s-1&gt;,<lb>
        </lb>It has Koff with respect to P-cadherin of less than 0.002 less than 0.003 &lt;s-1&gt; &lt;s-1&gt; or less than 0.001 &lt;s-1&gt;.<lb>
        </lb>Usually, there is no minimum in the value of Koff.<lb>
        </lb>However, it can be assumed for the practical objective that a minimum is abbreviation 1x10 &lt;-7s-1&gt;.</p>
    <p n="0009" xml:id="_2ff0350067">D) In other embodiment, P-cadherin antibody or its part has IC50 100 nM or less measured by P-cadherin dependence cell-adhesion assay.<lb>
        </lb>In the further embodiment, said IC50 is less than 50 nM, less than 40 nM, less than 20 nM, less than 10 nM, less than 1 nM, less than 500 pM, less than 200 pM, less than 100 pM, or less than 10 pM and it is measured by P-cadherin dependence cell-adhesion assay.<lb>
        </lb>Usually, there is no minimum in the value of IC50 measured by P-cadherin dependence cell-adhesion assay.<lb>
        </lb>However, it can be assumed for the practical objective that a minimum is about 1 pM.</p>
    <p n="0010" xml:id="_2ff0350071">E) In other embodiment, P-cadherin antibody or its part has IC50 100 nM or less measured by P-cadherin dependence cell aggregation assay.<lb>
        </lb>In the further embodiment, said IC50 is less than 50 nM, less than 40 nM, less than 20 nM, less than 10 nM, less than 1 nM, less than 500 pM, less than 200 pM, less than 100 pM, or less than 1 pM and it is measured by P-cadherin dependence cell aggregation assay.<lb>
        </lb>Usually, there is no minimum in the value of IC50 measured by P-cadherin dependence cell aggregation assay.<lb>
        </lb>However, it can be assumed for the practical objective that a minimum is about 1 pM.</p>
    <p n="0011" xml:id="_2ff0350075">F) In other embodiment, P-cadherin antibody or its part increases spheroid destruction at least 2 times compared with the control specimen in which it is P-cadherin dependence spheroid destructive assay, and IgG does not exist.<lb>
        </lb>In the further embodiment, P-cadherin antibody or its part,<lb>
        </lb>By P-cadherin dependence spheroid destructive assay, spheroid destruction is increased compared with the control specimen in which IgG does not exist at least 3 times at least 4 times at least 6 times at least 10 times or at least 15 times.</p>
    <p n="0012" xml:id="_2ff0350078">G) P-cadherin antibody or its part competes with the antibody selected from the group which consists of 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4; and g-129-1c4 about a coupling|bonding with P-cadherin in other embodiment.</p>
    <p n="0013" xml:id="_2ff0350079">H) In other embodiment, P-cadherin antibody or its part carries out cross|intersection competition with the antibody selected from the group which consists of 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4; and g-129-1c4 about a coupling|bonding with P-cadherin.</p>
    <p n="0014" xml:id="_2ff0350080">I) P-cadherin antibody or its part is couple|bonded with the epitope of the same P-cadherin as the antibody selected from the group which consists of 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4; and g-129-1c4 in other embodiment.</p>
    <p n="0015" xml:id="_2ff0350081">J) At other embodiment, P-cadherin antibody or its part is couple|bonded with P-cadherin by the substantially same KD as the antibody selected from the group which consists of 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4; and g-129-1c4.</p>
    <p n="0016" xml:id="_2ff0350082">K) At other embodiment, P-cadherin antibody or its part is couple|bonded with P-cadherin by the substantially same Koff as the antibody selected from the group which consists of 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4; and g-129-1c4.</p>
    <p n="0017" xml:id="_2ff0350083">The further aspect of this invention includes VH domain where sequence number 1 - 13, and any one and the amino acid sequence of 320-325 are the same in at least 90 %,<lb>
        </lb>They are an antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part.<lb>
        </lb>In one Embodiment, the said V H domain has sequence number 1 - 12, and same any one and amino acid sequence of 320-325 in at least 91 %, at least 93 %, at least 95 %, at least 97 %, at least 99 %, or 100 %.</p>
    <p n="0018" xml:id="_2ff0350086">In the further embodiment, an antibody or its part has at least 1 among the functional characteristics described by said A to K,<lb>
        </lb>It is sequence number 1 - 13 and any one of 320-the 325,<lb>
        </lb>Or a different VH domain from sequence number 1 - 13 and any one of 320-the 325 is included by having at least 1 piece(s) of conservative amino acid substitution.<lb>
        </lb>For example, VH domain may differ from sequence number 1 - 13 and any one of 320-the 325 by 1, 2, 3, 4, 5, 6, 7 and 8, 9 or 10 conservative amino acid substitution.<lb>
        </lb>In the further embodiment, either of such conservative amino acid substitution may occur in CDR1, CDR2, and/or CDR3 area|region.</p>
    <p n="0019" xml:id="_2ff0350091">The further aspect of this invention includes VL domain where sequence number 14 - 23, and any one and the amino acid sequence of 326-331 are the same in at least 90 %,<lb>
        </lb>They are an antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part.<lb>
        </lb>In one Embodiment, the said V L domain has sequence number 14 - 23, and same any one and amino acid sequence of 326-331 in at least 91 %, at least 93 %, at least 95 %, at least 97 %, at least 99 %, or 100 %.</p>
    <p n="0020" xml:id="_2ff0350094">In the further embodiment, an antibody or its part has at least 1 among the functional characteristics described by said A to K,<lb>
        </lb>It is sequence number 14 - 23 and any one of 326-the 331,<lb>
        </lb>Or a different VL domain from sequence number 14 - 23 and any one of 326-the 331 is included by having at least 1 piece(s) of conservative amino acid substitution.<lb>
        </lb>For example, VL domain may differ from sequence number 14 - 23 and any one of 326-the 331 by 1, 2, 3, 4, 5, 6, 7 and 8, 9 or 10 conservative amino acid substitution.<lb>
        </lb>In the further embodiment, either of such conservative amino acid substitution may occur in CDR1, CDR2, and/or CDR3 area|region.</p>
    <p n="0021" xml:id="_2ff0350099">The other aspect of this invention is an antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part,<lb>
        </lb>The VL and VH domain,<lb>
        </lb>An antibody 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4;, any one VL of g-129-1c4 and VH domain, and an amino acid sequence are the same in at least 90 % respectively.<lb>
        </lb>For example, VL and VH domain,<lb>
        </lb>An antibody 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4;, any one VL of g-129-1c4 and VH domain, and an amino acid sequence are at least 91%, 93%, 95%, 97%, 99% or 100% the same respectively.</p>
    <p n="0022" xml:id="_2ff0350104">The other aspect of this invention is an antibody including VH domain shown by a sequence number 1, and VL domain shown by sequence number 14, or its part;<lb>
        </lb>b) Antibody including VH domain shown by sequence number 2, and VL domain shown by sequence number 14, or its part;<lb>
        </lb>c) Antibody including VH domain shown by sequence number 2, and VL domain shown by sequence number 15, or its part;<lb>
        </lb>d) Antibody including VH domain shown by sequence number 3, and VL domain shown by sequence number 16, or its part;<lb>
        </lb>e) Antibody including VH domain shown by sequence number 4, and VL domain shown by sequence number 17, or its part;<lb>
        </lb>f) Antibody including VH domain shown by sequence number 4, and VL domain shown by sequence number 23, or its part;<lb>
        </lb>g) Antibody including VH domain shown by sequence number 5, and VL domain shown by sequence number 18, or its part;<lb>
        </lb>h) Antibody including VH domain shown by sequence number 6, and VL domain shown by sequence number 23, or its part;<lb>
        </lb>i) Antibody including VH domain shown by sequence number 7, and VL domain shown by sequence number 23, or its part;<lb>
        </lb>j) Antibody including VH domain shown by sequence number 8, and VL domain shown by sequence number 23, or its part;<lb>
        </lb>k) Antibody including VH domain shown by sequence number 9, and VL domain shown by sequence number 23, or its part;<lb>
        </lb>l) Antibody including VH domain shown by sequence number 10, and VL domain shown by sequence number 19, or its part;<lb>
        </lb>m) Antibody including VH domain shown by sequence number 11, and VL domain shown by sequence number 20, or its part;<lb>
        </lb>n) Antibody including VH domain shown by sequence number 12, and VL domain shown by sequence number 21, or its part;<lb>
        </lb>o) Antibody including VH domain shown by sequence number 13, and VL domain shown by sequence number 22, or its part;<lb>
        </lb>p) Antibody including VH domain shown by sequence number 320, and VL domain shown by sequence number 326, or its part;<lb>
        </lb>q) Antibody including VH domain shown by sequence number 321, and VL domain shown by sequence number 327, or its antigen binding part;<lb>
        </lb>r) Antibody including VH domain shown by sequence number 322, and VL domain shown by sequence number 328, or its part;<lb>
        </lb>s) Antibody including VH domain shown by sequence number 323, and VL domain shown by sequence number 329, or its part;<lb>
        </lb>t) Antibody including VH domain shown by sequence number 324, and VL domain shown by sequence number 330, or its part;<lb>
        </lb>and<lb>
        </lb>u) They are an antibody selected from the group which consists of an antibody including VH domain shown by sequence number 325, and VL domain shown by sequence number 331, or its part, or its antigen binding part.</p>
    <p n="0023" xml:id="_2ff0350126">At the further embodiment, VH and/or VL domain may differ from specific sequence number enumerated in it by at least 1 conservative amino acid substitution in either the antibody described by said group of a-u, or its part.<lb>
        </lb>For example, VH and/or VL domain may differ from enumerated sequence number by 1, 2, 3, 4, 5, 6, 7 and 8, 9 or 10 conservative amino acid substitution.<lb>
        </lb>In the further embodiment, either of such conservative amino acid substitution may occur in CDR1, CDR2, and/or CDR3 area|region.</p>
    <p n="0024" xml:id="_2ff0350129">In other embodiment, this invention provides the antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part,<lb>
        </lb>It includes the arrangement|sequence which differs from sequence number 1 - 13 and any one of 320-the 325 by VH domain independently selected from sequence number 1 - 13 and any one of 320-the 325, or at least 1 piece(s) of conservative amino acid substitution,<lb>
        </lb>The arrangement|sequence which differs from sequence number 14 - 23 and any one of 326-the 331 by VL domain independently selected from sequence number 14 - 23 and any one of 326-the 331 or at least 1 piece(s) of conservative amino acid substitution is further included.<lb>
        </lb>For example, VH and VL domain,<lb>
        </lb>It may differ from any one of sequence number 1 - 13, 320-325, 14-23, and the 326-331 each independently by 1, 2, 3, 4, 5, 6, 7 and 8, 9 or 10 conservative amino acid substitution.</p>
    <p n="0025" xml:id="_2ff0350134">In the further embodiment, this invention provides the antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part,<lb>
        </lb>The said antibody or a part includes the arrangement|sequence which differs from sequence number 26 - 37 and any one of 91-the 256 by VHCDR3 selected from sequence number 26 - 37 and any one of 91-the 256, or at least 1 piece(s) of conservative amino acid substitution.<lb>
        </lb>For example, VHCDR3 may differ from sequence number 26 - 37 and any one of 91-the 256 by 1 and 2, 3 or 4 conservative amino acid substitution.</p>
    <p n="0026" xml:id="_2ff0350137">In the further embodiment, this invention provides the antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part includes the arrangement|sequence which differs from sequence number 40 - 47 and any one of 257-the 319 by VLCDR3 selected from sequence number 40 - 47 and any one of 257-the 319, or at least 1 piece(s) of conservative amino acid substitution.<lb>
        </lb>For example, VLCDR3 may differ from sequence number 40 - 47 and any one of 257-the 319 by 1, 2, 3, 4 or 5 conservative amino acid substitution.</p>
    <p n="0027" xml:id="_2ff0350140">In the further embodiment, this invention provides an antibody or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part is an arrangement|sequence which differs from sequence number 24 by VHCDR1 shown by sequence number 24, or at least 1 piece(s) of conservative amino acid substitution;<lb>
        </lb>Arrangement|sequence which differs from sequence number 25 by VHCDR2 shown by sequence number 25, or at least 1 piece(s) of conservative amino acid substitution;<lb>
        </lb>And the arrangement|sequence which differs from sequence number 26 - 37 and any one of 91-the 256 by VHCDR3 independently selected from sequence number 26 - 37 and any one of 91-the 256 or at least 1 piece(s) of conservative amino acid substitution is included.<lb>
        </lb>For example, CDR1 of above mentioned VH, CDR2, and CDR3 sequence may differ from each enumerated sequence number each independently by 1, 2, 3, 4 or 5 conservative amino acid substitution.</p>
    <p n="0028" xml:id="_2ff0350145">In the further embodiment, this invention provides an antibody or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part is an arrangement|sequence which differs from sequence number 38 by VLCDR1 shown by sequence number 38, or at least 1 piece(s) of conservative amino acid substitution;<lb>
        </lb>Arrangement|sequence which differs from sequence number 39 by VLCDR2 shown by sequence number 39, or at least 1 piece(s) of conservative amino acid substitution;<lb>
        </lb>And the arrangement|sequence which differs from sequence number 40 - 47 and any one of 257-the 319 by VLCDR3 independently selected from sequence number 40 - 47 and any one of 257-the 319 or at least 1 piece(s) of conservative amino acid substitution is included.<lb>
        </lb>For example, CDR1 of above mentioned VL, CDR2, and CDR3 sequence may differ from each enumerated sequence number each independently by 1, 2, 3, 4 or 5 conservative amino acid substitution.</p>
    <p n="0029" xml:id="_2ff0350150">It is VHCDR1 by which this invention further provides an antibody or its antigen binding part, and the said antibody or an antigen binding part is shown by sequence number 24;<lb>
        </lb>VHCDR2 shown by sequence number 25;<lb>
        </lb>VHCDR3 selected from sequence number 26 - 37 and any one of 91-the 256;<lb>
        </lb>VLCDR1 shown by sequence number 38;<lb>
        </lb>VLCDR2 shown by sequence number 39;<lb>
        </lb>And VLCDR3 selected from sequence number 40 - 47 and any one of 257-the 319 is included.<lb>
        </lb>In the further embodiment, CDR1 of quoted VH and VL, CDR2, and CDR3 sequence may also differ from specific sequence number enumerated above each independently by at least 1 conservative amino acid substitution.<lb>
        </lb>for example, CDR1, CDR2, and CDR3 sequence -- 1, 2, 3, 4 or five conservative amino acid substitution -- being the said -- it may differ from each specific sequence number come out of and enumerated each independently.</p>
    <p n="0030" xml:id="_2ff0350158">This invention further provides an antibody or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part,<lb>
        </lb>An antibody 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4;.<lb>
        </lb>And CDR3 of CDR2 of CDR1 of VH recognized in the inside in any one of g129-1c4 and VL, VH, and VL, VH, and VL is included.</p>
    <p n="0031" xml:id="_2ff0350162">This invention is selected from sequence number 1 - 13 and any one of 320-the 325,<lb>
        </lb>Or an antibody including VH domain which differs from sequence number 1 - 13 and any one of 320-the 325 by 1-10 conservative amino acid substitution, or its antigen binding part is further provided.</p>
    <p n="0032" xml:id="_2ff0350164">This invention is selected from sequence number 14 - 23 and any one of 326-the 331,<lb>
        </lb>Or an antibody including VL domain which differs from sequence number 14 - 23 and any one of 326-the 331 by 1-10 conservative amino acid substitution, or its antigen binding part is further provided.</p>
    <p n="0033" xml:id="_2ff0350166">VH domain where this invention is independently selected from sequence number 1 - 13 and any one of 320-the 325,<lb>
        </lb>Or the arrangement|sequence which differs from sequence number 1 - 13 and any one of 320-the 325 by 1-10 conservative amino acid substitution is included,<lb>
        </lb>VL domain independently selected from sequence number 14 - 23 and any one of 326-the 331,<lb>
        </lb>Or the antibody which further includes the arrangement|sequence which differs from sequence number 14 - 23 and any one of 326-the 331 by 1-10 conservative amino acid substitution, or its antigen binding part is further provided.</p>
    <p n="0034" xml:id="_2ff0350170">This invention further provides an antibody or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part is an arrangement|sequence which differs from sequence number 24 by VHCDR1 shown by sequence number 24, or 1-4 conservative amino acid substitution;<lb>
        </lb>Arrangement|sequence which differs from sequence number 25 by VHCDR2 shown by sequence number 25, or 1-4 conservative amino acid substitution;<lb>
        </lb>And the arrangement|sequence which differs from sequence number 26 - 37 and any one of 91-the 256 by VHCDR3 selected from sequence number 26 - 37 and any one of 91-the 256 or 1-4 conservative amino acid substitution is included.</p>
    <p n="0035" xml:id="_2ff0350174">This invention further provides an antibody or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part is an arrangement|sequence which differs from sequence number 38 by VLCDR1 shown by sequence number 38, or 1-4 conservative amino acid substitution;<lb>
        </lb>Arrangement|sequence which differs from sequence number 39 by VLCDR2 shown by sequence number 39, or 1-4 conservative amino acid substitution;<lb>
        </lb>And the arrangement|sequence which differs from sequence number 40 - 47 and any one of 257-the 319 by VLCDR3 selected from sequence number 40 - 47 and any one of 257-the 319 or 1-4 conservative amino acid substitution is included.</p>
    <p n="0036" xml:id="_2ff0350178">This invention further provides the antibody which has at least 1 among the functional characteristics described by said A to K, or its antigen binding part,<lb>
        </lb>The said antibody or an antigen binding part is VHFR1 shown by sequence number 48;<lb>
        </lb>VHFR2 shown by sequence number 49;<lb>
        </lb>VHFR3 selected from any one of the sequence number 50 - 55;<lb>
        </lb>VHFR4 selected from sequence number 56 and any one of the 57;<lb>
        </lb>VLFR1 selected from sequence number 58 and any one of the 59;<lb>
        </lb>VLFR2 selected from any one of the sequence number 60 - 62;<lb>
        </lb>VLFR3 selected from any one of the sequence number 63 - 66;<lb>
        </lb>And VLFR4 shown by sequence number 67 is included.<lb>
        </lb>In the further embodiment, FR1 of quoted VH and VL, FR2, FR3, and 4 arrangement|sequence of FR(s) may also differ from specific sequence number enumerated above each independently by at least 1 conservative amino acid substitution.<lb>
        </lb>For example, FR1, FR2, FR3 and 4 arrangement|sequence of FR(s) may differ from each specific sequence number enumerated above each independently by 1, 2, 3, 4, 5, 6, 7 and 8, 9 or 10 conservative amino acid substitution.<lb>
        </lb>In the further embodiment, FR1, FR2, FR3 and either of 4 arrangement|sequence of the FR(s) may mutate each independently, and may adapt with each germ-line framework arrangement|sequence.</p>
    <p n="0037" xml:id="_2ff0350190">The further embodiment of this invention is IgG, IgM, IgE, IgA or an IgD molecule|numerator, or is either of the antibodies as described in this specification originating in it.<lb>
        </lb>For example, IgG1 or IgG2 may be sufficient as an antibody.<lb>
        </lb>For example, in one Embodiment, IgG is IgG1,<lb>
        </lb>In the light chain constant area|region, the C-terminal lysine residue of sequence number 344 may be cut|disconnected for the heavy chain constant region including sequence number 344, including sequence number 345.</p>
    <p n="0038" xml:id="_2ff0350194">Other embodiment A Fab fragment, F(abs') 2 fragment|piece,<lb>
        </lb>Either [ which is Fv fragment|piece, a single-chain Fv fragment|piece, a single-chain VH fragment|piece, a single-chain VL fragment|piece, humanized antibody, a chimeric antibody, or a bispecific antibody ] the antibody as described in the above or an antigen binding part is provided.</p>
    <p n="0039" xml:id="_2ff0350196">The further embodiment is the derivatization antibody or antigen binding part containing the antibody as described in this specification or either of the part, and the further at least 1 molecule|numerator component.<lb>
        </lb>For example, the further at least 1 molecule|numerator component,<lb>
        </lb>The protein or the peptide which can carry the part of other antibody (For example, a bispecific antibody or diabody), the active substance for a detection, a label|marker, a cytotoxicity effect substance, pharmaceutical active substance and/or an antibody, or an antibody and the coupling|bonding of other molecule|numerator (The streptavidine core area|region, polyhistidine-tag, etc.) may be sufficient.<lb>
        </lb>For example, a fluorescent compound including fluorescein, a fluorescein isothiocyanate, rhodamine, a chlorination 5-dimethylamine 1-naphthalene sulfonyl, a phycoerythrin, a lanthanide phosphorescent substance etc. is among the useful active substance for a detection which can derivatize the antibody or antigen binding part of this invention.<lb>
        </lb>An antibody can also be label|marked with a useful enzyme to the detection of a Western horseradish peroxidase, beta-galactosidase, a luciferase, an alkaline phosphatase, glucose oxidase, etc.<lb>
        </lb>In the further embodiment, the antibody of this invention or its part can also be label|marked with the predetermined polypeptide epitope (For example, the arrangement|sequence of the pair of a leucine zipper, the coupling|bond-region of a secondary antibody, a metallic bond domain, an epitope tag) which is a biotin or is recognized by the secondary reporter.<lb>
        </lb>At the further embodiment of this invention, either an antibody or its part can also be derivatized by polyethyleneglycol (PEG), methyl or an ethyl group, and chemical groups, such as carbohydrate group.</p>
    <p n="0040" xml:id="_2ff0350203">In some embodiment, P-cadherin antibody or the antigen binding part currently indicated by this specification has couple|bonded with the solid support body.</p>
    <p n="0041" xml:id="_2ff0350204">In some embodiment, the lysine|ricin of the C terminal of the heavy chain in any one of P-cadherin antibody of this invention is cut|disconnected.<lb>
        </lb>In various embodiment of this invention, the heavy chain and light chain of P-cadherin antibody may also include an N terminal signal sequence.<lb>
        </lb>For example, sequence number 346 may be sufficient as a heavy-chain signal sequence, and sequence number 347 may be sufficient as a light chain signal sequence.</p>
    <p n="0042" xml:id="_2ff0350207">In the further embodiment, this invention relates to either the antibody as described in this specification which is of human origin, or its antigen binding part.</p>
    <p n="0043" xml:id="_2ff0350208">This invention also also provides the antibody as described in the above or either of the antigen binding part, and the pharmaceutical composition containing a pharmacologically acceptable support|carrier.</p>
    <p n="0044" xml:id="_2ff0350209">In other embodiment, this invention relates to an isolated nucleic acid molecule including the nucleotide sequence which codes either the antibody as described in this specification, or its antigen binding part.<lb>
        </lb>Specific one Embodiment is an isolated nucleic acid molecule including the nucleotide sequence shown by sequence number 68 - 90 and any one of 332-the 343.<lb>
        </lb>This invention relates to the vector containing either of the nucleic acid molecules as described in this specification further.<lb>
        </lb>A vector may also include the expression regulatory sequence operatively connected with the nucleic acid molecule.</p>
    <p n="0045" xml:id="_2ff0350213">Other embodiment provides the host cell which contains any one of the vectors as described in this specification, or contains any one of the nucleic acid molecules as described in this specification.<lb>
        </lb>This invention also contains the isolated cell system|strain which produces either the antibody as described in this specification, or an antigen binding part, or also produces the heavy chain or light chain in any one of the said antibody or the said antigen binding part.</p>
    <p n="0046" xml:id="_2ff0350215">In other embodiment, this invention relates to the method to produce P-cadherin antibody or its antigen binding part,<lb>
        </lb>Its method is a step which culture|cultivates the host cell or cell lineage as described in this specification on relevant conditions,<lb>
        </lb>The step which collect|recovers the said antibody or antigen binding parts is included.</p>
    <p n="0047" xml:id="_2ff0350218">This invention also relates also to the non-human transgenic animal or transgenic plant containing either of the nucleic acids as described in this specification.<lb>
        </lb>A non-human transgenic animal or a transgenic plant expresses the said nucleic acid.</p>
    <p n="0048" xml:id="_2ff0350220">This invention further provides the method to isolate the antibody couple|bonded with P-cadherin, or its antigen binding part,<lb>
        </lb>Its method contains the step which isolates an antibody from the non-human transgenic animal as described in this specification, or a transgenic plant.</p>
    <p n="0049" xml:id="_2ff0350222">This invention also provides the method to also treat the abnormal cell proliferation in a mammal with the need,<lb>
        </lb>Its method contains the step which administers either the antibody as described in this specification, or its antigen binding part either [ pharmaceutical composition ] to the said mammal.<lb>
        </lb>The method to treat the abnormal cell proliferation in the mammal whose this invention is an antibody couple|bonded with P-cadherin or its antigen binding part and which has the need is further provided,<lb>
        </lb>Its method contains the step which administers either of the nucleic acid molecules as described in this specification to the said mammal in effective amount on the relevant conditions which enable the expression of the said nucleic acid molecule.<lb>
        </lb>In other embodiment, the method of treating abnormal cell proliferation further contains the step which becomes effective together when treating the said abnormal cell proliferation about 1 or several substance selected from an anti-tumor agent, an anti-angiogenic agent, signaling inhibitor, and an anti- proliferation agent and which carries out quantity administration.<lb>
        </lb>In specific embodiment, the said abnormal cell proliferation is cancerous|carcinomatous.</p>
    <p n="0050" xml:id="_2ff0350228">This invention further provides the method to reduce P-cadherin dependence cell aggregation,<lb>
        </lb>Its method contains the step which either and the cell of pharmaceutical composition as described in either the antibody as described in this specification or its antigen binding part and this specification are made to contact.</p>
    <p n="0051" xml:id="_2ff0350230">The other aspect of this invention is an antibody including the heavy-chain variable-region amino acid sequence using human VH-3 family gene, or its antigen binding part.<lb>
        </lb>In one Embodiment, human VH-3 family gene is VH-3-23, for example.</p>
    <p n="0052" xml:id="_2ff0350232">The other aspect of this invention provides either the antibody as described in this specification which is a human antibody, or its antigen binding part.<lb>
        </lb>In the further aspect, the said antibody or an antigen binding part is a human recombinant antibody.</p>
    <p n="0053" xml:id="_2ff0350234">This invention also also provides the method to produce P-cadherin antibody or its antigen binding part,<lb>
        </lb>Its method contains the step which synthesize|combines the library of the human antibody on a phage, the step which screens library in P-cadherin or its antigenic part, the step which isolates the phage couple|bonded with P-cadherin, and the step which obtains an antibody from a phage.</p>
    <p n="0054" xml:id="_2ff0350236">A definition and a general technique<lb>
        </lb>Unless it defines specially in this specification, the technology term used regarding this invention shall include the meaning normally understood by the expert.<lb>
        </lb>Furthermore, unless it requires for the stage according to context top, the term of a singular form shall contain plurality and the term of the plural form shall contain a singular form.<lb>
        </lb>Generally, the nomenclature used regarding the cell as described in this specification, tissue culture, molecular biology, an immunology, a microbiology, genetics, protein, nucleic acid chemistry, and hybridization and its technique are known at this technical field,<lb>
        </lb>Normal use is carried out.</p>
    <p n="0055" xml:id="_2ff0350241">Generally, unless it shows specially, the method and technique of this invention are implemented as it describes in the various general reference literature and more concrete reference literature which were referred and discussed over whole this specification in accordance with the known conventional method by this technical field.<lb>
        </lb>Sambrook et al. [ for example, ] by whom the indication is integrated in this specification by the reference,<lb>
        </lb>Molecular Cloning:A Laboratory Manual, the 3rd edition, Cold Spring Harbor Laboratory Press,<lb>
        </lb>Please refer New York state Cold Spring Harbor(2000);Ausubel et al., Short Protocols in Molecular Biology:A Compendium of Methods from Current Protocols in Molecular Biology, Wiley,John&amp;Sons,Inc.(2002);Harlow, Lane, Using Antibodies:A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York state Cold Spring Harbor(1998);, Coligan et al., and Short Protocols in Protein Science, Wiley,John&amp;Sons,Inc.(2003).<lb>
        </lb>An enzyme reaction and refinement|purification techniques are implemented according to a manufacturer's specification as described in this specification so that it may be normally carried out by this technical field.<lb>
        </lb>By this technical field, the nomenclature used regarding the analytical chemistry as described in this specification, the synthetic|combination organic chemistry, the pharmaceutical, and the pharmaceutical chemistry, its experiment procedure, and a technique are known, and normal use is carried out.<lb>
        </lb>A standard technique is used for chemo synthesis, a chemical analysis, a formulation, prescription, delivery, and a patient's treatment.</p>
    <p n="0056" xml:id="_2ff0350248">It is known that the structural unit of a fundamental antibody contains a tetramer.<lb>
        </lb>Each tetramer consists of the two same pairs of a polypeptide chain|strand, and each pair has one "light" chain|strand (about 25 kDa) and one "heavy" chain|strand (about 50-70 kDa).<lb>
        </lb>The amino terminal part of each chain|strand contains the variable region which is mainly concerned in antigen recognition and which consists of about 100 - a 120 or more amino acid.<lb>
        </lb>The carboxy terminal|end part of each chain|strand prescribes|regulates the constant region which is mainly concerned in an effector function.<lb>
        </lb>A human light chain is classified into (kappa) and (lambda) light chain.<lb>
        </lb>The heavy chain is classified into (micro|micron|mu), (delta), (gamma), and (alpha) or (epsilon), and defines the isotype of an antibody as IgM, IgD, IgG, IgA, and IgE, respectively.<lb>
        </lb>A variable region and a constant region are couple|bonded within the heavy chain and a light chain by the "J" area|region which consists of about 12 or more amino acid, and the heavy chain also includes the "D" area|region which consists of about 3 or more amino acid.<lb>
        </lb>Generally, please refer (The whole is integrated in this specification by the reference for all the objective.) Fundamental Immunology and Chapter 7 (Paul, W. knitting|edition, the 2nd edition, Raven Press, New York state (1989)).<lb>
        </lb>Variable-region (VH and VL) of each pair of the heavy chain/light chain forms an antibody combining site.<lb>
        </lb>Therefore, for example, a perfect IgG antibody has two coupling|bond-regions.<lb>
        </lb>Two coupling|bond-regions are the same except bifunctionality or a bispecific antibody.</p>
    <p n="0057" xml:id="_2ff0350259">The variable region of the heavy chain and a light chain shows the same general structure of the framework region (FR) which is couple|bonded by three hypervariable regions called a complementarity determining region or CDR and which is preserve|saved comparatively.<lb>
        </lb>The term "variable" points out the arrangement|sequence of the specific part of a variable domain being large between antibodies, and differing, and it is used in the coupling|bonding and specificity with respect to the specific antigen of specific each antibody.<lb>
        </lb>However, the variability is not necessarily uniformly distributed over the whole variable domain of an antibody, and is concentrated in CDR isolate|separated by FR preserve|saved more highly.<lb>
        </lb>CDR of two chain|strands of each pair aligns by FR, and becomes combinable with a specific epitope by it.<lb>
        </lb>By a C terminal, a light chain and the heavy chain contain a domain FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4 from an N terminal.<lb>
        </lb>As for allocation of the amino acid with respect to each domain, the indication is integrated in this specification by the reference,<lb>
        </lb>Kabat Sequences of Proteins of Immunological Interest(National Institutes of Health, Maryland state Bethesda (1987 and 1991)),<lb>
        </lb>Or the definition of Chothia, Lesk, J.Mol.Biol., 196:901-917(1987);Chothia et al., and Nature, 342:878-883(1989) is followed.</p>
    <p n="0058" xml:id="_2ff0350267">Unless the following term is shown specially, it shall be understood that it has the following meaning:</p>
    <p n="0059" xml:id="_2ff0350268">Unless it shows specially in particular, the term "P-cadherin" points out a human P-cadherin,<lb>
        </lb>It is intrinsic membrane protein,<lb>
        </lb>It is a component of the classic cadherin family of the trans-membrane glycoprotein which controls a cell adhesion.<lb>
        </lb>For example, the cloning and an arrangement|sequence of the human P-cadherin have been reported by Shimoyama et al. and J.Cell Biol., 109(4 Pt 1), 1787-1794(1989) by which the indication is integrated in this specification by the reference.<lb>
        </lb>A term called P-cadherin shall contain a recombinant human P-cadherin and P-cadherin of a recombinant chimera type.<lb>
        </lb>It can also be prepared by the standard recombinant expressing method,<lb>
        </lb>Or it can also purchase commercially.<lb>
        </lb>(R&amp;D Systems 861-PC-100).</p>
    <p n="0060" xml:id="_2ff0350276">Unless it shows specially in particular, in this specification, the term "E-cadherin" points out a human E-cadherin,<lb>
        </lb>It is intrinsic membrane protein,<lb>
        </lb>It is a component of the classic cadherin family of the trans-membrane glycoprotein which controls a cell adhesion.<lb>
        </lb>E-cadherin is described by Takeichi, Science, 251:1451-1455(1991) by which the indication is integrated in this specification by the reference, for example.<lb>
        </lb>A term called E-cadherin shall contain a recombinant human E-cadherin and E-cadherin of a recombinant chimera type.<lb>
        </lb>It can also be prepared by the standard recombinant expressing method,<lb>
        </lb>Or it can also purchase commercially (R&amp;D 648-EC-100).</p>
    <p n="0061" xml:id="_2ff0350283">A term called "polypeptide" includes nature or an artificial protein, a protein fragment, and the polypeptide analog of a protein arrangement|sequence.<lb>
        </lb>A monomer may be sufficient as polypeptide or a polymer may be sufficient as it.</p>
    <p n="0062" xml:id="_2ff0350285">The term a "isolated protein", "isolation polypeptide", or an "isolation antibody" is origin or derivation origin,<lb>
        </lb>(1) It does not couple|bond with structural component accompanying it couple|bonded naturally in the natural state,<lb>
        </lb>(2) Other protein derived from the same seed|species is not included,<lb>
        </lb>(3) Cell derived from different seed|species expresses,<lb>
        </lb>or<lb>
        </lb>(4) It is the protein, polypeptide, or the antibody which does not exist naturally.<lb>
        </lb>Therefore, the polypeptide synthesize|combined by a different cell lineage from the cell which is chemo-synthesized or it produces naturally is "isolate""ed from the structural component couple|bonded naturally.<lb>
        </lb>The protein can use known protein purification techniques by this technical field, and can also carry out them by isolation, excluding substantially the structural component couple|bonded naturally.</p>
    <p n="0063" xml:id="_2ff0350293">There exist P-cadherin antibody affinity-purified using P-cadherin and a P-cadherin antibody synthesize|combined by the cell lineage in vitro in the example of an isolation antibody.</p>
    <p n="0064" xml:id="_2ff0350294">Protein or polypeptide is "substantially pure" when at least about 60 to 75% of sample shows polypeptide of single seed|species,<lb>
        </lb>It is "substantially homogeneous",<lb>
        </lb>Or "having refine|purified substantially" is carried out.<lb>
        </lb>A monomer may be sufficient as polypeptide or protein, or a multimer may be sufficient as it.<lb>
        </lb>substantially pure polypeptide or protein -- normally about 50 % -- the protein sample of w/w may be included 70%, 80% or 90% 60% -- more -- general -- about 95 %,<lb>
        </lb>Preferably, exceeding 99 %, it is pure and obtains.<lb>
        </lb>Protein purity and the homogeneity can show visualization of polyacrylamidegel electrophoresis of a protein sample, and the single polypeptide band after a known stain|dye liquid dye|stains a gel by this technical field after that, etc. by some known means by this technical field.<lb>
        </lb>A high resolution can be brought about by using another known means by the technical fields of HPLC or a refinement|purification for the specific objective.</p>
    <p n="0065" xml:id="_2ff0350302">In this specification, the term a "polypeptide fragment|piece" points out the polypeptide which has deletion of an amino terminal and/or a carboxy terminus,<lb>
        </lb>However,<lb>
        </lb>The amino acid sequence which remain|survives is the same as that of the corresponding position during arrangement|sequence which exists naturally.<lb>
        </lb>In some embodiment, the fragment|piece is 5, 6, 8, or 10 amino acids in length at least.<lb>
        </lb>In other embodiment, the fragment|piece is at least 14, at least 20, at least 50, at least 70, 80, 90, 100, 150, or 200 amino acids in length.</p>
    <p n="0066" xml:id="_2ff0350307">In this specification, the term an "analog" or a "polypeptide analog" has the substantial identity with respect to a certain reference|standard amino acid sequence,<lb>
        </lb>Polypeptide containing the segment which has the substantially same function or activity as a reference|standard amino acid sequence is pointed out.<lb>
        </lb>Usually, a polypeptide analog contains the conservative amino acid substitution (or insertion or deletion) with respect to a reference sequence.<lb>
        </lb>The analog may be at least 20 or 25 amino acids in length,<lb>
        </lb>Or length may be 50, 60, 70, 80, 90, 100, 150 or 200 amino acids or more at least,<lb>
        </lb>It may be length often comparable as full length polypeptide.<lb>
        </lb>Some embodiment of this invention contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 polypeptide fragment|pieces, or polypeptide resemblance|analogue antibody from a germ-line amino acid sequence.<lb>
        </lb>The fragment|piece or analog of an antibody or an immuno-globulin molecule|numerator can receive teaching of this specification, and can prepare it easily by an expert.</p>
    <p n="0067" xml:id="_2ff0350315">At specific embodiment, they are P-cadherin antibody or an amino acid substitution with respect to the antigen binding part,<lb>
        </lb>(1) Sensitivity with respect to proteolysis is reduced,<lb>
        </lb>(2) Sensitivity with respect to oxidation is reduced,<lb>
        </lb>(3) Binding affinity of protein complex formation is changed,<lb>
        </lb>(4) Other physicochemical or functional characteristic of such an analog is provided or modified|changed,<lb>
        </lb>However,<lb>
        </lb>The specific binding property with respect to P-cadherin is still hold|maintained.<lb>
        </lb>An analog may include various substitution with respect to the peptide sequence which exists naturally.<lb>
        </lb>For example, a single-or-several amino acid substitution,<lb>
        </lb>Preferably, conservative amino acid substitution is during the arrangement|sequence which exists naturally, and it can perform it in the part of the polypeptide which exists on the outer side of the domain which forms intermolecular contact (some), for example.<lb>
        </lb>An amino acid substitution can also be performed in the domain (some) which forms intermolecular contact, and, thereby, can improve the activity of polypeptide.<lb>
        </lb>The conservative amino acid substitution should not change the structural characteristics of parent_sequence|host_array substantially;<lb>
        </lb>For example, the substituted amino acid should not destroy the other type|mold secondary structure by which changes the reverse direction beta-sheet which comprises the immuno-globulin binding domain which exists in parent_sequence|host_array, or parent_sequence|host_array is characterized.<lb>
        </lb>Generally, glycine and proline are not used in a reverse direction beta-sheet.<lb>
        </lb>The example of the secondary structure of polypeptide and a tertiary structure currently recognized by this technical field is Proteins and Structures and Molecular Principles(A Creighton knitting|edition, W.H.Freeman and Company, New York(1984));Introduction to Protein Structure(C.Branden, a J.Tooze knitting|edition, Garland Publishing, New York state New York (1991)) which are integrated in this specification by the reference;<lb>
        </lb>And it describes in Thornton et al., Nature, and 354:105 (1991).</p>
    <p n="0068" xml:id="_2ff0350331">In this specification, the term an "antibody" is synonymous with an immuno-globulin, and it should be understood as normally known for this technical field.<lb>
        </lb>Specifically, a term called an antibody is not limited by the arbitrary specific methods of producing an antibody.<lb>
        </lb>Although not restricted to a term called an antibody so,<lb>
        </lb>There exist a recombinant antibody, a monoclonal antibody, and a polyclonal antibody.</p>
    <p n="0069" xml:id="_2ff0350335">The term the "antigen binding part" (or only "antibody part") of an antibody points out 1 or several fragment|piece of the antibody holding the capability to couple|bond with an antigen (for example, P-cadherin) specifically, in this specification.<lb>
        </lb>It is shown that the antigen joint function of an antibody can be fulfill|performed with the fragment|piece of a full-length antibody.<lb>
        </lb>For the example of the binding fragment included in the term the "antigen binding part" of an antibody,<lb>
        </lb>(i) Monovalent|monohydric fragment|piece which consists of VL, VH, CL and CH1 domain which are called Fab fragment;<lb>
        </lb>Bivalent fragment|piece containing two Fab fragments which are called F(ab')2 fragment|piece, and which were connected with disulfide bridge in hinge region;<lb>
        </lb>(iii) Fd fragment|piece which consists of VH and CH1 domain;<lb>
        </lb>Fv fragment|piece which consists of VL and VH domain of single arm part of antibody,<lb>
        </lb>(v) DAb fragment|piece (Ward et al., Nature, (1989)341:544-546) which consists of a VH domain;<lb>
        </lb>and<lb>
        </lb>There exists an isolated complementarity determining region (CDR).<lb>
        </lb>Furthermore, two domain VL and VH of Fv fragment|piece are coded by the separate gene,<lb>
        </lb>However,<lb>
        </lb>They use a recombinant method,<lb>
        </lb>It is combinable by the synthetic|combination linker which makes it possible to produce them as a chain|strand (known as the single chain Fv (scFv)) of the single protein which VL and VH area|region become a pair and forms a monovalent|monohydric molecule|numerator;<lb>
        </lb>For example, please refer Bird et al., Science (1988) 242:423-426, Huston et al., Proc.Natl.Acad.Sci.USA, 85:5879-5883 (1988).<lb>
        </lb>Such a single-chain antibody shall also be included in the term the "antigen binding part" of an antibody.<lb>
        </lb>Other type|mold single-chain antibodies, such as diabody, are also included.<lb>
        </lb>diabody is a bivalent bispecific antibody,<lb>
        </lb>VH and VL domain express on a single polypeptide chain|strand,<lb>
        </lb>However,<lb>
        </lb>The linker which is too short to form a pair between two domains on the same chain|strand is used,<lb>
        </lb>By it, the domain forms the complementarity domain of another chain|strand, and a pair,<lb>
        </lb>Two antigen binding sites produce|generate (For example, Holliger et al., Proc.Natl.Acad.Sci.USA, 90:6444-6448 (1993); Poljak et al., Structure, and 2:1121-1123 (1994) were referred.).</p>
    <p n="0070" xml:id="_2ff0350358">Furthermore, a part of big immune adherence molecule formed by a covalent bond or noncovalent bond of an antibody, an antibody part and 1 or several other protein, or a peptide may be sufficient as an antibody or its antigen binding part.<lb>
        </lb>The use (Kipriyanov et al., Human Antibodies and Hybridomas, 6:93-101 (1995)) of the streptavidine core area|region for producing a tetramer scFv molecule|numerator for the example of such an immune adherence molecule,<lb>
        </lb>And there exists use (Kipriyanov et al., Mol.Immunol., 31:1047-1058(1994)) of the cysteine residue for producing bivalence and a biotinylation scFv molecule|numerator, a marker peptide, and C-terminal polyhistidine-tag.<lb>
        </lb>1 or several CDR derived from an antibody may be integrated in a molecule|numerator by a covalent bond or noncovalent bond at another example, and it may be made the immune adherence factor specifically couple|bonded with the antigen which makes it object, such as P-cadherin.<lb>
        </lb>In such embodiment, CDR (some) can also be integrated as some bigger polypeptide chain|strands, and can also be covalently bonded with another polypeptide chain|strand,<lb>
        </lb>Or it is also incorporable by noncovalent bond.<lb>
        </lb>Prior arts, such as papain digesting of the whole antibody and pepsin digestion, can be used, respectively, and antibody parts, such as Fab and an F(ab')2 fragment|piece, can be prepared from the whole antibody.<lb>
        </lb>Furthermore, standard recombinant DNA technology can be used as described in this specification, and an antibody, an antibody part, and an immune adherence molecule can be obtained.</p>
    <p n="0071" xml:id="_2ff0350366">When you mention an "antibody" by this specification regarding this invention, please also understand that the antigen binding part can be used.<lb>
        </lb>An antigen binding part competes with a complete antibody in specific binding.<lb>
        </lb>Generally, please refer Fundamental Immunology and Chapter 7 (Paul, W. knitting|edition, the 2nd edition, Raven Press, New York state (1989)) (The whole is integrated by the reference for all the objective.).<lb>
        </lb>An antigen binding part is producible by the enzymatic or chemical cutting|disconnection of recombinant DNA technology or a complete antibody.<lb>
        </lb>In some embodiment, to an antigen binding part,<lb>
        </lb>There exist Fab, Fab', F(ab')2, Fd, Fv, dAb, a complementarity determining region (CDR) fragment|piece, a single-chain antibody (scFv), a chimeric antibody, diabody, and polypeptide containing at least one part of sufficient antibody to provide specific antigen-binding with respect to polypeptide.<lb>
        </lb>In embodiment which has 1 or several coupling|bond-region, a coupling|bond-region may mutually be the same or may differ.</p>
    <p n="0072" xml:id="_2ff0350373">The term as used herein a "human antibody" means the arbitrary antibodies whose arrangement|sequences of a variable domain and a constant domain are human arrangement|sequences.<lb>
        </lb>Although the term has the arrangement|sequence originating in a human gene, it includes the antibody changed, for example so that the immunogenic fall considered, affinity increase, the removal of the cysteine which may cause undesirable folding etc. may be performed.<lb>
        </lb>The term also includes such an antibody that can also give the glycosylation which is not peculiar to a human cell and that was produced by recombination in the non-human cell.<lb>
        </lb>These antibodies can be prepared in various forms as described in the following.</p>
    <p n="0073" xml:id="_2ff0350377">The term as used herein a "chimeric antibody" means antibodies including the antibody derived from different seed|species including the area|region derived from two or more different antibodies.<lb>
        </lb>For example, 1 or several CDR of a chimeric antibody may originate in a human P-cadherin antibody.<lb>
        </lb>For example, CDR derived from a human antibody is combinable with CDR derived from non-human antibodies, such as a mouse|mouth and a rat.<lb>
        </lb>In another example, all the CDR may originate in a human P-cadherin antibody.<lb>
        </lb>In another example, CDR originating in a several human P-cadherin antibody is combinable in a chimeric antibody.<lb>
        </lb>For example, a chimeric antibody may contain CDR2 of CDR1 of the 1st light chain of a human P-cadherin antibody, and the light chain of a 2nd human P-cadherin antibody, and CDR3 of the light chain of a 3rd human P-cadherin antibody,<lb>
        </lb>CDR of the heavy chain may originate in 1 or several other P-cadherin antibody.<lb>
        </lb>Furthermore, the term a "chimeric antibody" shall include the arbitrary combination containing a human antibody and a non-human antibody mentioned to the above.</p>
    <p n="0074" xml:id="_2ff0350385">In this specification, the term "humanized antibody" points out the antibody derived from a non-human, and is substituted by the residue by which an amino acid residue characteristic of the antibody arrangement|sequence of non-human seed|species is recognized in the position where a human antibody respond|corresponds.<lb>
        </lb>This "humanized" process is considered to reduce the immunogenicity in the human of that antibody acquired as a result.<lb>
        </lb>It will be understood that a known technique is used by this technical field, and the antibody derived from a non-human can be humanized.<lb>
        </lb>For example, please refer Winter et al., Immunol.Today, 14:43-46(1993).<lb>
        </lb>The antibody made into object is producible in engineering by the recombinant DNA technology which substitutes CH1, CH2, CH3, hinged main and/or a framework domain by corresponding human arrangement|sequence.<lb>
        </lb>For example, please refer WO92/02190, US Patent 5,530,101, 5,585,089, 5,693,761, 5,693,792, 5,714,350, and 5,777,085.<lb>
        </lb>In this specification, the term "humanized antibody" contains a chimera human antibody and a CDR transplant antibody within the range of the meaning.<lb>
        </lb>The chimera human antibody of this invention includes VH of the antibody of non-human seed|species, VL, CH of a human antibody, and CL domain.<lb>
        </lb>The CDR transplant antibody of this invention is obtained in CDR of VH of a human antibody, and VL by [ of the antibody of animals other than a human ] substituting by CDR of VH and VL, respectively.</p>
    <p n="0075" xml:id="_2ff0350394">In this specification, the term "ELISA" points out an enzyme-linked immunosorbent assay.<lb>
        </lb>This assay is known to an expert.<lb>
        </lb>The example of this assay can be recognized in Example 7 of Vaughan, T.J. et al., Nat.Biotech., 14:309-314(1996), and this application.</p>
    <p n="0076" xml:id="_2ff0350397">In this specification, the BIACORE (trademark) type|system|group (Pharmacia Biosensor AB, Sweden Uppsala, and New Jersey state Piscataway) is used for the term "surface plasmon resonance", for example,<lb>
        </lb>The optical phenomenon which enables an analysis of real-time biological-body specific interaction is pointed out by detecting the change of the protein concentration within a biosensor matrix.<lb>
        </lb>Please refer Jonsson et al., Ann.Biol.Clin., 51:19-26 (1993);<lb>
        </lb>Jonsson et al., Biotechniques, 11:620-627 (1991);<lb>
        </lb>Jonsson et al., J.Mol.Recognit., 8:125-131 (1995);<lb>
        </lb>And Johnsson et al., Anal.Biochem., 198:268-277 (1991) for the further description.</p>
    <p n="0077" xml:id="_2ff0350403">The term "KD" points out the equilibrium constant of the binding affinity of interaction of a specific antibody and an antigen.<lb>
        </lb>KD of an antibody is &lt;=1mM,<lb>
        </lb>Preferably it is &lt;=100nM,<lb>
        </lb>When it is &lt;=10nM most preferably, it can be said that it couple|bonds with an antigen specifically.<lb>
        </lb>A BIACORE (trademark) type|system|group can be used for a KD joint compatible constant, and it can measure it by surface plasmon resonance so that it may discuss in Example 6.</p>
    <p n="0078" xml:id="_2ff0350408">The term "Koff" points out the dissociation rate constant of interaction of a specific antibody and an antigen.<lb>
        </lb>The Koff dissociation rate constant can use a BIACORE (trademark) type|system|group, and can measure it by surface plasmon resonance so that it may discuss in Example 6.</p>
    <p n="0079" xml:id="_2ff0350410">In this specification, the term "P-cadherin dependence cell-adhesion assay" points out the assay used for the measurement of the capability of P-cadherin antibody which interrupts|blocks adhesion|attachment of the receptor P-cadherin and cell which are fix|immobilized on the solid support body.<lb>
        </lb>This type|mold assay can be implemented by fix|immobilizing P-cadherin on solid support bodies, such as a plastics, for example.<lb>
        </lb>Subsequently, the cell which overexpresses P-cadherin is adhere|attached on a solid support body through interaction between P-cadherins.<lb>
        </lb>Subsequently, the level of adhesion|attachment can be quantified in a state with P-cadherin antibody, and the state which is not.<lb>
        </lb>Subsequently, the adhesion|attachment as a function of antibody concentration can be used and IC50 value can be determined.<lb>
        </lb>The further detail of P-cadherin dependence cell-adhesion assay used for the measurement of IC50 value of P-cadherin antibody at Example 3 is shown.</p>
    <p n="0080" xml:id="_2ff0350416">In this specification, the term "P-cadherin dependence cell aggregation assay" points out the assay which measures the capability of P-cadherin antibody which interrupts|blocks aggregation of the cell which is expressing P-cadherin on the surface.<lb>
        </lb>For example, the cell lineage which overexpresses P-cadherin can be used in this type|mold assay,<lb>
        </lb>The cell is put in suspension and the aggregate of P-cadherin dependence is formed.<lb>
        </lb>Subsequently, using the aggregation assay, the capability of P-cadherin antibody which prevents this aggregation is quantified by measuring the size of the cell aggregate which arises in a state with an antibody, and the state which is not.<lb>
        </lb>Subsequently, the size of the cell aggregate as a function of P-cadherin antibody concentration can be used, and IC50 value can be determined.<lb>
        </lb>The further detail of P-cadherin dependence cell aggregation assay used for the measurement of IC50 value of several P-cadherin antibody at Example 4 is shown.</p>
    <p n="0081" xml:id="_2ff0350422">In this specification, the term "P-cadherin dependence spheroid destructive assay" points out the assay which measures the capability of P-cadherin antibody which destroys the cell aggregate of P-cadherin dependence formed previously.<lb>
        </lb>IC50 value can be determined by measuring the size fall of the aggregate as a function of antibody concentration.<lb>
        </lb>The further detail of P-cadherin dependence spheroid destructive assay used for the measurement of IC50 value of P-cadherin antibody at Example 5 is shown.</p>
    <p n="0082" xml:id="_2ff0350425">In this specification, the term a "molecule|numerator selectivity" points out the binding affinity of the larger antibody with respect to a specific antigen than the thing with respect to a related antigen.<lb>
        </lb>For example, the antibody of this invention is selective with respect to P-cadherin compared with E-cadherin,<lb>
        </lb>As for this, the binding affinity of the antibody with respect to P-cadherin means 4 time, 10 time, or a thing large 50 time or 100 times or more at least 2 times from the thing with respect to E-cadherin.<lb>
        </lb>Such a binding affinity can be measured using the standard technique known by the expert.</p>
    <p n="0083" xml:id="_2ff0350429">The term an "epitope" contains the thing which interacts with an immuno-globulin, a T-cell receptor, or other molecule|numerators, and the arbitrary protein determinants which can be specifically bound.<lb>
        </lb>An epitopic determinant consists of a molecule|numerator group of the surface where an amino acid, a carbohydrate, a saccharide|sugar side chain, etc. are chemically active, and, generally has the characteristics of specific three-dimensional structure, and the characteristics of specific electric charge.<lb>
        </lb>"Linear" may be sufficient as an epitope or "3D_structural|conformational" may be sufficient as it.<lb>
        </lb>In a linear epitope, all of the interaction point of protein and interaction molecule|numerators (antibody etc.) exist linearly along a protein primary amino acid sequence.<lb>
        </lb>In a 3D_structural|conformational epitope, an interaction point exists ranging over the amino acid residue on the protein which is mutually separated.<lb>
        </lb>After determining the desired epitope on an antigen, the technique described by this invention can be used and the antibody with respect to the epitope can be produced|generated.<lb>
        </lb>Or the information about a desired epitope may be elucidated by the production|generation of an antibody, and characterization between the processes to discover.<lb>
        </lb>Subsequently, an antibody can be competitively screened about a coupling|bonding with the same epitope from this information.<lb>
        </lb>The method of implement|achieving this is finding the antibody which does a cross|intersection competition test and it mutually couple|bonds competitively, i.e., the antibody which competes about a coupling|bonding with an antigen.<lb>
        </lb>The method of the high-throughput ability which carries out "binning" of the antibody based on those cross|intersection competition is described in international patent publication WO03/48731.</p>
    <p n="0084" xml:id="_2ff0350439">The term of "competing" in this specification means that a 1st antibody or its antigen binding part competes with an antibody 2nd about a coupling|bonding, or its antigen binding part regarding an antibody,<lb>
        </lb>the coupling|bonding of a 1st antibody and its affiliated epitope can detect in presence of a 2nd antibody compared with the coupling|bonding of the 1st antibody in the absence of a 2nd antibody -- a grade fall is carried out.<lb>
        </lb>Also the coupling|bonding of a 2nd antibody and its epitope, and in the alternative detectable in presence of a 1st antibody which carries out a grade fall, it corresponds, but that does not need to be right.<lb>
        </lb>That is, the 1st antibody can inhibit the coupling|bonding of a 2nd antibody and its epitope, even if a 2nd antibody does not inhibit the coupling|bonding of a 1st antibody and each of its epitope.<lb>
        </lb>However,<lb>
        </lb>When [ from which each antibody can detect the coupling|bonding of another antibody and its affiliated epitope, or a ligand also by a small grade also according to a large grade also at the same grade ] carrying out grade inhibition, the antibody can mutually be said "To carry out cross|intersection competition" about the coupling|bonding of each of the epitope (some).<lb>
        </lb>Both of competition antibodies and cross|intersection competition antibodies are included in this invention.<lb>
        </lb>Independently [ the mechanism (For example, a coupling|bonding with steric hindrance, a structural change, a common epitope, or its one part, etc.) in which such competition or cross|intersection competition occurs ], if it is an expert,<lb>
        </lb>Based on teaching provided by this specification, such competition and/or a cross|intersection competition antibody are included, and he will understand that it can become useful to the method indicated by this specification.</p>
    <p n="0085" xml:id="_2ff0350448">The term as used herein of "utilizing" regarding a specific gene means that the amino acid sequence of the specific area|region in an antibody was finally induced|guided|derived from the gene between maturing of a B cell.<lb>
        </lb>For example, the words and phrases "the heavy-chain variable-region amino acid sequence using human VH-3 family gene" point out the condition induced|guided|derived from the gene segment of VH-3 family between maturing of VH area|region of an antibody of a B cell.<lb>
        </lb>There exist more than 30 separate functional heavy-chain variable genes in a human B cell, and it produces|generates an antibody using it.<lb>
        </lb>Therefore, use of a specific heavy-chain variable gene suggests preferable binding motif of interaction of an antibody and an antigen regarding the characteristic with which a coupling|bonding and function activity with an antigen were match|combined.<lb>
        </lb>Although it will be understood, only a general view to which the structure of the antibody was restricted brings about a gene utilization analysis.<lb>
        </lb>Although it does not restrict when a human B cell produces|generates a V-D-J heavy-chain transcription|transfer material or a V-J(kappa) light chain transcription|transfer material stochastic so,<lb>
        </lb>Some secondary processes including somatic-cell highly frequent mutation, n addition, and CDR3 extension|expansion are performed.<lb>
        </lb>For example, please refer Mendez et al., Nature Genetics, 15:146-156(1997).</p>
    <p n="0086" xml:id="_2ff0350456">In this specification, 20 conventional amino acid and its abbreviation conventions follow the conventional using method.<lb>
        </lb>Please refer Immunology-A Synthesis (The 2nd edition, E.S.Golub, a D.R.Gren knitting|edition, Sinauer Associates, Massachusetts state Sunderland (1991)) integrated in this specification by the reference.</p>
    <p n="0087" xml:id="_2ff0350458">As for a term called "polynucleotide" mentioned in this specification, length means one of type|mold nucleotide of at least 10 bases superposition|polymerization type|mold nucleotide, a ribonucleotide, deoxy nucleotide, or the modified form.<lb>
        </lb>The term includes the form of a single strand and a double strand.</p>
    <p n="0088" xml:id="_2ff0350460">The term as used herein "isolation polypeptide" means a genome, cDNA, the polynucleotide derived from a synthesis|combination, or some of its combination,<lb>
        </lb>"Isolated polynucleotide" is by the origin,<lb>
        </lb>(1) Also in nature, "isolated polynucleotide" does not couple|bond with all or one part of polynucleotide recognized,<lb>
        </lb>(2) In nature, it connects with polynucleotide which has not been connected operatively,<lb>
        </lb>or<lb>
        </lb>(3) Naturally, it does not exist as a part of big arrangement|sequence.</p>
    <p n="0089" xml:id="_2ff0350466">In this specification, the term "the nucleotide which exists naturally" contains the deoxyribonucleotide and a ribonucleotide.<lb>
        </lb>In this specification, the term a "modified nucleotide" contains the nucleotide which has the sugar group (sugar group) etc. which were modified or substituted.<lb>
        </lb>The term the "oligonucleotide binding" mentioned by this specification includes oligonucleotide bindings, such as a phosphorothioate, a phosphoro dithioate, phosphoroselenoate, phosphorodiselenoate, phosphoroanilothioate, a phosphor annealer date, and phosphoroamidate.<lb>
        </lb>LaPlanche et al. [ for example, ] by whom the indication is integrated in this specification by the reference,<lb>
        </lb>Nucl.Acids Res., 14:9081(1986);Stec et al., J.Am.Chem.Soc., 106:6077(1984);Stein et al.,<lb>
        </lb>Nucl.Acids Res., 16:3209(1988);Zon et al., Anti-Cancer Drug Design, 6:539(1991);Zon et al., Oligonucleotides and Analogues:APractical Approach, pp.87 - 108 (F. Eckstein knitting|edition, Oxford University Press, U.K. Oxford (1991));<lb>
        </lb>US Patent 5,151,510;<lb>
        </lb>Please refer Uhlmann and Peyman, Chemical Reviews, 90:543(1990).<lb>
        </lb>Oligonucleotide may include the label|marker for a detection as needed.</p>
    <p n="0090" xml:id="_2ff0350475">the expression regulatory sequence which adjoins the gene which the arrangement|sequence "connected operatively" makes object, and a trans|transformer -- or both of expression regulatory sequences which adjust the gene which is work|functioned in the distant place and made into object are included.</p>
    <p n="0091" xml:id="_2ff0350476">The term as used herein an "expression regulatory sequence" means a polynucleotide sequence required for the expression of a coding sequence and the implementation of processing which were connected with it.<lb>
        </lb>The suitable transcription|transfer start for an expression regulatory sequence, a conclusion, a promoter, and enhancer arrangement|sequence;<lb>
        </lb>RNA processing signal with the sufficient efficiency of splicing, the polyadenylation signal, etc.;<lb>
        </lb>Arrangement|sequence which stabilizes cytoplasm mRNA;<lb>
        </lb>Arrangement|sequence which improves translation efficiency (namely, Kozak consensus sequence);<lb>
        </lb>Arrangement|sequence which improves protein stability;<lb>
        </lb>And when desiring, there exists an arrangement|sequence which raises protein secretion.<lb>
        </lb>The properties of such a regulatory sequence differ according to a host organism;<lb>
        </lb>Generally in a prokaryote, such a regulatory sequence has a promoter, a ribosome binding site, and a transcription termination arrangement|sequence;<lb>
        </lb>Generally in an eukaryote, such a regulatory sequence has a promoter and a transcription termination arrangement|sequence.<lb>
        </lb>The term a "regulatory sequence" shall contain at a minimum all the structural components with the presence indispensable for an expression and processing.<lb>
        </lb>The further structural component that becomes advantageous by the presence, for example, a leader sequence, and a fusion partner arrangement|sequence can also be included.</p>
    <p n="0092" xml:id="_2ff0350488">The term as used herein a "vector" means the nucleic acid molecule which can convey the other nucleic acid which is by bonding|connecting with it.<lb>
        </lb>In some embodiment, a vector is a plasmid, i.e., the DNA piece of a cyclic|annular double strand which can connect the further DNA segment in it.<lb>
        </lb>In some embodiment, a vector is viral vector and can connect the further DNA segment in the viral genome.<lb>
        </lb>In some embodiment, the vector can perform autonomous reproduction in the host cell into which it is introduce|transduced (For example, the bacterial vector and episome mammal vector which have a bacterial replication starting point).<lb>
        </lb>In other embodiment, after introduce|transducing a vector (for example, non-episome mammal vector) in a host cell, it can be integrated in the genome of a host cell, and it is replicated by it together with a host genome.<lb>
        </lb>Furthermore, the specific vector can induce|guide|derive the expression of the gene operatively connected with it.<lb>
        </lb>Such a vector is called a "recombinant expression vector" (or simply "expression vector") in this specification.</p>
    <p n="0093" xml:id="_2ff0350495">The term as used herein a "recombinant host cell" (or simply "host cell") means the cell into which it recombines in it and the expression vector is introduce|transduced.<lb>
        </lb>Please understand that a "recombinant host cell" and a "host cell" mean not only a specific object cell but the offspring|progeny of such a cell.<lb>
        </lb>A specific change may arise in the next generation under mutation or environmental influence,<lb>
        </lb>Therefore<lb>
        </lb>Such offspring|progeny may not actually be the same as that of a parent cell,<lb>
        </lb>However,<lb>
        </lb>It is still contained in the range of the term the "host cell" in this specification.</p>
    <p n="0094" xml:id="_2ff0350502">In this specification, the term a "germ-line" points out the nucleotide sequence of the antibody gene and gene segment which are transmitted from parents to offspring|progeny through a reproductive cell.<lb>
        </lb>The arrangement|sequence of this germ-line is distinguished with the nucleotide sequence which codes the antibody in a mature B cell which is changing with recombination and the phenomena of highly frequent mutation between the mature processes of a B cell.</p>
    <p n="0095" xml:id="_2ff0350504">In connection with a nucleic acid sequence, when aligning the term "% sequence identity" so that an equivalence|correspondence may become the maximum, it means the residue during two same arrangement|sequences.<lb>
        </lb>More generally the length of a comparison of sequence identity is at least about 32 nucleotides more typically at least about 28 nucleotides at least about 24 nucleotides at least about 18 nucleotides at least about 9 nucleotides,<lb>
        </lb>Preferably it may be longer than at least about 36 and a succession of 48 nucleotides or more.<lb>
        </lb>There exists a different algorithm of some which can be used for the measurement of nucleotide sequence identity and which are known for this technical field.<lb>
        </lb>For example, FASTA, Gap, or Bestfit which is a program in the Wisconsin Package 10.0th edition, Genetics Computer Group(GCG), and Wisconsin state Madison is used,<lb>
        </lb>A polynucleotide sequence can be compared.<lb>
        </lb>For example, FASTA containing the programs FASTA2 and FASTA3 provides the alignment and % sequence identity of a best overlapping region between a question arrangement|sequence and a search arrangement|sequence.<lb>
        </lb>(Pearson, Methods Enzymol. which are integrated in this specification by the reference,<lb>
        </lb>183:63-98(1990);Pearson, Methods Mol.Biol.,<lb>
        </lb>132:185-219(2000);Pearson, Methods Enzymol., 266:227-258(1996);Pearson, J.Mol.Biol., 276:71-84 (1998)).<lb>
        </lb>As long as there is no special designation|designated, a specific program or the initialization parameter of an algorithm is used.<lb>
        </lb>For example, % sequence identity between nucleic acid sequences uses FASTA with the initialization parameter (Word size is a NOPAM factor (NOPAM factor) about 6 and a score matrix.),<lb>
        </lb>Or it can determine using Gap with the initialization parameter provided by the GCG 6.1st edition integrated in this specification by reference.</p>
    <p n="0096" xml:id="_2ff0350517">As long as there is no special designation|designated in reference to a nucleotide sequence, the complementary body is included.<lb>
        </lb>Therefore, please understand that the complementary strand which has the complementary sequence is included for reference to the nucleic acid which has a specific arrangement|sequence.</p>
    <p n="0097" xml:id="_2ff0350519">The term "substantial similarity" or "substantial sequence similarity" when mentioning a nucleic acid or its fragment|piece is about 85% of at least of a nucleotide base, when it is made to align optimal with another nucleic acid (or the complementary strand) using insertion or deletion of suitable nucleotide,<lb>
        </lb>Preferably it is at least about 90 %,<lb>
        </lb>It means that there exists identity of a nucleotide sequence by 97%, 98% or 99% at least about 95 % and 96% more preferably,<lb>
        </lb>It is measured by the arbitrary sequence identity algorithms which are common knowledge of FASTA and BLAST which were discussed above, Gap, etc.</p>
    <p n="0098" xml:id="_2ff0350523">In connection with an amino acid sequence, when aligning the term "% sequence identity" so that an equivalence|correspondence may become the maximum, it means the residue during two same arrangement|sequences.<lb>
        </lb>Generally the length of a comparison of sequence identity at least about 5 amino acids At least about 20 amino acids,<lb>
        </lb>More generally it may be further more typically longer at least about 30 amino acids than about 150 and a succession of 200 amino acids or more at least about 100 amino acids more typically at least about 50 amino acids.<lb>
        </lb>There exists a different algorithm of some which can be used for the measurement of amino-acid-sequence identity and which are known for this technical field.<lb>
        </lb>For example, FASTA, Gap, or Bestfit which is a program in the Wisconsin Package 10.0th edition, Genetics Computer Group(GCG), and Wisconsin state Madison is used,<lb>
        </lb>An amino acid sequence can be compared.</p>
    <p n="0099" xml:id="_2ff0350529">When applying to polypeptide, the term "substantial identity" or "substantial similarity",<lb>
        </lb>When two amino acid sequences make it align optimal by the program GAP or BESTFIT using the weight of the initialization gap supplied with the program, it is sequence identity of 70%, 75% or 80% at least,<lb>
        </lb>Preferably it is sequence identity of at leaset 90% or 95%,<lb>
        </lb>It means, having sequence identity of 97%, 98% or 99% at least more preferably.<lb>
        </lb>In specific embodiment, the position of the residue which is not the same changes with conservative amino acid substitution.</p>
    <p n="0100" xml:id="_2ff0350534">"Conservative amino acid substitution" is substituted in this specification by the other amino acid residue in which an amino acid residue has the side chain R group to which chemical property (for example, an electric charge or hydrophobicity) was similar.<lb>
        </lb>Generally, in conservative amino acid substitution, a protein functional characteristic does not change substantially.<lb>
        </lb>When an at least two amino acid sequence mutually changes with conservative substitution, % sequence identity can be adjusted upwards and a substituted conservative property can be corrected.<lb>
        </lb>A means to perform this adjustment is known to an expert.<lb>
        </lb>For example, please refer Pearson, Methods Mol.Biol., 243:307-31(1994).<lb>
        </lb>In the example of the group of an amino acid which has the side chain to which chemical property was similar, they are 1 aliphatic-side-chain:glycine, alanine, valine, a leucine, and isoleucine;<lb>
        </lb>2) Aliphatic hydroxyl side chain : serine and threonine;<lb>
        </lb>3) Amide|amido containing side chain : asparagine and glutamine;<lb>
        </lb>4) Aromatic side chain : phenylalanine, tyrosine, and tryptophan;<lb>
        </lb>5) Basic side chain;<lb>
        </lb>A lysine|ricin, arginine, and histidine;<lb>
        </lb>6) Acidic side chain : aspartic acid and glutamic acid;<lb>
        </lb>and<lb>
        </lb>7) Sulfur containing side chain : there exist cysteine and methionine.<lb>
        </lb>For example, the groups of conservative amino acid substitution may be valine- leucine-isoleucine, phenylalanine tyrosine, leucine- arginine, alanine-valine-, glutamic acid-aspartic acid and asparagine- glutamine.</p>
    <p n="0101" xml:id="_2ff0350549">Or conservative substitution is arbitrary changes which become a positive value in PAM250 log-likelihood procession currently indicated by Gonnet et al. and Science, 256:1443-45(1992).<lb>
        </lb>Substitution "conservative medium|moderate" is arbitrary changes which become a value which is not negative in PAM250 log-likelihood procession.</p>
    <p n="0102" xml:id="_2ff0350551">The sequence similarity of polypeptide is normally measured using a sequence-analysis software.<lb>
        </lb>Using the scale of the similarity allocated to various substitution including conservative amino acid substitution, deletion, and another modification, a protein analysis software adjusts an arrangement|sequence.<lb>
        </lb>For example, GCG uses it with the initialization parameter designated by the program including programs, such as "Gap" and "Bestfit",<lb>
        </lb>A sequence homology or sequence identity can be determined between polypeptide relevant to close contact of biological-origin homologous polypeptide of different seed|species, etc., or between wild-type protein and its homologue.<lb>
        </lb>For example, please refer the GCG 6.1st edition (University of Wisconsin, Wisconsin state).<lb>
        </lb>FASTA which uses the parameter which is initialization or is recommended can be used, and a polypeptide sequence can also be compared.<lb>
        </lb>Please refer the GCG 6.1st edition.<lb>
        </lb>FASTA (for example, FASTA2 and FASTA3) provides the alignment and % sequence identity of a best overlapping region between a question arrangement|sequence and a search arrangement|sequence.<lb>
        </lb>(Pearson, Methods Enzymol., 183:63-98(1990);Pearson, Methods Mol.Biol., 132:185-219(2000)).<lb>
        </lb>Another algorithm preferable when the arrangement|sequence of a database and this invention including many arrangement|sequences originating in various living organism|raw_foods is compared is the computer program BLAST which uses the initialization parameter supplied with a program,<lb>
        </lb>It is especially blastp or tblastn.<lb>
        </lb>For example, please refer Altschul et al., J.Mol.Biol., 215:403-410(1990);Altschul et al., Nucleic Acids Res., 25:3389-402(1997).</p>
    <p n="0103" xml:id="_2ff0350563">The length of the polypeptide compared about homology will usually be at least about 16 amino acid residue,<lb>
        </lb>Generally it becomes at least about 20 residues,<lb>
        </lb>More generally it becomes at least about 24 residues,<lb>
        </lb>Typically, it becomes at least about 28 residues,<lb>
        </lb>It becomes the length over about 35 residues preferably.<lb>
        </lb>When searching a database including the biological-origin arrangement|sequence from which many differ, it is preferable to compare an amino acid sequence.</p>
    <p n="0104" xml:id="_2ff0350569">In this specification, "a label|marker (label)" or the term of "having label|marked" (labeled) points out the built-in of the other molecule|numerator in an antibody.<lb>
        </lb>In one Embodiment, a label|marker is a detectable marker,<lb>
        </lb>For example, it is a coupling|bonding of a biotinyl part and polypeptide detectable by the built-in of the radiolabeled amino acid, or the avidin (For example, streptavidine including a fluorescent marker or enzyme activity detectable with optical means or a colorimetric method) which put the mark.<lb>
        </lb>In other embodiment, the thing, for example, the drug conjugate, or toxin regarding a treatment may be sufficient as a label|marker or a marker.<lb>
        </lb>The various methods of label|marking polypeptide and glycoprotein are learned for this technical field, and a thing using the same is made.<lb>
        </lb>Although not restricted to the example of the label|marker for polypeptide so,<lb>
        </lb>Some are following:<lb>
        </lb>A radioisotope or a radionuclide (For example, &lt;3&gt;H, &lt;14&gt;C, &lt;15&gt;N, &lt;35&gt;S, &lt;90&gt;Y, &lt;99&gt;Tc, &lt;111&gt;In, and &lt;125&gt;I, &lt;131&gt;I),<lb>
        </lb>Fluorescent labeling (For example, FITC, rhodamine, a lanthanide phosphorescent substance), enzyme label (For example, a Western horseradish peroxidase, the beta-galactosidase, a luciferase, an alkaline phosphatase), chemiluminescent marker, and biotinyl group, the predetermined polypeptide epitope (For example, the arrangement|sequence of the pair of a leucine zipper, the coupling|bond-region of a secondary antibody, a metallic bond domain, an epitope tag) recognized by the secondary reporter,<lb>
        </lb>Toxins, such as magnetic action substances, such as gadolinium chelate, and a pertussis toxin, a taxol, the cytochalasin B, the gramicidin D, the ethidium bromide, an emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, a doxorubicin, the daunorubicin,<lb>
        </lb>Dideoxy anthra- sin|syn dione, a mitoxantrone, the mithramycin, actinomycin D, 1-dehydro testosterone, a glucocorticoid, procaine, a tetracaine, a lidocaine, a propranolol, a puromycin and its analog, or the homologue.<lb>
        </lb>In some embodiment, a label|marker is couple|bonded by the spacer arm of various length, and potential steric hindrance is reduced.</p>
    <p n="0105" xml:id="_2ff0350581">"Treatment-effective quantity" refers to the quantity of the active substance for a treatment in which 1 or several symptom of the disorder|damage|failure to treat is thereby relieve|moderated to some extent or more and to administer.<lb>
        </lb>Treatment-effective quantity refers to the quantity which has at least 1 among the following effects regarding the treatment of cancer:<lb>
        </lb>The fall of tumor size; inhibition (Namely, a certain amount of delay,<lb>
        </lb>Preferably it stopped.) of a tumor metastasis; a certain amount of inhibition (Namely, a certain amount of delay,<lb>
        </lb>Preferably it stopped.) of tumor proliferation, and a certain amount of relief|moderation of 1 or several symptom related to cancer<lb>
        </lb>or<lb>
        </lb>Preferably it lose|disappeared.</p>
    <p n="0106" xml:id="_2ff0350588">"treating" and "treatment" "to treat" (treat) refer to the method of relieve|moderating or suppressing the symptom which accompanies a biological disorder|damage|failure and/or it.<lb>
        </lb>It means that the life expectancy of the individual suffered from cancer only extends these terms regarding cancer, or 1 or several symptom of a disease is reduced.</p>
    <p n="0107" xml:id="_2ff0350590">With "a contact (Contacting)", it points out mixing the antibody of this invention, the antigen binding part and a target P-cadherin, or its epitope in the form where an antibody can exert influence on the biological activity of P-cadherin.<lb>
        </lb>It is "in vitro", namely, can perform such a "contact" in a test tube, a Petri dish, etc.<lb>
        </lb>In a test tube, since only an antibody, the antigen binding part and P-cadherin, or its epitope is concerned in a contact, the whole cell may involve.<lb>
        </lb>It can be made to be able to maintain or propagate in a cell culture plate, and a cell can also be made to also contact with an antibody or its antigen binding part in the environment.<lb>
        </lb>In relation to this, before trying in-vivo use of the antibody in a more complicated living organism|raw_food, the specific antibody which exerts influence on P-cadherin related disorder|damage|failure or the capability of the antigen binding part, i.e., IC50 of an antibody, can be determined.<lb>
        </lb>About the cell out of a living organism|raw_food, the several method which P-cadherin is made to contact with an antibody or its antigen binding part exists, and it is known to an expert.</p>
    <p n="0108" xml:id="_2ff0350596">In this specification, "abnormal cell proliferation" refers to the cell growth (for example, loss of a contact inhibition) unrelated to a normal control system including the abnormal proliferation of healthy cells, and the proliferation of an abnormal cell, unless it shows specially.<lb>
        </lb>Although not restricted to this so,<lb>
        </lb>Abnormal proliferation of the tumor cells (tumor) propagated by the expression of tyrosine kinase or the overexpression of receptor tyrosine kinase which mutated;<lb>
        </lb>Abnormal proliferation of the beningnant and malignant cell of the other proliferative disease from which activation of abnormal tyrosine kinase arises;<lb>
        </lb>Abnormal proliferation of the arbitrary tumor propagated by receptor tyrosine kinase;<lb>
        </lb>Abnormal proliferation of the arbitrary tumor propagated by activation of abnormal serine / threonine kinase;<lb>
        </lb>Abnormal proliferation of the beningnant and malignant cell of the other proliferative disease from which activation of abnormal serine / threonine kinase arises;<lb>
        </lb>Abnormal proliferation of the tumor of both the benignancy in which the activation Ras oncogene is expressing, and malignancy;<lb>
        </lb>Abnormal proliferation of the tumor cells of both the benignancy by which Ras protein was activated as a result of the carcinogenic mutation in another gene, and malignancy;<lb>
        </lb>The abnormal proliferation of the beningnant and malignant cell of the other proliferation disease from which abnormal Ras activation arises is included.<lb>
        </lb>The examples of such a benign proliferative disease are psoriasis, a benign prostatic hypertrophy, a human papilloma virus (HPV), and restenosis.<lb>
        </lb>"Abnormal cell proliferation" also points out the abnormal proliferation of the cell of both the benignancy which arises from the activity of enzyme farnesyl protein transferase, and malignancy, and contains it.</p>
    <p n="0109" xml:id="_2ff0350608">The term "abnormal cell proliferation" and "hyperproliferation disorder" is used as that which is compatible in this application.</p>
    <p n="0110" xml:id="_2ff0350609">Although not restricted only to it with "in vitro", for example,<lb>
        </lb>The procedure followed in artificial environments, such as inside of a test tube or a culture medium, is pointed out.</p>
    <p n="0111" xml:id="_2ff0350611">Although not restricted only to it with "in vivo",<lb>
        </lb>The procedure followed within living organism|raw_foods, such as a mouse|mouth, a rat, and a rabbit, is pointed out.</p>
    <head xml:id="_2ff0350613">PREFERRED EMBODIMENT OF THE INVENTION</head>
    <p n="0112" xml:id="_2ff0350614">Human P-cadherin antibody<lb>
        </lb>This invention relates to the isolation human antibody couple|bonded with a human P-cadherin, or its antigen binding part.<lb>
        </lb>Preferably, a human antibody is a recombinant human P-cadherin antibody which has large affinity with respect to P-cadherin from E-cadherin.<lb>
        </lb>Various aspects of this invention are related also with such an antibody, an antigen binding part, and its pharmaceutical composition also at the nucleic acid, recombinant expression vector, and host cell for producing such an antibody and an antigen binding part.<lb>
        </lb>Using the antibody and antigen binding part of this invention, in vitro or the method of detecting a human P-cadherin in vivo or inhibiting human P-cadherin activity is also included by this invention.</p>
    <p n="0113" xml:id="_2ff0350619">The amino acid and nucleotide sequence including a human of P-cadherin originating in several seed|species are known.<lb>
        </lb>(For example, accession number NM_001793.3 was referred.).<lb>
        </lb>A human P-cadherin or its antigenic part can also be prepared in accordance with a known method to an expert, or can also be purchased from a commercial dealer (For example, R&amp;D Systems 861-PC-100).</p>
    <p n="0114" xml:id="_2ff0350622">In specific embodiment, the antibody of this invention is IgG called 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09;200-h06;g-194-b09;g-194-g09;g-196-g03;g-196-h02;g-194-e01;g-194-e06;129-1c4; and g-129-1c4.<lb>
        </lb>The high-throughput ability screening of scFv phage display library was used, 129-1c4scFv was identified, and it was converted into IgG after that so that it might discuss further in detail in Example 1.<lb>
        </lb>129-1c4 is a parent antibody of the system|strain which was corresponded to the read|lead antibody identified between the first phage display screenings, and some other antibodies of this invention derived.<lb>
        </lb>Some antibodies derived like that are called 194-e06;194-a02;194-b09;195-e11;194-g09;196-h02;194-e01;196-d10;196-g03;196-e06;195-a09;198-a09; and 200-h06, and are corresponded to the antibody optimized within the 129-1c4 parent line|system.<lb>
        </lb>g-129-1c4 antibody is a 129-1c4 parent antibody of a germ-line-ized type|mold,<lb>
        </lb>The specific amino acid in the framework region of VH and VL domain mutates, and it adjusts with the amino acid in a germ-line framework region.<lb>
        </lb>The arbitrary, above mentioned antibodies can also be germ-line-ized,<lb>
        </lb>As a result, a framework region arrangement|sequence becomes the same as that of a germ-line framework region similarly to g-129-1c4.<lb>
        </lb>For example, in one Embodiment of this invention, an antibody g-194-b09, g-194-g09, g-196-g03, g-196-h02, g-194-e01, g-195-e11, g-200-h06 and g-194-e06 are respectively 194-b09, 194-g09, 196-g03, 196-h02, 194-e01, 195-e11, 200-h06 of a germ-line-ized type|mold, and 194-e06.<lb>
        </lb>The specific amino acid which mutated and reached the germ-line-ized type|mold becomes clear to an expert by performing an arrangement|sequence comparison of a germ-line-ized antibody opposite non-germ-line-ized antibody.<lb>
        </lb>The specific amino acid sequence of the antibody of this invention is described in Tables 1-3 and FIG. 1 so that it may discuss below.</p>
    <p n="0115" xml:id="_2ff0350633">The strong deflection|deviation towards utilization of the VH3 gene family of a heavy-chain variable region was given, and the antibody of this invention was produced|generated.<lb>
        </lb>Specifically, the 129-1c4 parent antibody was derived from the VH3-23 variable gene segment.<lb>
        </lb>There exist more than 30 separate functional heavy-chain variable genes in a human B cell, and it produces|generates an antibody using it.<lb>
        </lb>Therefore, a deflection|deviation suggests preferable binding motif of interaction of an antibody and an antigen regarding the characteristic which combined a coupling|bonding and function activity with an antigen.</p>
    <p n="0116" xml:id="_2ff0350637">Although it will be understood, only a general view to which the structure of the antibody was restricted brings about a gene utilization analysis.<lb>
        </lb>Although it does not restrict when a human B cell produces|generates a V-D-J heavy-chain transcription|transfer material or a V-J(kappa) light chain transcription|transfer material stochastic so,<lb>
        </lb>Some secondary processes including somatic-cell highly frequent mutation, n addition, and CDR3 extension|expansion are performed.<lb>
        </lb>For example, please refer the USA publication patent application 2003-0070185 for which it applied to Mendez et al., Nature Genetics, 15:146-156 (1997), and 2002/2/19.<lb>
        </lb>Therefore, in order to further investigate the structure of the antibody of this invention, the estimation amino acid sequence of the antibody was produced|generated from cDNA obtained from the clone.<lb>
        </lb>Furthermore, the N terminal amino acid sequence was acquired by a protein sequencing.<lb>
        </lb>In FIG. 1, the arrangement|sequence of nucleotide of the heavy chain of some antibodies of this invention and a light chain variable region and an amino acid is shown.</p>
    <p n="0117" xml:id="_2ff0350644">Specific, above mentioned each antibody can be described by the variable domain sequence of the heavy chain (VH) and light chain (VL) which are shown by Table 1 and 2.<lb>
        </lb>The specific arrangement|sequence which these sequence number points out is shown in FIG. 1.<lb>
        </lb>As shown to Table 1 and 2, the amino acid and DNA sequence of VH and VL to which the above mentioned antibody respond|corresponds are described by sequence number 1 - 23, 68-90, and 320-343.</p>
    <p n="0118" xml:id="_2ff0350647">
        <figure xml:id="_2ff0350649">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0119" xml:id="_2ff0350650">
        <figure xml:id="_2ff0350652">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0120" xml:id="_2ff0350653">The further antibody and antigen binding part of this invention can also be described as a thing including various CDR and FR arrangement|sequence which also form the heavy chain and light chain variable region of an antibody which are shown by Table 1 and 2.<lb>
        </lb>Therefore, various CDR of the antibody of this invention and sequence number corresponding to FR arrangement|sequence are shown in Table 3.<lb>
        </lb>Furthermore, the heavy chain of a 129-1c4 parent antibody and randomization mutation of many in light chain CDR3 area|region are also implemented,<lb>
        </lb>Thereby, P-cadherin affinity improves,<lb>
        </lb>The 10 to 417 time as many improvements measured by the epitope competitive assay (refer Example 8) were attained to.<lb>
        </lb>These sequence number (Sequence number 91 - 256, and 257-319) of VH and VL CDR3 sequence that mutated is also contained in following Table 3.</p>
    <p n="0121" xml:id="_2ff0350659">
        <figure xml:id="_2ff0350661">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0122" xml:id="_2ff0350662">Method to produce an antibody<lb>
        </lb>Phage display library<lb>
        </lb>The antibody or antigen binding part of this invention can be prepared in accordance with some methods known for this technical field.<lb>
        </lb>For example, using a phage display technique, the library which affinity with respect to P-cadherin comes out variously, and contains the repertory of a certain antibody can be provided.<lb>
        </lb>Subsequently, such library can be screened, and the antibody which has desired affinity with respect to P-cadherin can be identified and isolated.</p>
    <p n="0123" xml:id="_2ff0350667">For example, the recombinant human P-cadherin antibody of this invention can be isolated by screening a recombinant combinatorial antibody library.<lb>
        </lb>Preferably, library is scFv phage display library produced|generated using human VL and VHcDNA which were prepared from mRNA isolated from the human B cell.<lb>
        </lb>The method of preparing and screening such library is known for this technical field.<lb>
        </lb>The kit which produces|generates phage display library is marketed.<lb>
        </lb>(For example, Pharmacia Recombinant Phage Antibody System, the catalog number 27-9400-01;<lb>
        </lb>And a Stratagene SurfZAP (trademark) phage display kit, the catalog number 240612).<lb>
        </lb>There also exist the other method and reagent which can be used by the production|generation of antibody display library and screening (For example, US Patent 5,223,409;<lb>
        </lb>The PCT publication|presentation WO92/18619, WO91/17271, WO92/20791, WO92/15679, WO93/01288, WO92/01047 and WO92/09690;<lb>
        </lb>Fuchs et al., Bio/Technology, 9:1370-1372(1991);Hay et al., Hum.Antibod.Hybridomas, 3:81-85(1992);Huse et al.,<lb>
        </lb>Science, 246:1275-1281(1989);McCafferty et al., Nature, 348:552-554(1990);Griffiths et al.,<lb>
        </lb>EMBO J., 12:725-734(1993);Hawkins et al., J.Mol.Biol., 226:889-896(1992);Clackson et al.,<lb>
        </lb>Refer Nature, 352:624-628(1991);Gram et al., Proc.Natl.Acad.Sci.USA, 89:3576-3580(1992);Garrad et al., Bio/Technology, 9:1373-1377(1991);Hoogenboom et al., Nuc.Acid Res., 19:4133-4137(1991);Barbas et al., Proc.Natl.Acad.Sci.USA, 88:7978-7982(1991);, Griffiths et al., and the EMBO J., 13:3245-3260(1994);<lb>
        </lb>These are all integrated in this specification by the reference.).</p>
    <p n="0124" xml:id="_2ff0350680">The other method of preparing the library of the antibody used with a phage display technique,<lb>
        </lb>The step which carries out the immunity sensitization of the non-human animal containing a human immuno-globulin gene locus in P-cadherin or its antigenic part, and produces an immune response,<lb>
        </lb>The step which isolates RNA which codes the heavy chain and light chain of an antibody of this invention from the step which extracts an antibody producing cell from the animal which carried out the immunity sensitization, and the extracted cell,<lb>
        </lb>The step which reversely transcripts RNA and produces cDNA, the step which amplifies cDNA using a primer, and the step which inserts cDNA in a phage display vector so that an antibody may express on a phage are included.<lb>
        </lb>It is not necessary to immortalize the B cell derived from the animal which carried out the immunity sensitization in preparation of such a repertory.<lb>
        </lb>Rather, the first B cell can be directly used as a supply source of DNA.<lb>
        </lb>It was obtained from the B cell, for example, the mixture of cDNA originating in spleen is used,<lb>
        </lb>An expression library, for example, the phage display library transfected in E. coli, is prepared.<lb>
        </lb>Finally the clone of the library which produces the binding affinity of the desired magnitude|size with respect to an antigen is identified, DNA which codes the product which is concerned in such a coupling|bonding is collect|recovered and treated, and a standard recombinant expression is performed.<lb>
        </lb>Phage display library can be constructed|assembled using the nucleotide sequence treated previously, and it can also be screened in a similar form.<lb>
        </lb>Generally, cDNA which codes the heavy chain and a light chain forms Fv analog for being supplied independently, or connecting them and producing in phage library.<lb>
        </lb>Subsequently, affinity with respect to P-cadherin screens phage library about the antibody which is a maximum, and it collect|recovers genetic materials from a suitable clone.<lb>
        </lb>The screening of the further frequency|count can raise affinity of the isolated original antibody.</p>
    <p n="0125" xml:id="_2ff0350693">In one Embodiment, in order to isolate and produce the human P-cadherin antibody which has the desired characteristics, the human P-cadherin antibody as described in this specification is used initially,<lb>
        </lb>The human heavy chain and light chain sequence which have a similar binding activity with respect to P-cadherin using the epitope imprinting method of PCT publication|presentation WO93/06213 integrated in this specification by the reference are selected.<lb>
        </lb>The antibody library used with this method,<lb>
        </lb>PCT publication|presentation WO92/01047, McCafferty et al. by which the all are preferably integrated in this specification by reference,<lb>
        </lb>It is the scFv library prepared and screened as described in Nature, 348:552-554(1990);, Griffiths et al., and EMBO J., 12:725-734(1993).<lb>
        </lb>A human P-cadherin can be used as an antigen and a scFv antibody library can be screened.<lb>
        </lb>Affinity with respect to P-cadherin screens phage library about the antibody which is a maximum, and it collect|recovers genetic materials from a suitable clone.<lb>
        </lb>The screening of the further frequency|count can raise affinity of the isolated original antibody.</p>
    <p n="0126" xml:id="_2ff0350701">The first human VL and VH domain were selected,<lb>
        </lb>Then, a pair with initially selected VL and various VH segments is screened about the coupling|bonding of P-cadherin,<lb>
        </lb>"Mixing and adjustment" experiment which selects the preferable combination of a VL/VH pair can be conducted.<lb>
        </lb>After this mixing and adjustment experiment mutate VH and VL segment at random as described in the following and also optimize a coupling|bonding, they can also be conducted.<lb>
        </lb>Furthermore, VL and VH segment (some) of a VL/VH pair preferable in order to raise the quality of an antibody,<lb>
        </lb>Preferably, it is a process of the in-vivo somatic mutation which is concerned in the affinity maturation of the antibody during natural-immunity response, and a similar process, and can also make it mutate at random in the CDR3 area|region of VH and/or VL.<lb>
        </lb>This in-vitro affinity maturation for example,<lb>
        </lb>By amplifying VH and VL domain using the PCR primer complementary to VHCDR3 or VLCDR3, respectively, can implement|achieve and the primer,<lb>
        </lb>So that the acquired PCR product may code VH and VL segment by which random mutation is introduce|transduced in VH and/or VLCDR3 area|region.<lb>
        </lb>The "spike" is contained in the specific position with the random mixture of four nucleotide bases.<lb>
        </lb>These VH and VL segments that mutated at random can be again screened about a coupling|bonding with P-cadherin, and the arrangement|sequence which shows high affinity and the low dissociation speed|rate with respect to P-cadherin can be selected.<lb>
        </lb>As discussed above, it mutates at random,<lb>
        </lb>Some VH and VL CDR3 sequence of this invention which showed the affinity improvement are shown by sequence number 91 - 256, and 257-319.</p>
    <p n="0127" xml:id="_2ff0350714">P-cadherin antibody of this invention was screened and isolated from recombinant immuno-globulin display library,<lb>
        </lb>Then, the nucleic acids which code the selected antibody are collect|recovered from a display package for example, from a phage genome,<lb>
        </lb>It can subclone in another expression vector by standard recombinant DNA technology.<lb>
        </lb>As needed, a nucleic acid can further be processed as described in the following, and the other antibody type|mold of this invention can be produced.<lb>
        </lb>In order to make the recombinant human antibody isolated by the screening of combinatorial library as described in the following express, DNA which codes an antibody is recombined and it clones in an expression vector,<lb>
        </lb>It introduce|transduces in a host cell.</p>
    <p n="0128" xml:id="_2ff0350720">Immunity sensitization<lb>
        </lb>In other embodiment, a human P-cadherin antibody is producible by carrying out the immunity sensitization of the non-human transgenic animal which contains part or all of the human immuno-globulin heavy chain and a light chain gene seat in the genome with P-cadherin antigen.<lb>
        </lb>For example, the XenoMouse (trademark) animal (Abgenix, Inc., California state Fremont) may be sufficient as a non-human animal.</p>
    <p n="0129" xml:id="_2ff0350723">A XenoMouse (trademark) mouse|mouth is a system|strain of the mouse|mouth produced in engineering, and production of a mouse antibody is lose|deleting it including the human immuno-globulin heavy chain and the big fragment|piece of a light chain gene seat.<lb>
        </lb>For example, please refer Green et al., Nature Genetics,<lb>
        </lb>7:13-21 (1994), US Patent 5,916,771, 5,939,598, 5,985,615, 5,998,209, 6,075,181, 6,091, 001, 6,114,598, 6,130,364, 6,162,963, and 6,150,584.<lb>
        </lb>Please also refer WO91/10741, WO94/02602, WO96/34096, WO96/33735, WO98/16654, WO98/24893, WO98/50433, WO99/45031, WO99/53049, WO00/09560 and WO00/037504.</p>
    <p n="0130" xml:id="_2ff0350727">The method currently indicated in these articles is changeable like US Patent 5,994,619 integrated in this specification by the reference.<lb>
        </lb>US Patent 5,994,619 has described about the method of producing the gene transfer CICM cell in which the novel culture|cultivation inner-cell-mass (CICM) cell and cell lineage originating in an pig|lid and a female cow, and different kind|species DNA are inserted.<lb>
        </lb>A CICM gene transfer cell can be used and the transgenic embryo, the fetus, and offspring|progeny who cloned can be produced.<lb>
        </lb>The patent of '619 is described also about the method of also producing the transgenic animal which can transmit different kind|species DNA to the offspring|progeny.<lb>
        </lb>A rat, a sheep, an pig|lid, a goat, a cow, a hen, and a horse are among the examples of the non-human animal which can be used by these methods.</p>
    <p n="0131" xml:id="_2ff0350732">A XenoMouse (trademark) mouse|mouth produces the adult -like human repertory of a fully human antibody, and produces|generates an antigen-specific human antibody.<lb>
        </lb>In some embodiment, a XenoMouse (trademark) mouse|mouth contains about 80% of human antibody V gene repertoire by introduce|transducing the germ-line structure fragment|piece of human heavy chain locus in a yeast artificial chromosome (YAC) of mega base size, and (kappa) light chain gene seat.<lb>
        </lb>In other embodiment, a XenoMouse (trademark) mouse|mouth further contains the human (lambda) light chain gene seat of almost all.<lb>
        </lb>Please refer Mendez et al. by whom the indication is integrated in this specification by the reference, Nature Genetics, 15:146-156(1997), Green, Jakobovits, J.Exp.Med., 188:483-495(1998), and WO98/24893.</p>
    <p n="0132" xml:id="_2ff0350736">In some embodiment, the non-human animal containing a human immuno-globulin gene is an animal which has the human immuno-globulin "mini-gene locus."<lb>
        </lb>By the method of a mini gene locus, an exogenous Ig gene locus is copied by including each gene of Ig gene locus.<lb>
        </lb>Therefore, 1 or several VH gene, 1 or several DH gene,<lb>
        </lb>1 or several JH gene, (micro|micron|mu) constant domain, and a 2nd constant domain (preferably (gamma) constant domain) are formed in the construct for insertion in an animal.<lb>
        </lb>This method is described in US Patent 5,545,807, 5,545,806, 5,569,825, 5,625,126, 5,633,425, 5,661,016, 5,770,429, 5,789,650, 5,814,318, 5,591,669, 5,612,205, 5,721,367, 5,789,215 integrated in this specification by the reference, and 5,643,763.</p>
    <p n="0133" xml:id="_2ff0350741">Subsequently, the immunity sensitization of the non-human animal as described in the above can be carried out with P-cadherin antigen on the conditions which make an antibody production possible as described in the following.<lb>
        </lb>An antibody producing cell is isolated from an animal and the nucleic acid which codes the heavy chain and light chain of P-cadherin antibody which are made into object is isolated from the immortalized cell system|strain produced from the isolated antibody producing cell or such a cell.<lb>
        </lb>Then, using the technique known by the expert, these nucleic acids are produced in engineering so that it may further describe below, the quantity of a non-human arrangement|sequence is reduced, namely, an antibody is humanized, and the immune response in a human is reduced.</p>
    <p n="0134" xml:id="_2ff0350744">In some embodiment, P-cadherin isolated and/or refine|purified may be sufficient as P-cadherin antigen.<lb>
        </lb>In some embodiment, P-cadherin antigen is a human P-cadherin.<lb>
        </lb>In other embodiment, the cell which expresses or overexpresses P-cadherin may be sufficient as P-cadherin antigen.<lb>
        </lb>In other embodiment, P-cadherin antigen is the recombinant protein which recombined from bacteria, such as yeast, an insect cell, and colon_bacillus|E._coli, or another supply source, and was made to express with a technique.<lb>
        </lb>The immunity sensitization of an animal may be based on the arbitrary methods known for this technical field.<lb>
        </lb>For example, please refer Harlow and Lane, Antibodies:A Laboratory Manual, New York:Cold Spring Harbor Press(1990).<lb>
        </lb>The method of carrying out the immunity sensitization of the non-human animals, such as a mouse|mouth, a rat, a sheep, a goat, an pig|lid, a cow, and a horse, is known at this technical field.<lb>
        </lb>For example, please refer Harlow, Lane, the above, and US Patent 5,994,619.<lb>
        </lb>For example, P-cadherin antigen can be administered with the adjuvant which irritate|stimulates an immune response.<lb>
        </lb>There exists completeness or an incomplete Freund (Freund) adjuvant, RIBI (muramyl dipeptide), or ISCOM (immunostimulation composite_body|complex) in an illustrative adjuvant.<lb>
        </lb>Such an adjuvant can protect it from rapid dispersion|distribution by isolating polypeptide in a local deposit,<lb>
        </lb>Or an adjuvant may contain the substance which secretes the factor which irritate|stimulates a host and has a chemotaxis for the other structural component of a macrophage and an immune system.<lb>
        </lb>Preferably, when administering polypeptide, the plan of the immunity sensitization includes two administration or more of polypeptide made scattered over some weeks.</p>
    <p n="0135" xml:id="_2ff0350757">For example, the immunity sensitization of the transgenic animal as described in the above was carried out by P-cadherin,<lb>
        </lb>Then, a primary cell (for example, spleen or a peripheral blood B cell) can be isolated from the transgenic animal which carried out the immunity sensitization, and each cell which produces a specific antibody to a desired antigen can be identified.<lb>
        </lb>Subsequently, polyadenylation mRNA derived from each each cell is isolated,<lb>
        </lb>Reverse transcription polymerase chain reaction (RT-PCR) is performed using a variable domain array and the sense primer (For example, the degenerate primer which recognizes most or all of FR1 area|region of the human heavy chain and a light chain variable-region gene and the antisense primer which regular or it anneals with a connection area|region arrangement|sequence) to anneal.<lb>
        </lb>Subsequently, cDNA of a heavy-chain and light chain variable domain is cloned,<lb>
        </lb>The constant domain of the heavy chain, and (kappa) or (lambda), etc. make it express in arbitrary appropriate host cells, for example, a myeloma cell, as a chimeric antibody which has each immuno-globulin constant region.<lb>
        </lb>Please refer Babcook et al. and Proc.Natl.Acad.Sci.USA, 93:7843-48, (1996) which are integrated in this specification by reference.<lb>
        </lb>Subsequently, P-cadherin antibody can be identified and isolated as described in this specification.</p>
    <p n="0136" xml:id="_2ff0350765">The recombinant method for producing an antibody<lb>
        </lb>The antibody or antibody part of this invention can be prepared by the recombinant expression of an immuno-globulin light-heavy chain gene in a host cell.<lb>
        </lb>For example, in order to make an antibody express by recombination, 1 or several recombinant expression vector which has a DNA fragment which codes the immuno-globulin light chain and heavy chain of an antibody is transfected to a host cell,<lb>
        </lb>As a result, a light chain and heavy chain expresses in a host cell,<lb>
        </lb>Preferably it is secreted in the culture medium by which the host cell is cultured in it, and antibodies can be collect|recovered from the culture medium.<lb>
        </lb>Sambrook by which the indication is integrated in this specification by the reference,<lb>
        </lb>Fritsch, Maniatis (knitting|edition), Molecular Cloning;A Laboratory Manual,<lb>
        </lb>Although it describes in the 2nd edition, New York state Cold Spring Harbor(1989), Ausubel,F.M. et al. (knitting|edition), Current Protocols in Molecular Biology, Greene Publishing Associates(1989), and US Patent 4,816,397, standard recombinant DNA method [ like ] is used,<lb>
        </lb>The heavy chain and light chain gene of an antibody are obtained,<lb>
        </lb>These genes are recombined, and it integrates in an expression vector, and introduce|transduces a vector in a host cell.</p>
    <p n="0137" xml:id="_2ff0350775">Mutation and modification|change<lb>
        </lb>In order to make P-cadherin antibody of this invention express, either of the methods as described in the above is used,<lb>
        </lb>The DNA fragment which codes VH and VL area|region can be obtained initially.<lb>
        </lb>The standard method known by the expert can be used and various mutation, deletion, and/or addition can also be introduce|transduced in a DNA sequence.<lb>
        </lb>For example, the nucleotide which mutated can be integrated in a PCR primer and mutagenesis can be performed using the standard methods a PCR product includes desired mutation as a result, such as PCR mediational|mediated mutagenesis and site-specific mutagenesis.<lb>
        </lb>For example, the substitution of one type|mold which can be performed is although 1 or several cysteine in an antibody which may have the reactivity chemically is not restricted only to it,<lb>
        </lb>It is making it change to other residues, such as alanine and serine.<lb>
        </lb>For example, there may exist substitution of non-standard cysteine.<lb>
        </lb>It is in CDR of the variable domain of an antibody, or a framework region, or can substitute in a constant domain.<lb>
        </lb>In some embodiment, cysteine is standard.</p>
    <p n="0138" xml:id="_2ff0350785">An antibody can be mutated in the variable domain of the heavy chain and/or a light chain, for example, the binding characteristic of an antibody can also be changed.<lb>
        </lb>For example, mutation is raise|generated in 1 or several CDR region,<lb>
        </lb>KD of the antibody with respect to P-cadherin is increased or reduced,<lb>
        </lb>Koff is increased or reduced,<lb>
        </lb>Or binding specificity of an antibody can be changed.<lb>
        </lb>The technique of site-specific mutagenesis is known at this technical field.<lb>
        </lb>For example, please refer Sambrook et al. and Ausubel et al. which are integrated in this specification by the reference, and the above.<lb>
        </lb>For example, according to the procedure discussed above, many 129-1c4 parents' variation|mutation VH and VL CDR3 sequence are produced so that it may discuss further in detail in Example 8,<lb>
        </lb>It is shown as sequence number 91 - 256 (VHCDR3 variant) in FIG. 1, and sequence number 257 - 319 (VLCDR3 variant).</p>
    <p n="0139" xml:id="_2ff0350794">Mutation can be raise|generated in a framework region or a constant domain, and the half life of P-cadherin antibody can also be extended.<lb>
        </lb>For example, please refer PCT publication|presentation WO00/09560 integrated in this specification by the reference.<lb>
        </lb>Mutation is raise|generated in a framework region or a constant domain,<lb>
        </lb>The immunogenicity of an antibody is changed,<lb>
        </lb>A covalent bond with another molecule|numerator or a noncovalent bond site|part is brought about,<lb>
        </lb>Or characteristics, such as a complement fixation, a FcR coupling|bonding, and antibody-dependent cell mediated cytotoxicity effect (ADCC), can also be changed.<lb>
        </lb>according to this invention, a single antibody is in 1 or several arbitrary CDR of a variable domain, or a framework region -- it is -- you may have mutation in a constant domain.</p>
    <p n="0140" xml:id="_2ff0350801">At the process known as "germ-line-izing", VH and the specific amino acid during VL arrangement|sequence are mutated,<lb>
        </lb>It can be made to adjust with the amino acid which is arranging germ-line VH and VL and is recognized naturally.<lb>
        </lb>Specifically, the amino acid sequence of the framework region during VH and VL arrangement|sequence is mutated,<lb>
        </lb>An immunogenic risk when it is made to adjust with a germ-line arrangement|sequence and an antibody is administered can be reduced.<lb>
        </lb>The germ-line DNA sequence of human VH and VL gene is known for this technical field.<lb>
        </lb>(For example, a "Vbase" human germ-line sequence database should be referred.;<lb>
        </lb>I would like to also refer Kabat, E.A. et al., (1991)Sequences of Proteins of Immunological Interest, the 5th edition, U.S.Department of Health and Human Services, NIH Publication No.91-3242;Tomlinson et al., (1992), J.Mol.Biol., 227:776-798;, Cox et al., and Eur.J.Immunol., 24:827-836(1994);<lb>
        </lb>Especially each of the content is integrated in this specification by the reference.).</p>
    <p n="0141" xml:id="_2ff0350809">The other type|mold amino acid substitution which can be performed is removing the potential proteolytic site|part in an antibody.<lb>
        </lb>Such a site|part is in CDR of the variable domain of an antibody, or a framework region, or may arise in a constant domain.<lb>
        </lb>By the substitution of a cysteine residue, and the removal of a proteolytic site|part, the risk of the different type of an antibody product can be reduced, therefore the property of the same kind can be increased.<lb>
        </lb>Another type|mold amino acid substitution is removing the pair of asparagine- glycine which forms a potential deamidization site|part by changing the one or both of the residue.<lb>
        </lb>In another example, the lysine|ricin in the C terminal of the heavy chain of P-cadherin antibody of this invention can be cut|disconnected.<lb>
        </lb>In various embodiment of this invention, the heavy chain and light chain of P-cadherin antibody may also include N terminal signal sequences, such as what is shown by sequence number 346 and 347.</p>
    <p n="0142" xml:id="_2ff0350815">After obtaining the DNA fragment which codes VH and VL segment of this invention, these DNA fragments are further processed by standard recombinant DNA technology,<lb>
        </lb>For example, a variable-region gene is convertible into a full-length antibody chain|strand gene at a Fab fragment gene or a scFv gene.<lb>
        </lb>In these processes, the DNA fragment which codes VL or VH is operatively connected with the other DNA fragment which codes other proteins, such as a constant region of an antibody, and a flexible linker.<lb>
        </lb>The term used in this context of "connecting operatively" shall mean that 2 of DNA fragment connects so that the amino acid sequence coded by two DNA fragments may continue being in-frame (inch-frame).</p>
    <p n="0143" xml:id="_2ff0350819">Isolation DNA which codes VH area|region is convertible into a full-length heavy chain gene by connecting operatively DNA which codes VH with the other DNA molecule which codes a heavy chain constant region (CH1, CH2, and CH3).<lb>
        </lb>The arrangement|sequence of the human heavy chain constant region gene is known for this technical field (For example, please refer Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest,<lb>
        </lb>The 5th edition, U.S.Department of Health and Human Services, NIH Publication No.91-3242.), and the DNA fragment which includes these area|regions can be obtained by standard PCR amplification.<lb>
        </lb>Although the constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD may be sufficient as a heavy chain constant region,<lb>
        </lb>Most preferably, it is a constant region of IgG1 or IgG2.<lb>
        </lb>Arbitrary various alleles or the allotype by which different things which it is interpersonal and are produced, such as Gm (1), Gm (2), Gm (3), and Gm (17), are known may be sufficient as an IgG1 constant-region arrangement|sequence.<lb>
        </lb>These allotypes are corresponded to the amino acid substitution which exists in the nature in IgG1 constant region.<lb>
        </lb>For example, sequence number 344 may be sufficient as heavy-chain IgG1 constant region.<lb>
        </lb>In a Fab fragment heavy chain gene, DNA which codes VH can be operatively connected with the other DNA molecule which codes only a heavy-chain CH1 constant region.<lb>
        </lb>A CH1 heavy chain constant region may originate in arbitrary heavy chain genes.</p>
    <p n="0144" xml:id="_2ff0350829">Isolation DNA which codes VL area|region,<lb>
        </lb>DNA which codes VL is convertible into a full-length light chain gene (and Fab light chain gene) by connecting with the other DNA molecule which codes light chain constant area|region CL operatively.<lb>
        </lb>The arrangement|sequence of human light chain constant region gene is known for this technical field (For example, please refer Kabat, E.A. et al. (1991) Sequences of Proteins of Immunological Interest,<lb>
        </lb>The 5th edition, U.S.Department of Health and Human Services, NIH Publication No.91-3242.), and the DNA fragment which includes these area|regions can be obtained by standard PCR amplification.<lb>
        </lb>The constant region of (kappa) or (lambda) may be sufficient as a light chain constant area|region.<lb>
        </lb>Arbitrary various alleles by which a different thing which it is interpersonal and is produced is known, such as Inv (1), Inv (2), and Inv (3), may be sufficient as (kappa) constant region.<lb>
        </lb>(lambda) constant region may originate in either of three (lambda) genes.<lb>
        </lb>For example, sequence number 347 may be sufficient as light chain IgG1 constant region.</p>
    <p n="0145" xml:id="_2ff0350837">In order to produce a scFv gene, a flexible linker is coded for the DNA fragment which codes VH and VL, for example, it connects with the other fragment|piece which codes the amino acid sequence (Gly4-Ser)3 operatively,<lb>
        </lb>As a result, it can be made to express as continuous single-chain protein which has VL and VH area|region which connected VH and VL arrangement|sequence by the flexible linker (For example, Bird et al., Science, 242:423-426 (1988);<lb>
        </lb>Huston et al., Proc.Natl.Acad.Sci.USA, 85:5879-5883 (1988);<lb>
        </lb>Please refer McCafferty et al., Nature, and 348:552-554 (1990).).<lb>
        </lb>When using only single VH and VL, a unit price may be sufficient as a single-chain antibody,<lb>
        </lb>Bivalence may be sufficient when using two VH and VL,<lb>
        </lb>Or polyvalent may be sufficient when using more VL than two and VH.<lb>
        </lb>The bispecificity or the polyvalent antibody specifically couple|bonded with P-cadherin and another molecule|numerator is generable.</p>
    <p n="0146" xml:id="_2ff0350845">In other embodiment, the fusion antibody or immune adherence molecule containing all or one part of P-cadherin antibody of this invention connected with other polypeptide is producible.<lb>
        </lb>Only the variable domain of P-cadherin antibody is connected with polypeptide in other embodiment.<lb>
        </lb>At other embodiment, VH domain of P-cadherin antibody is connected with 1st polypeptide in the form which VH and VL domain mutually interact and can form an antigen binding site,<lb>
        </lb>On the other hand, VL domain of P-cadherin antibody is connected with 1st polypeptide and united 2nd polypeptide.<lb>
        </lb>Subsequently, a VH-linker VL antibody is connected with the polypeptide made into object.<lb>
        </lb>In other preferable embodiment, a linker isolate|separates VH domain with VL domain,<lb>
        </lb>As a result, VH and VL domain can mutually interact.<lb>
        </lb>Furthermore, the fusion antibody which the two single-chain (more than) antibody mutually connected is producible.<lb>
        </lb>This is useful to produce a bispecific antibody when you want to produce bivalence or a multivalent antibody on a single polypeptide chain|strand.</p>
    <p n="0147" xml:id="_2ff0350854">In other embodiment, the nucleic acid molecule which codes P-cadherin antibody can be used, and another modified antibody can be prepared.<lb>
        </lb>For example, teaching of this specification can be received and "Kappa body" (Ill et al., Protein Eng., 10:949-57 (1997)), "Minibody" (Martin et al., EMBO J., 13:5303-9 (1994)),<lb>
        </lb>"Diabody" (Holliger et al. and Proc.Natl.Acad.Sci.USA --)<lb>
        </lb>90:6444-6448 (1993), or "Janusin" (Traunecker et al., EMBO J., 10:3655-3659 (1991), and Traunecker et al.)<lb>
        </lb>Int.J.Cancer, 7:51 (Suppl.)-52 (1992) can be prepared using a standard molecular-biological technique.</p>
    <p n="0148" xml:id="_2ff0350859">With various methods including fusion of a hybridoma, or connection of the Fab' fragment|piece, a bispecific antibody or an antigen binding fragment is producible.<lb>
        </lb>For example, please refer Songsivilai&amp;Lachmann, Clin.Exp.Immunol., 79:315-321(1990), Kostelny et al., J.Immunol., 148:1547-1553(1992).<lb>
        </lb>Furthermore, a bispecific antibody can be formed as "diabody" or "Janusin."<lb>
        </lb>A bispecific antibody couple|bonds with the 2 different epitope of P-cadherin in some embodiment.<lb>
        </lb>In some embodiment, 1 or several variable domain or CDR region derived from the human P-cadherin antibody provided by this specification can be used, and the modified antibody as described in the above can be prepared.</p>
    <p n="0149" xml:id="_2ff0350864">A vector and a host cell<lb>
        </lb>In order to make the antibody and antigen binding part of this invention express, DNA which was obtained as described in the above and which is partial or codes the light chain and heavy chain of full-length is inserted in an expression vector,<lb>
        </lb>As a result, a gene connects with transcription|transfer and a translational-control arrangement|sequence operatively.<lb>
        </lb>In this context, the term of "connecting operatively" connects an antibody gene in a vector,<lb>
        </lb>As a result, the transcription|transfer in a vector and a translational-control arrangement|sequence shall mean fulfill|performing the intended function which controls transcription|transfer and translation of an antibody gene.<lb>
        </lb>An expression vector and an expression regulatory sequence are selected so that it may adapt with the host cell for an expression to be used.<lb>
        </lb>There exist plant viruses, such as a plasmid, a retrovirus, adenovirus, an adeno-associated virus (AAV), cauliflower mosaic virus, and a tobacco mosaic virus, a cosmid, YAC, an EBV origin episome, etc. in an expression vector.<lb>
        </lb>The intended function in which connect an antibody gene in a vector and the transcription|transfer in a vector and a translational-control arrangement|sequence, as a result, control transcription|transfer and translation of an antibody gene is fulfill|performed.<lb>
        </lb>An expression vector and an expression regulatory sequence are selected so that it may adapt with the host cell for an expression to be used.<lb>
        </lb>An antibody light chain gene and an antibody heavy chain gene can be inserted in a separate vector.<lb>
        </lb>In preferable embodiment, both of genes are inserted in the same expression vector.<lb>
        </lb>An antibody gene is inserted in an expression vector by standard method (For example, when connection of the complementary restriction site and vector on an antibody-gene fragment|piece or a restriction site does not exist, it is flush-end connection.).</p>
    <p n="0150" xml:id="_2ff0350876">Convenient vectors are VH arbitrary as described in the above.<lb>
        </lb>Or functionally perfect human CH or CL immuno-globulin arrangement|sequence which has the suitable restriction site produced in engineering so that VL arrangement|sequence could be inserted easily and could be made to express is coded.<lb>
        </lb>In such a vector, splicing occurs also in the splice area|region which is between the splice donor site in inserted J area|region, and the splice acceptor site preceded with a human C domain, and exists in a human CH exon normally.<lb>
        </lb>Polyadenylation and transcription termination occur by the natural chromosome site|part which exists downstream from a coding region.<lb>
        </lb>The recombinant expression vector can also code the signal peptide which accelerates|stimulates secretion of the antibody chain|strand derived from a host cell.<lb>
        </lb>An antibody chain|strand gene can be cloned in a vector so that signal peptide may connect with the amino terminal of an immuno-globulin chain|strand by in-frame.<lb>
        </lb>Immuno-globulin signal peptide may be sufficient as signal peptide, or the different type signal peptide (Namely, signal peptide derived from non-immuno-globulin protein) may be sufficient as it.</p>
    <p n="0151" xml:id="_2ff0350883">In addition to an antibody chain|strand gene, the recombinant expression vector of this invention has a control sequence which adjusts the expression of the antibody chain|strand gene in a host cell.<lb>
        </lb>It will be understood by the expert that it may be dependent on factors, such as selection of the host cell which design of an expression vector transforms, and a protein expression level for which it desires, including selection of a control sequence.<lb>
        </lb>In a control sequence preferable to a host_mammalian_cell expression,<lb>
        </lb>The retrovirus LTR, a cytomegalovirus (CMV) (CMV promoter/enhancer etc.),<lb>
        </lb>Simian virus 40 (Simian Virus 40) (SV40) (SV40 promoter/enhancer etc.),<lb>
        </lb>A promoter, an enhancer, etc. originating in adenovirus (For example, adenovirus main late promoter (AdMLP)) and polyoma,<lb>
        </lb>There exists a mammal promoter with the virus element which induces|guides|derives the high level protein expression in a mammalian cell and a natural immuno-globulin, a strong promoter of actin, etc.<lb>
        </lb>Please refer US Patent 5,168,062, US Patent 4,510,245, and US Patent 4,968,615 for a virus controllable element and the further description of the arrangement|sequence, for example.<lb>
        </lb>The methods of making an antibody express in a plant including description of the transformation of a promoter, a vector, and a plant are known for this technical field.<lb>
        </lb>For example, please refer US Patent 6,517,529 integrated in this specification by the reference.<lb>
        </lb>The method of making polypeptide express in a bacteria cell or a fungi cell, for example, a yeast cell, is also known at this technical field.</p>
    <p n="0152" xml:id="_2ff0350894">In addition to an antibody chain|strand gene and a control sequence, the recombinant expression vector of this invention may have the further arrangement|sequence of the arrangement|sequence (for example, replication starting point) which controls replication of the vector in a host cell, a selective-marker gene, etc.<lb>
        </lb>A selective-marker gene accelerates|stimulates selection of the host cell into which the vector is introduce|transduced.<lb>
        </lb>(For example, please refer US Patent 4,399,216 integrated in this specification by the reference, and 4,634,665 and 5,179,017.).<lb>
        </lb>For example, a selective-marker gene provides the tolerance with respect to medicines, such as G418, a hygromycin, and a methotrexate, normally on the host cell into which the vector is introduce|transduced.<lb>
        </lb>Dehydro folic acid reductase (DHFR) gene (It is used with methotrexate selection / amplification by a dhfr-host cell.), a neomycin phosphotransferase gene (for G418 selection), and a glutamate synthesis enzyme gene are one of preferable selective-marker genes.</p>
    <p n="0153" xml:id="_2ff0350899">The vector containing the nucleic acid molecules which code P-cadherin antibody, and these nucleic acid molecules can be used for the transfection of an appropriate mammal, a plant, bacteria, or a yeast host cell.<lb>
        </lb>Transformation may depend a polynucleotide on the arbitrary methods of being known introduce|transduced in a host cell.<lb>
        </lb>The method to introduce|transduce a different type polynucleotide in a mammalian cell is known at this technical field,<lb>
        </lb>It has micro injection|pouring directly [ of enclosure of the polynucleotide to the inside of a dextran mediational|mediated transfection, calcium-phosphate precipitation, a polybrene mediational|mediated transfection, protoplast fusion, electroporation, and a liposome (some), and DNA to the inside of a nucleus ].<lb>
        </lb>Furthermore, a nucleic acid molecule can be introduce|transduced in a mammalian cell by viral vector.<lb>
        </lb>The method of transforming a cell is known at this technical field.<lb>
        </lb>For example, please refer US Patent 4,399,216, 4,912,040, 4,740,461 integrated in this specification by the reference, and 4,959,455.<lb>
        </lb>For example, the method of transforming plant cells including the Agrobacterium (Agrobacterium) mediational|mediated transformation, particle bombardment transformation, direct injection|pouring, electroporation, and viral transformation is known at this technical field.<lb>
        </lb>The method of transforming bacteria and a yeast cell is also known at this technical field.</p>
    <p n="0154" xml:id="_2ff0350908">The mammalian cell system|strain which can be utilized as a host for an expression is known at this technical field, and there exist many immortalized cell system|strains which can be obtained from a USA reference|standard strain preservation|save mechanism (ATCC) in it.<lb>
        </lb>In these, for example A Chinese hamster ovary (CHO) cell,<lb>
        </lb>There exist a NSO cell, SP2 cell, HEK-293 T cell, NIH-3T3 cell, a HeLa cell, a young hamster kidney (BHK) cell, an African green monkey renal cell (COS), human hepatocarcinoma cells (for example, Hep G2), an A549 cell, and some other cell lineages.<lb>
        </lb>An especially preferable cell lineage is selected by determining which cell lineage has a high expression level.<lb>
        </lb>The other cell lineages which can be used are insect cell lineages, such as Sf9 and Sf21 cell.<lb>
        </lb>When the recombinant expression vector which codes an antibody gene is introduce|transduced in a host_mammalian_cell, it is an expression of the antibody in a host cell about a host cell,<lb>
        </lb>or<lb>
        </lb>An antibody is produced by [ to enable secretion of the antibody to the inside of the culture medium which the host cell is propagating / sufficient in it more preferably ] carrying out period culture|cultivation.<lb>
        </lb>A standard protein purification method can be used and antibodies can be collect|recovered from a culture medium.<lb>
        </lb>There exist tobacco (Nicotiana), Arabidopsis thaliana (Arabidopsis), Spirodela, maize, wheat, a potato etc. in a plant host cell.<lb>
        </lb>There exist colon_bacillus|E._coli and Streptomyces seed|species in a bacteria host cell.<lb>
        </lb>There exist fission yeast (Schizosaccharomyces pombe), a budding yeast (Saccharomyces cerevisiae), and a Pichia pastoris (Pichia pastoris) in a yeast host cell.</p>
    <p n="0155" xml:id="_2ff0350920">Furthermore, some techniques known can be used and production of the antibody of this invention from a production cell lineage can be raised.<lb>
        </lb>For example, glutamine synthetase (GS type|system|group) and a DHFR gene expression system are the general methods of raising an expression on specific conditions.<lb>
        </lb>Prior arts, such as limiting-dilution cloning and a micro drop (Microdrop) technique, can be used, and a high expression cell clone can be identified.<lb>
        </lb>GS type|system|groups are EP Patent 0 216 846, 0 256 055, 0 323 997 and 0. 338 It is discussed by 841.</p>
    <p n="0156" xml:id="_2ff0350924">a different cell lineage -- or the antibody which expressed in the transgenic animal has high possibility of having a mutually different glycosylation.<lb>
        </lb>However, all antibodies including the amino acid sequence which is coded by the nucleic acid molecule provided by this specification, or is provided by this specification are a part of this invention regardless of a glycosylation of an antibody.</p>
    <p n="0157" xml:id="_2ff0350926">A transgenic animal and a plant<lb>
        </lb>P-cadherin antibody of this invention is also producible by a gene transfer through generation|occurrence|production of the mammal or plant which also gene-transferred the immuno-globulin heavy chain and light chain sequence which are made into object, and production of the antibody in a form recoverable from it.<lb>
        </lb>Regarding production by the gene transfer in a mammal, P-cadherin antibody can be produced in the milk of a goat, a female cow, or another animal, and can be collect|recovered.<lb>
        </lb>For example, please refer US Patent 5,827,690, 5,756,687, 5,750,172 integrated in this specification by the reference, and 5,741,957.<lb>
        </lb>At some embodiment, the immunity sensitization of the non-human transgenic animal which contains a human immuno-globulin gene locus as described in the above is carried out in P-cadherin or its immunogenic part.<lb>
        </lb>The method of producing an antibody in a plant is described in US Patent 6,046,037 integrated in this specification by the reference, and 5,959,177, for example.</p>
    <p n="0158" xml:id="_2ff0350932">In some embodiment, a non-human transgenic animal or a plant is produced by introduce|transducing 1 or several nucleic acid molecule which codes P-cadherin antibody of this invention, or its antigen binding part in an animal or a plant with standard gene transfection technology.<lb>
        </lb>Please refer said Hogan and US Patent 6,417,429.<lb>
        </lb>An embryonic stem cell, a somatic cell, or a fertilized egg may be sufficient as the gene transfer cell used for preparation of a transgenic animal.<lb>
        </lb>The heterozygote of a chimera and a non-chimera and the homozygote of a non-chimera may be sufficient as a gene transfer non-human living organism|raw_food.<lb>
        </lb>For example, please refer Hogan et al. and Manipulating the Mouse Embryo:A Laboratory Manual by which all are integrated in this specification by the reference, the 2nd edition, Cold Spring Harbor Press(1999);Jackson et al., Mouse Genetics and Transgenics:A Practical Approach, Oxford University Press(2000);, and Pinkert, Transgenic Animal Technology:A Laboratory Handbook, Academic Press(1999).<lb>
        </lb>In some embodiment, a gene transfer non-human animal has the target destruction and substitution by the targeting construct which codes the heavy chain and/or light chain which are made into object.<lb>
        </lb>P-cadherin antibody is producible in arbitrary transgenic animals.<lb>
        </lb>In preferable embodiment, a non-human animal is a mouse|mouth, a rat, a sheep, an pig|lid, a goat, a cow, or a horse.<lb>
        </lb>A non-human transgenic animal expresses the coded said polypeptide in the blood, the milk, urine, a saliva, tears, a viscous fluid, and another bodily fluid.</p>
    <p n="0159" xml:id="_2ff0350941">Class switch<lb>
        </lb>By the arbitrary methods known for this technical field, the class (For example, IgG, IgM, IgE, IgA, or IgD) and subclass (For example, IgG1, IgG2, IgG3, or IgG4) of P-cadherin antibody can be determined.<lb>
        </lb>Generally, a specific antibody can be used for the specific class and subclass of an antibody, and the class and subclass of an antibody can be determined.<lb>
        </lb>Such an antibody is marketed.<lb>
        </lb>A class and a subclass can be determined with ELISA or a western blotting, and another technique.<lb>
        </lb>Or a class and a subclass determine the arrangement|sequence of all or one part of the constant domain of the heavy chain of an antibody, and/or a light chain,<lb>
        </lb>The amino acid sequence is compared with the known amino acid sequence of various classes of an immuno-globulin, and a subclass,<lb>
        </lb>It can also determine by determining the class and subclass of an antibody.<lb>
        </lb>IgG, IgM, IgE, IgA or an IgD molecule|numerator may be sufficient as P-cadherin antibody of this invention.<lb>
        </lb>For example, IgG1, IgG2, IgG3 or IgG which is IgG4 subclass may be sufficient as P-cadherin antibody.<lb>
        </lb>In one Embodiment, P-cadherin antibody may have a heavy chain constant region shown by sequence number 344, and a light chain constant area|region shown by sequence number 345.</p>
    <p n="0160" xml:id="_2ff0350952">1 aspect of this invention provides the method of converting the class or subclass of P-cadherin antibody into another class or subclass.<lb>
        </lb>In some embodiment, the nucleic acid molecule which codes VL or VH which does not include the arrangement|sequence which codes CL or CH is isolated by this technical field using a known method.<lb>
        </lb>Subsequently, it connects with the nucleic acid sequence which codes CL or CH derived from a class or a subclass of an immuno-globulin for which it desires a nucleic acid molecule operatively.<lb>
        </lb>This is realizable using the vector or nucleic acid molecule which contains CL or CH chain|strand as described in the above.<lb>
        </lb>For example, the origin can carry out the class switch of the P-cadherin antibody which was IgM to IgG.<lb>
        </lb>Furthermore, a class switch can be used and one IgG subclass can be converted into another thing, for example from IgG1 IgG2.<lb>
        </lb>The other method of producing the antibody of this invention containing the isotype for which it desires,<lb>
        </lb>The step which isolates the nucleic acid which codes the light chain of the nucleic acid which codes the heavy chain of P-cadherin antibody, and P-cadherin antibody,<lb>
        </lb>The step which isolates the arrangement|sequence which codes VH area|region,<lb>
        </lb>The step connecting with the arrangement|sequence which codes the heavy chain constant domain of the isotype for which it desires VH arrangement|sequence, the step which makes the construct of a light chain gene and the heavy chain express in a cell, and the step which collects P-cadherin antibodies which have an isotype for which it desires are included.</p>
    <p n="0161" xml:id="_2ff0350962">The de- immunity reagin<lb>
        </lb>In the other aspect of this invention, the technique described, for example (the reference integrates in this specification) in PCT publication|presentation WO98/52976 and WO00/34317 is used,<lb>
        </lb>The de- immunity sensitization of an antibody or its antigen binding part is carried out,<lb>
        </lb>The immunogenicity can be reduced.</p>
    <p n="0162" xml:id="_2ff0350966">Derivatization and a labeled antibody<lb>
        </lb>P-cadherin antibody or the antigen binding part of this invention is derivatized, or it can connect with another molecule|numerator (for example, another peptide or protein).<lb>
        </lb>Generally, an antibody or its part is derivatized so that the coupling|bonding of P-cadherin may not be received by derivatization or label|marker.<lb>
        </lb>Therefore, the antibody and antibody part of this invention shall contain both human P-cadherin antibodies as described in this specification of a perfect form and the modified form.<lb>
        </lb>The antibody and antibody part of this invention For example, the other antibody (For example, a bispecific antibody or diabody),<lb>
        </lb>Protein or a peptide etc. which can carry the part of the active substance for a detection, a label|marker, a cytotoxicity effect substance, pharmaceutical active substance and/or an antibody, or an antibody, and the coupling|bonding of other molecule|numerator (The streptavidine core area|region, polyhistidine-tag, etc.),<lb>
        </lb>It can connect with 1 or several other molecule|numerator component and a (A chemical bond, a gene fusion, a noncovalent bond, or the other method) function target.</p>
    <p n="0163" xml:id="_2ff0350973">The derivatization antibody of one type|mold is produced by bridge|crosslinking a (A type|mold which is the same type|mold, or is different in order to produce a bispecific antibody) at least two antibody.<lb>
        </lb>There exists the thing (For example, m-maleimide benzoyl- N-hydroxysuccinimide ester) which has two group which was isolate|separated by the suitable spacer, and which reacts separately and which is hetero bifunctionality, or a thing (for example, disuccinimidyl suberate) which is homo bifunctionality in an appropriate crosslinking agent.<lb>
        </lb>Such a linker can be obtained from Pierce Chemical Company and Illinois state Rockford.</p>
    <p n="0164" xml:id="_2ff0350976">The other type|mold derivatization antibody is a labeled antibody.<lb>
        </lb>A fluorescent compound including fluorescein, a fluorescein isothiocyanate, rhodamine, a chlorination 5-dimethylamine 1-naphthalene sulfonyl, a phycoerythrin, a lanthanide phosphorescent substance etc. is among the useful active substance for a detection which can derivatize the antibody or antigen binding part of this invention.<lb>
        </lb>An antibody can also be label|marked with a useful enzyme to the detection of a Western horseradish peroxidase, beta-galactosidase, a luciferase, an alkaline phosphatase, glucose oxidase, etc.<lb>
        </lb>When it label|marks with the enzyme which can detect an antibody, it is detected by adding the further reagent that produces the reaction product which uses an enzyme and can be identified.<lb>
        </lb>For example, when the Western horseradish peroxidase of active substance exists and hydrogen peroxide and a diamino benzidine are added, the colored reaction product arises and it is detectable.<lb>
        </lb>An antibody can be label|marked with a biotin and can also be detected through the indirect measurement of the coupling|bonding of an avidin or streptavidine.<lb>
        </lb>An antibody can also be label|marked with the predetermined polypeptide epitope (For example, the arrangement|sequence of the pair of a leucine zipper, the coupling|bond-region of a secondary antibody, a metallic bond domain, an epitope tag) recognized by the secondary reporter.<lb>
        </lb>In some embodiment, a label|marker is couple|bonded by the spacer arm of various length, and potential steric hindrance is reduced.<lb>
        </lb>P-cadherin antibody can also be derivatized by polyethyleneglycol (PEG), methyl or an ethyl group, and chemical groups, such as carbohydrate group.<lb>
        </lb>Such groups are useful for the improvement of the biological feature of an antibody, for example, extension of a serum half life.</p>
    <p n="0165" xml:id="_2ff0350986">The binding affinity of P-cadherin antibody with respect to P-cadherin<lb>
        </lb>The binding affinity (KD) and dissociation speed|rate (Koff) of P-cadherin antibody with respect to P-cadherin or its antigen binding part can be determined by the method known for this technical field.<lb>
        </lb>A binding affinity can be measured by surface plasmon resonance, such as ELISA, RIA, a flow cytometry or BIACORE (trademark).<lb>
        </lb>A dissociation speed|rate can be measured by surface plasmon resonance.<lb>
        </lb>Preferably, a binding affinity and a dissociation speed|rate are measured by surface plasmon resonance.<lb>
        </lb>More preferably, a binding affinity and a dissociation speed|rate are measured using BIACORE (trademark).<lb>
        </lb>By using the method known for this technical field, it can be determined whether it has KD as P-cadherin antibody with substantially same antibody.<lb>
        </lb>Such a method of determining KD and Koff can be used between the first screening steps and between subsequent optimization steps.</p>
    <p n="0166" xml:id="_2ff0350994">The identification of P-cadherin epitope recognized by P-cadherin antibody<lb>
        </lb>This invention couple|bonds with P-cadherin, competes or competes [ cross|intersection ] with the same epitope as the arbitrary antibodies described by Table 1 or 2, and provides the human P-cadherin antibody and/or couple|bonded with it.<lb>
        </lb>By using the method known for this technical field, it can be determined whether an antibody couple|bonds with the same epitope or carries out cross|intersection competition with P-cadherin antibody of this invention about a coupling|bonding.<lb>
        </lb>In one Embodiment, the capability of the test antibody which is made to couple|bond P-cadherin antibody of this invention with P-cadherin on saturated conditions, and is then couple|bonded with P-cadherin is measured.<lb>
        </lb>A test antibody is couple|bonded with a different epitope from P-cadherin antibody when a test antibody can couple|bond with P-cadherin in same time as P-cadherin antibody.<lb>
        </lb>However,<lb>
        </lb>A test antibody is couple|bonded with the epitope which is adjoining to the same epitope, the overlapping epitope, or the epitope which the human P-cadherin antibody couple|bonded when a test antibody cannot couple|bond with P-cadherin in same time.<lb>
        </lb>This experiment can be conducted using ELISA, RIA, BIACORE (trademark), or a flow cytometry.<lb>
        </lb>In preferable embodiment, experiment is conducted using ELISA.</p>
    <p n="0167" xml:id="_2ff0351003">Inhibition of P-cadherin activity by P-cadherin antibody<lb>
        </lb>Using some assays, P-cadherin antibody which inhibits P-cadherin activity can be identified.<lb>
        </lb>A cell aggregation assay brings about the method of measuring cell aggregation of P-cadherin dependence, for example.<lb>
        </lb>Using the cell lineage which overexpresses P-cadherin, this type|mold assay puts that cell in suspension, and forms the aggregate of P-cadherin dependence.<lb>
        </lb>Subsequently, using the aggregation assay, the capability of P-cadherin antibody which prevents this aggregation is quantified by measuring the size of the cell aggregate which arises in a state with an antibody, and the state which is not.<lb>
        </lb>Subsequently, the size of the cell aggregate as a function of P-cadherin antibody concentration can be used, and IC50 value can be determined.<lb>
        </lb>The further detail of P-cadherin dependence aggregation assay used for the measurement of IC50 value of several P-cadherin antibody at Example 4 is shown.</p>
    <p n="0168" xml:id="_2ff0351010">Using a cell-adhesion assay, the capability of P-cadherin antibody which interrupts|blocks adhesion|attachment of the receptor P-cadherin and cell which are fix|immobilized on the solid support body can also be measured.<lb>
        </lb>This type|mold assay can be implemented by fix|immobilizing P-cadherin on solid support bodies, such as a plastics, for example.<lb>
        </lb>Subsequently, the cell which overexpresses P-cadherin is adhere|attached on a solid support body through interaction between P-cadherins.<lb>
        </lb>Subsequently, the level of adhesion|attachment can be quantified in a state with P-cadherin antibody, and the state which is not.<lb>
        </lb>Subsequently, using the adhesion|attachment as a function of antibody concentration, IC50 value is determined.<lb>
        </lb>The further detail of P-cadherin dependence cell-adhesion assay used for the measurement of IC50 value of P-cadherin antibody at Example 3 is shown.</p>
    <p n="0169" xml:id="_2ff0351016">Inhibition of P-cadherin activity can also be measured using P-cadherin dependence spheroid destructive assay.<lb>
        </lb>This type|mold assay measures the capability of P-cadherin antibody which destroys the cell aggregate of P-cadherin dependence formed previously.<lb>
        </lb>IC50 value can be determined by measuring the size fall of the aggregate as a function of antibody concentration.<lb>
        </lb>The further detail of P-cadherin dependence spheroid destructive assay used for the measurement of IC50 value of P-cadherin antibody at Example 5 is shown.<lb>
        </lb>The method and assay as described in the above which determine inhibition of P-cadherin activity by various antibodies or the antigen binding part of those can be used between the first screening steps and between subsequent optimization steps.</p>
    <p n="0170" xml:id="_2ff0351021">Molecule|numerator selectivity<lb>
        </lb>The selectivity of P-cadherin antibody of this invention in comparison with other cadherins, such as E-cadherin, can be determined by this technical field using a known method.<lb>
        </lb>For example, a western blotting, a flow cytometry, ELISA, immunoprecipitation technique, or RIA can be used, and a selectivity can be determined.<lb>
        </lb>The further detail of the ELISA assay used for the measurement of the selectivity of the specific antibody with respect to P-cadherin in comparison with E-cadherin at Example 7 is shown.<lb>
        </lb>The method and assay as described in the above which determine the selectivity with respect to various antibodies or P-cadherin of the antigen binding part can be used between the first screening steps and between subsequent optimization steps.</p>
    <p n="0171" xml:id="_2ff0351026">Pharmaceutical composition and administration<lb>
        </lb>This invention relates also to the pharmaceutical composition for also treating the abnormal cell proliferation in a mammal including a human.<lb>
        </lb>It contains P-cadherin antibody as described in this specification of a quantity effective in the treatment of abnormal cell proliferation or its antigen binding part, and a pharmacologically acceptable support|carrier.</p>
    <p n="0172" xml:id="_2ff0351029">The antibody and antigen binding part of this invention are incorporable in the pharmaceutical composition suitable for administration to object.<lb>
        </lb>Usually, pharmaceutical composition contains the antibody or antigen binding part, and pharmacologically acceptable support|carrier of this invention.<lb>
        </lb>in this specification, a "pharmacologically acceptable support|carrier" adapts physiologically -- it is arbitrary and means all the solvent, a dispersion medium, coating|cover, an antibacterial agent, an antifungal, an isotonic agent, an absorption retarder, etc.<lb>
        </lb>The one part examples of a pharmacologically acceptable support|carrier are the combination, such as water, salt solution, phosphoric acid buffer salt solution, dextrose, a glycerol, and ethanol.<lb>
        </lb>In many cases, it is preferable that polyalcohols, such as an isotonic agent, for example, saccharide|sugar, and a mannitol, sorbitol, or sodium chloride is included in a composition.<lb>
        </lb>The further examples of a pharmacologically acceptable substance are a small amount of adjuvants, such as a moistening agent, a moistening agent or an emulsifier, a preservative, and a buffering agent, and it improves the shelf life or effectiveness of an antibody.</p>
    <p n="0173" xml:id="_2ff0351035">The thing of the dosage form of liquids, such as various forms (for example, liquid agent which can be inject|poured [ that injection is possible and ]), for example, a liquid agent, a dispersing agent or a suspension agent, a tablet, a pill, a powder, a liposome, and a suppository, a semi-solid, and solid may be sufficient as the composition of this invention.<lb>
        </lb>A preferable form is decided by the dosage form intended and application for a treatment.<lb>
        </lb>Usually, a preferable composition is a form of solvents which can be inject|poured so that injection is possible, such as a composition similar to what is used for the passive immunity sensitization of a human.<lb>
        </lb>A preferable dosage form is parenteral (for example, inside of intravenous, percutaneous|transdermal, intraperitoneal, and stripe|line|muscle) administration.<lb>
        </lb>In preferable embodiment, an antibody is administered by intravenous administration or injection.<lb>
        </lb>In other preferable embodiment, an antibody is administered by the inside of a stripe|line|muscle, or percutaneous|transdermal injection.<lb>
        </lb>The formulation for injection is a unit dosage form, and is an ampule which does not add or add a preservative, for example, or it can provide it with the container of two or more dosage amount.<lb>
        </lb>The composition can take forms, such as a suspension agent, a liquid agent, and an emulsion agent in oiliness or an aqueous medium, and may contain active substance for a formulation (formulatory agent), such as a suspending agent, a stabilizer, and/or a dispersing agent.<lb>
        </lb>Or an active ingredient may be a medium appropriate before use, and the form of the powder melted with the sterilized water which does not contain a pyrogen, for example may be sufficient as it.</p>
    <p n="0174" xml:id="_2ff0351044">Therapeutic composition must be abacterial and stable on condition of manufacture and storage normally.<lb>
        </lb>A composition can be formulated as another regular structure suitable for a solvent, a microemulsion agent, a dispersing agent, a liposome, or high drug concentration.<lb>
        </lb>The sterilization solvent which can be injected can be prepared by putting the antibody of required amount in a suitable solvent including one or its combination of the component enumerated above as needed, and sterile-filtering after that.<lb>
        </lb>Generally, a dispersing agent is prepared by putting an active compound in the dispersion medium used as a foundation, and the sterilization medium which contains another required component from what was enumerated to the above.<lb>
        </lb>the active ingredient + from the solution in which the preferable preparation method carried out sterilization filtration previously in the case of the sterilization powder for sterilization solvent preparation which can be injected -- it is the vacuum-drying and lyophilization|freeze-dry with which the powder of the further arbitrary desired components is obtained.<lb>
        </lb>The suitable fluidity|liquidity of a solvent is maintainable by coating|coated use of a lecithin etc., the maintenance of particle|grain size required in the case of a dispersing agent, and use of a surface active substance, for example.<lb>
        </lb>Extension of absorption of the composition which can be injected can be brought about by including in a composition the active substance which delays absorption, for example, the monostearic acid salt, and gelatin.</p>
    <p n="0175" xml:id="_2ff0351051">The antibody or antibody part of this invention can be administered by various methods known for this technical field,<lb>
        </lb>However,<lb>
        </lb>In application for many treatments, preferable administration route/form are intravenous administration in percutaneous|transdermal and a stripe|line|muscle.<lb>
        </lb>Although it will be understood by the expert, an administration route and/or a form become various according to a desired result.</p>
    <p n="0176" xml:id="_2ff0351055">In specific embodiment, the antibody composition of this invention can be prepared with the support|carrier which protects a compound from the rapid discharge|release of a controlled release formulation including graft lock|tablet, a transdermal patch, and the microcapsulation delivery type|system|group, etc.<lb>
        </lb>The biodegradability of an acetic acid ethylene vinyl, a poly anhydride, polyglycolic acid, collagen, polyorthoester, polylactic acid, etc. and a biocompatible polymer can be used.<lb>
        </lb>Generally many methods of preparing such a formulation are known by the expert.<lb>
        </lb>For example, please refer the Sustained and Controlled Release Drug Delivery Systems, J.R.Robinson knitting|edition and Marcel Dekker,Inc., New York(1978) which are integrated in this specification by the reference.</p>
    <p n="0177" xml:id="_2ff0351059">The further active compound is also incorporable in a composition.<lb>
        </lb>In specific embodiment, the inhibiting P-cadherin antibody of this invention can be formulated and/or administered simultaneously with 1 or several further active substance for a treatment.<lb>
        </lb>Although not restricted to such active substance so,<lb>
        </lb>There exists a peptide analog which inhibits the antibody couple|bonded with another target, an anti-tumor agent, an anti-angiogenic agent, signaling inhibitor, an anti- proliferation agent, a chemotherapy drug, or P-cadherin.<lb>
        </lb>Such a combination therapy may require the inhibiting P-cadherin antibody and the active substance to simultaneously administer of low dosage amount,<lb>
        </lb>The various toxicity or complication related to a single agent medical treatment which are considered are avoided by it.</p>
    <p n="0178" xml:id="_2ff0351065">The composition of this invention may contain the antibody or antigen binding part of this invention of "treatment-effective quantity" or a "prevention effective dose."<lb>
        </lb>"Treatment-effective quantity" is required dosage amount and a period, and refers to a quantity effective in implement|achieving a desired therapeutic result.<lb>
        </lb>The treatment-effective quantity of an antibody or an antigen binding part may become various according to factors, such as individual stage, age, sex and body weight, and a capability of the antibody or antibody part which induces a desired response in an individual.<lb>
        </lb>Treatment-effective quantity has an antibody or the arbitrary toxicity of an antigen binding part, or the effect useful therapeutically also won the harmful|toxic effect.<lb>
        </lb>"Prevention effective doses" is required dosage amount and a period, and refers to a quantity effective in implement|achieving a desired prevention result.<lb>
        </lb>Usually, since the administration on prevention is used in object in front of a disease or in its initial stage, a prevention effective dose may be less than treatment-effective quantity.</p>
    <p n="0179" xml:id="_2ff0351071">The administering method can be adjusted and an optimal desired response (for example, therapeutic or preventive response) can be brought about.<lb>
        </lb>For example, single bolus administration can also be performed and administration divided|segmented into some can also be performed over many hours as the urgency of the condition of a treatment shows,<lb>
        </lb>Or dosage amount can also be increased/decreased proportionally.<lb>
        </lb>When a parenteral composition is formulated by a unit dosage form with uniform dosage amount that it is easy to administer, it will become advantageous especially.<lb>
        </lb>In this specification, a unit dosage form refers to the physically separate unit for which it was suitable as unit dosage amount with respect to the mammal object treated,<lb>
        </lb>Each unit contains the active compound of the predetermined quantity calculated so that a desired therapeutic effect might be brought about with a required pharmacological support|carrier.<lb>
        </lb>Designation|designated of the unit dosage form of this invention,<lb>
        </lb>(a) Restriction|limiting intrinsic|native on P-cadherin antibody or the distinctive characteristics of the part, specific therapeutic or preventive effect implement|achieved, and technique of combining such an antibody for treatment of sensitivity in (b) individual determines,<lb>
        </lb>It is directly dependent on them.</p>
    <p n="0180" xml:id="_2ff0351080">The illustrative and non-limited range of a treatment-or-prevention effective dose of the antibody of this invention or an antibody part is 0.025-50 mg/kg,<lb>
        </lb>More preferably, it is 0.1-50 mg/kg,<lb>
        </lb>More preferably, it is 0.1-25, 0.1-10, or 0.1-3 mg/kg.<lb>
        </lb>In some embodiment, a formulation contains a 5 mg/mL antibody in sodium citrate, pH 5.5, 140 mM NaCl, and the 0.2 mg/mL buffer solution of the polysorbate 80 of 20 mM.<lb>
        </lb>The administration value should care about things variously by the type|mold and severity of illness of a state to relieve|moderate.<lb>
        </lb>About arbitrary specific object, you should adjust the concrete administering method in the process according to professional judgment of those who perform or instruct|indicate each necessity and administration of a composition,<lb>
        </lb>Please further understand that it is not what limits the range of a composition or the implementation which is illustrative as for the range of dosage amount shown by this specification, and concerns on a claim.</p>
    <p n="0181" xml:id="_2ff0351087">The other aspect of this invention provides the kit containing the composition containing P-cadherin antibody, the antigen binding part, such an antibody, or the part of this invention.<lb>
        </lb>A kit may be added to an antibody or a composition and may contain the object for a diagnosis, or the active substance for a treatment.<lb>
        </lb>A kit may also also contain the directions for use in a diagnosis or the treatment method.<lb>
        </lb>In preferable embodiment, a kit contains an antibody or a composition including the same, and the active substance for a diagnosis that can be used by the method as described in the following.<lb>
        </lb>In other preferable embodiment, a kit contains an antibody or a composition including the same, and 1 or several active substance for a treatment that can be used by the method as described in the following.</p>
    <p n="0182" xml:id="_2ff0351092">The diagnostic method to be used<lb>
        </lb>P-cadherin antibody or its antigen binding part can be used by the diagnostic method, and P-cadherin in a biological sample can be detected by in vitro or in vivo.<lb>
        </lb>Although for example, P-cadherin antibody is not restricted only to it,<lb>
        </lb>It can be used by conventional immunoassay including ELISA, RIA, a flow cytometry, an immunohistochemical analysis of a structure|tissue, a western blotting, or immunoprecipitation technique.<lb>
        </lb>P-cadherin antibody of this invention can be used and P-cadherin of a human can be detected.<lb>
        </lb>P-cadherin antibody can be used and a mouse|mouth, a rat, and P-cadherin of cynomolgus monkey (Macaca irus) can also be detected.</p>
    <p n="0183" xml:id="_2ff0351098">This invention provides the method of detecting P-cadherin in a biological sample, and its method contains the step which detects the antibody which couple|bonded the biological sample with P-cadherin antibody of this invention, and the step made to contact.<lb>
        </lb>At one Embodiment, it label|marks directly by the label|marker which can detect P-cadherin antibody.<lb>
        </lb>In other embodiment, P-cadherin antibody (primary antibody) is not label|marked but a secondary antibody combinable with P-cadherin antibody or another molecule|numerator is label|marked.<lb>
        </lb>Although it will probably be known to an expert, a secondary antibody specifically combinable with specific seed|species and the primary antibody of a class is selected.<lb>
        </lb>For example, when P-cadherin antibody is human IgG, antihuman IgG may be sufficient as a secondary antibody.<lb>
        </lb>Although not restricted to another molecule|numerator combinable with an antibody so,<lb>
        </lb>For example, there exist the protein A marketed by both from Pierce Chemical Co. and the protein G.</p>
    <p n="0184" xml:id="_2ff0351105">The label|marker suitable for an antibody or a secondary antibody is discussed above, and there exist various enzymes, a prosthetic group, a fluorescent material, a luminescent substance, and a radioactive substance in it.<lb>
        </lb>There exists a Western horseradish peroxidase, an alkaline phosphatase, beta-galactosidase, or acetylcholine esterase in the example of an appropriate enzyme,<lb>
        </lb>There exists the umbelliferone, fluorescein, a fluorescein isothiocyanate, rhodamine, the dichlorotriazinylamine fluorescein, a dansyl chloride or a phycoerythrin in the example of an appropriate prosthetic-group composite_body|complex,<lb>
        </lb>There exists a luminol in the example of a luminescent substance,<lb>
        </lb>There exists &lt;125&gt;I, &lt;131&gt;I, &lt;35&gt;S or &lt;3&gt;H in the example of an appropriate radioactive substance.</p>
    <p n="0185" xml:id="_2ff0351110">In other embodiment, P-cadherin can be assayed in a biological sample by competition immunoassay using P-cadherin reference material and the unlabel P-cadherin antibody which were label|marked by the detectable substance.<lb>
        </lb>In this assay, a biological sample, a label|marker P-cadherin reference material, and P-cadherin antibody are mixed, and the quantity of the label|marker P-cadherin reference material couple|bonded with the unlabel antibody is determined.<lb>
        </lb>The quantity of P-cadherin in a biological sample is in inverse proportion to the quantity of the label|marker P-cadherin reference material couple|bonded with P-cadherin antibody.</p>
    <p n="0186" xml:id="_2ff0351113">Immunoassay currently indicated above can be used for some the objective.<lb>
        </lb>For example, P-cadherin antibody can be used and P-cadherin can be detected in a cultured cell.<lb>
        </lb>In preferable embodiment, P-cadherin antibody is used and the quantity of P-cadherin produced by the cell processed with various compounds is determined.<lb>
        </lb>Using this method, the compound which adjusts the protein level of P-cadherin can be identified.<lb>
        </lb>In accordance with this method, the cell of one sample is processed for a while with a test compound, and, on the other hand, another sample is kept not processed.<lb>
        </lb>When measuring P-cadherin of a whole level, a cell is melt|dissolved and the whole P-cadherin level is measured using one of the immunoassay as described in the above.<lb>
        </lb>P-cadherin of the whole process cell opposite non-processing cell level is compared, and the effect of a test compound is determined.</p>
    <p n="0187" xml:id="_2ff0351120">Immunoassay preferable to the measurement of the whole P-cadherin level is a flow cytometry or an immunohistochemical analysis.<lb>
        </lb>Methods, such as ELISA, RIA, a flow cytometry, a western blotting, an immunohistochemical analysis, a cell surface label|marker of intrinsic membrane protein, and immunoprecipitation technique, are known at this technical field.<lb>
        </lb>For example, please refer Harlow, Lane, and the above.<lb>
        </lb>Furthermore, in order to test many compounds about activation or inhibition of P-cadherin expression, the scale of immunoassay is expandable to a high-throughput ability screening.</p>
    <p n="0188" xml:id="_2ff0351124">Using P-cadherin of this invention, the level of P-cadherin in the cell originating in a structure|tissue during a structure|tissue can also be determined.<lb>
        </lb>In some embodiment, a structure|tissue is a disease structure|tissue.<lb>
        </lb>In some embodiment of its method, a structure|tissue or its biopsy material is cut out from a patient.<lb>
        </lb>Subsequently, localization of the whole P-cadherin level or P-cadherin can be determined by the method which used a structure|tissue or biopsy material by immunoassay, for example, was discussed above.</p>
    <p n="0189" xml:id="_2ff0351128">The antibody of this invention can be used in vivo and the structure|tissue and organ which express P-cadherin can also be specified.<lb>
        </lb>One advantage which uses the human P-cadherin antibody of this invention is being able to use it safely in vivo, without being different with the antibody which has an antibody derived from a non-human, humanization, or a chimeric antibody, and inducing the substantial immune response with respect to an antibody after administration.</p>
    <p n="0190" xml:id="_2ff0351130">Its method contains the step which administers P-cadherin antibody label|marked so that it might become detectable, or a composition including the same to a patient with the need for such a diagnostic test, and the step which performs an imaging analysis to a patient and determines the position of P-cadherin expression structure|tissue.<lb>
        </lb>Although the imaging analysis is known in the iatrotechnique field|area and not being restricted to it so,<lb>
        </lb>X-ray analysis, magnetic resonance image forming (MRI), or computer tomography (CT) occurs.<lb>
        </lb>An antibody can be label|marked with magnetic contrast agents, such as gadolinium chelate which can be used for contrast agents, such as the arbitrary active substance suitable for in-vivo imaging, for example, the barium etc. which can be used for X-ray analysis, or MRI or CT.<lb>
        </lb>Although not restricted to the other active substance for a label|marker so,<lb>
        </lb>There exist radioisotopes, such as &lt;99&gt;Tc.<lb>
        </lb>In other embodiment, P-cadherin antibody is not label|marked but it image-forms by administering the secondary antibody which can be detected and can be couple|bonded with P-cadherin antibody, or another molecule|numerator.<lb>
        </lb>In one Embodiment, it is determined whether biopsy material is obtained from a patient and the structure|tissue which sets it as object expresses P-cadherin.</p>
    <p n="0191" xml:id="_2ff0351138">The treatment method to be used<lb>
        </lb>In other embodiment, this invention provides the method of inhibiting P-cadherin activity by administering P-cadherin antibody to a patient with the need.<lb>
        </lb>Therapeutically either the antibody as described in this specification or an antigen binding part can be used.<lb>
        </lb>In preferable embodiment, P-cadherin antibody is a human antibody, a chimeric antibody, or humanized antibody.<lb>
        </lb>In other preferable embodiment, P-cadherin is a human and a patient is a human patient.<lb>
        </lb>Or the mammal which expresses P-cadherin in which P-cadherin carries out a cross reaction may be satisfactory for a patient.<lb>
        </lb>An antibody can be administered to non-human mammal (For example, a rat, a mouse|mouth, or cynomolgus monkey (Macaca irus)) which is the veterinary objective or expresses P-cadherin in which an antibody carries out a cross reaction as animal model of a human disease.<lb>
        </lb>Such animal model may be useful although the therapeutic effect of the antibody of this invention is evaluated.</p>
    <p n="0192" xml:id="_2ff0351146">In other embodiment, P-cadherin antibody or its antibody part can be administered to the patient who expresses unsuitably high level P-cadherin.<lb>
        </lb>Although an antibody can be administered once,<lb>
        </lb>More preferably, it administers multiple times.<lb>
        </lb>An antibody can be administered at once from 3 times every six months or more on the 1st.<lb>
        </lb>s administration by 2 times on 3 times and 1, and it can perform ^ every 2 week(s) once in 1 time, 1 time per three days, and one week every two days on one on one by 1 time, 1 time per a month, 1 time per two months, 1 time per three months, or one plan per six months.<lb>
        </lb>An antibody can also be continuously administered with a mini pump.<lb>
        </lb>An antibody can be administered through the path|route within a mucous membrane path|route, an intraoral path|route, the path|route in a nose, the path|route that can be suck|inhaled, an intravenous path|route, a subcutaneous path|route, and a stripe|line|muscle, a parenteral path|route, or an intratumoral path|route.<lb>
        </lb>Once, at least 2-time or a state is treated, and an antibody can be administered for a while at least until it relieve|moderates or recovers.<lb>
        </lb>Generally, an antibody is administered, as long as a state exists.<lb>
        </lb>Generally an antibody is administered as a part of pharmaceutical composition as described in the above.<lb>
        </lb>Generally dosage amount of an antibody is 0.1-100 mg/kg,<lb>
        </lb>More preferably, it is 0.5-50 mg/kg,<lb>
        </lb>More preferably, it is 1-20 mg/kg,<lb>
        </lb>More preferably, it becomes 1-10 mg/kg.<lb>
        </lb>The serum density|concentration of an antibody can be measured by the arbitrary methods known for this technical field.</p>
    <p n="0193" xml:id="_2ff0351161">This invention relates also to the method of also treating the abnormal cell proliferation in a mammal including a human.<lb>
        </lb>Its method contains the step which carries out treatment-effective quantity administration of P-cadherin antibody as described in this specification effective in the treatment of abnormal cell proliferation, or its antigen binding part at the said mammal.</p>
    <p n="0194" xml:id="_2ff0351163">Although abnormal cell proliferation is not restricted only to it in one Embodiment of this method,<lb>
        </lb>Celothelioma, the hepatobiliary pipe|tube (liver and bile duct) tumor, the protopathic or secondary CNS tumor,<lb>
        </lb>A protopathic or secondary brain tumor, a lung cancer (NSCLC and SCLC),<lb>
        </lb>An osteocarcinoma, pancreatic cancer, skin cancer, a head-and-neck cancer, skin property or the intraocular melanoma, an ovarian cancer,<lb>
        </lb>Colon cancer, rectal cancer, the cancer of an anus area|region, stomach cancer, gastrointestines (stomach, colon and rectum, and duodenum) cancer,<lb>
        </lb>A breast cancer, a uterine cancer, oviduct cancer, endometrial cancer, a carcinoma of uterine cervix, vaginal cancer, vulva cancer, the Hodgkin's disease, an oesophageal cancer, small intestinal cancer, the cancer of an endocrine system, a thyroid cancer, parathyroid gland cancer, suprarenal-gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, a prostatic cancer, a testicular cancer, chronic, or acute leukemia,<lb>
        </lb>A chronic myeloid leukemia, a lymphocytic lymphoma, a bladder cancer, a kidney, or the cancer of the ureter,<lb>
        </lb>Renal cell carcinoma, renal pelvic carcinoma, the tumor of a central nervous system (CNS), primary CNS lymphoma,<lb>
        </lb>They are non-Hodgkin's lymphoma, the spinal-cord axis|shaft tumor, the brain stem glioma, a pituitary adenoma, adrenal cortex cancer, a gall bladder cancer, multiple myeloma, a bile duct cancer, a fibrosarcoma, a neuroblastoma, a retinoblastoma, or cancer including 1 or several combination of said cancer.</p>
    <p n="0195" xml:id="_2ff0351172">In preferable embodiment of this invention, cancer A lung cancer (NSCLC and SCLC),<lb>
        </lb>It selects from 1 or several combination of a head-and-neck cancer, an ovarian cancer, colon cancer, rectal cancer, the cancer of an anus area|region, stomach cancer, a breast cancer, a kidney or the cancer of the ureter, renal cell carcinoma, renal pelvic carcinoma, the tumor of a central nervous system (CNS), primary CNS lymphoma, non-Hodgkin's lymphoma, the spinal-cord axis|shaft tumor, or said cancer.</p>
    <p n="0196" xml:id="_2ff0351174">Cancer is selected from 1 or several combination of a lung cancer (NSCLC and SCLC), an ovarian cancer, colon cancer, rectal cancer, the cancer of an anus area|region, or said cancer in other preferable embodiment of this invention.</p>
    <p n="0197" xml:id="_2ff0351175">Although the said abnormal cell proliferation is not restricted only to it in other embodiment of the said method,<lb>
        </lb>It is a benign proliferative disease including psoriasis, a benign prostatic hypertrophy, or restenosis.</p>
    <p n="0198" xml:id="_2ff0351177">This invention also relates also to the method of treating the abnormal cell proliferation in a mammal.<lb>
        </lb>Its method A mitotic inhibition agent, an alkylating agent, an antimetabolite, insertion antibiotics,<lb>
        </lb>A growth factor inhibitor, a cell cycle blocker, an enzyme, a topoisomerase inhibitor,<lb>
        </lb>It combined with the anti-tumor agent selected from a biological response modifier, an antibody, a cytotoxic substance, antihormones, and the group that consists of anti-androgen,<lb>
        </lb>The step which administers P-cadherin antibody as described in this specification of a quantity effective in the treatment of abnormal cell proliferation or its antigen binding part to the said mammal is included.</p>
    <p n="0199" xml:id="_2ff0351182">This invention relates also to the pharmaceutical composition for also treating the abnormal cell proliferation in a mammal including a human.<lb>
        </lb>It A pharmacologically acceptable support|carrier, a mitotic inhibition agent, an alkylating agent,<lb>
        </lb>An antimetabolite, insertion antibiotics, a growth factor inhibitor, a cell cycle blocker, an enzyme,<lb>
        </lb>P-cadherin antibody as described in this specification of a quantity effective in the treatment of the abnormal cell proliferation combined with the anti-tumor agent selected from a topoisomerase inhibitor, a biological response modifier, antihormones, and the group that consists of anti-androgen, or its antigen binding part is included.</p>
    <p n="0200" xml:id="_2ff0351186">This invention also relates also to the method of treating the hyperproliferation disorder in a mammal.<lb>
        </lb>Its method An anti- proliferation agent, a kinase inhibitor, an antiangiogenic agent, a growth factor inhibitor,<lb>
        </lb>A cox-I inhibitor, a cox-II inhibitor, a mitotic inhibition agent, an alkylating agent,<lb>
        </lb>An antimetabolite, insertion antibiotics, a growth factor inhibitor, a radiation, a cell cycle blocker,<lb>
        </lb>An enzyme, a topoisomerase inhibitor, a biological response modifier, an antibody, a cytotoxic substance,<lb>
        </lb>The step which carries out treatment-effective quantity administration of P-cadherin antibody as described in this specification combined with the anti-tumor agent selected from antihormones, a statin, and the group that consists of anti-androgen, or its antigen binding part at the said mammal is included.</p>
    <p n="0201" xml:id="_2ff0351192">In one Embodiment of this invention, the anti-tumor agent used in combination with P-cadherin antibody as described in this specification or its antigen binding part, and pharmaceutical composition is an anti-angiogenic agent, a kinase inhibitor, a  kinase inhibitor, or a growth factor inhibitor.<lb>
        </lb>There exists SU-11248 (Pfizer, Inc, USA New York state) of US Patent 6,573,293 in a preferable  kinase inhibitor.</p>
    <p n="0202" xml:id="_2ff0351194">Although not restricted to an anti-angiogenic agent so,<lb>
        </lb>An EGF inhibitor, an EGFR inhibitor, a VEGF inhibitor, a VEGFR inhibitor,<lb>
        </lb>There exists active substance, such as TIE2 inhibitor, an IGF1R inhibitor, a COX-II (cyclooxygenase II) inhibitor, MMP-2 (matrix metalloprotease 2) inhibitor, and MMP-9 (matrix metalloprotease 9) inhibitor.<lb>
        </lb>There exists Avastin (bevacizumab) which is an anti- VEGF monoclonal antibody of Genentech of California state South San Francisco in a preferable VEGF inhibitor, for example.</p>
    <p n="0203" xml:id="_2ff0351198">In the further VEGF inhibitor, CP-547,632 (Pfizer Inc., USA New York state),<lb>
        </lb>AG13736(Pfizer Inc.), ZD-6474(AstraZeneca), AEE788(Novartis), AZD-2171, VEGF Trap(Regeneron, /Aventis), vatalanib (:Novartis&amp;Schering AG known also as PTK-787 and ZK-222584), Macugen(Pegaptanib 8 sodium, NX-1838, EYE-001, Pfizer Inc./Gilead/Eyetech), IM862 (Cytran Inc of USA Washington state Kirkland.);<lb>
        </lb>And angiozyme (angiozyme) which is a synthetic|combination ribozyme of Ribozyme (Colorado state Boulder) and Chiron (California state Emeryville), and its combination exist.<lb>
        </lb>The useful VEGF inhibitor is indicated by implementation of this invention US Patent 6,534,524 and 6,235,764, and the whole is integrated by both for all the objective.<lb>
        </lb>CP-547,632, AG13736, vatalanib, Macugen, and its combination exist in an especially preferable VEGF inhibitor.</p>
    <p n="0204" xml:id="_2ff0351203">The further VEGF inhibitor, for example WO99/24440 (it publish|presented to 1999/5/20),<lb>
        </lb>PCT international application PCT/IB99/00797 (it applied to 1999/5/3),<lb>
        </lb>WO95/21613 (it publish|presented to 1995/8/17), WO99/61422 (it publish|presented to 1999/12/2),<lb>
        </lb>US Patent 6,534,524 (AG13736 was indicated), US Patent 5,834,504 (it issued to 1998/11/10),<lb>
        </lb>WO98/50356 (it publish|presented to 1998/11/12), US Patent 5,883,113 (it issued to 1999/3/16), US Patent 5,886,020 (it issued to 1999/3/23),<lb>
        </lb>US Patent 5,792,783 (it issued to 1998/8/11), US Patent 6,653,308 (it issued to 2003/11/25),<lb>
        </lb>WO99/10349 (it publish|presented to 1999/3/4), WO97/32856 (it publish|presented to 1997/9/12),<lb>
        </lb>WO97/22596 (it publish|presented to 1997/6/26), WO98/54093 (it publish|presented to 1998/12/3),<lb>
        </lb>It describes in WO98/02438 (it publish|presented to 1998/1/22), WO99/16755 (it publish|presented to 1999/4/8), and WO98/02437 (it publish|presented to 1998/1/22),<lb>
        </lb>As for these all, the whole is integrated in this specification by the reference.</p>
    <p n="0205" xml:id="_2ff0351213">In the other anti- proliferation agent which can be used with the antibody of this invention, or its antigen binding part,<lb>
        </lb>US Patent Application09/221946 (it applied to 1998/12/28),<lb>
        </lb>No. 09th/454058 (it applied to 1999/12/2), No. 09th/501163 (it applied to 2000/2/9),<lb>
        </lb>No. 09th/539930 (it applied to 2000/3/31), No. 09th/202796 (it applied to 1997/5/22),<lb>
        </lb>The compound by which is indicated by No. 09th/384339 (it applied to 1999/8/26), and No. 09th/383755 (it applied to 1999/8/26), and the claim is carried out, and USA temporary patent-application 60/168207 (it applied to 1999/11/30),<lb>
        </lb>No. 60th/170119 (it applied to 1999/12/10), No. 60th/177718 (it applied to 2000/1/21),<lb>
        </lb>It is indicated by No. 60th/168217 (it applied to 1999/11/30), and No. 60th/200834 (it applied to 2000/5/1),<lb>
        </lb>There exist an inhibitor of enzyme farnesyl protein transferase including the compound by which the claim is carried out, and an inhibitor of the receptor tyrosine kinase PDGFr.<lb>
        </lb>As for said patent application and temporary patent-application, the whole is respectively integrated in this specification by the reference.</p>
    <p n="0206" xml:id="_2ff0351222">Although not restricted to a PDGFr inhibitor so,<lb>
        </lb>There exist some which are indicated by WO01/40217 publish|presented by 2001/7/7 and WO2004/020431 publish|presented by 2004/3/11,<lb>
        </lb>As for the content, the whole is integrated for all the objective.<lb>
        </lb>CP-673,451 of Pfizer, CP-868,596, and its pharmacologically acceptable its salt exist in a preferable PDGFr inhibitor.</p>
    <p n="0207" xml:id="_2ff0351226">There exists AG-2037 (Pelitrexol (pelitrexol) and pharmacologically acceptable its salt) of Pfizer in a preferable GARF inhibitor.<lb>
        </lb>The GARF inhibitor useful at implementation of this invention is indicated by US Patent 5,608,082 in which the whole is integrated for all the objective.</p>
    <p n="0208" xml:id="_2ff0351228">For the example of the useful COX-II inhibitor which can be used in combination with P-cadherin antibody as described in this specification or its antigen binding part, and the pharmaceutical composition as described in this specification,<lb>
        </lb>CELEBREX (trademark) (celecoxib), parecoxib, deracoxib, ABT-963,<lb>
        </lb>MK-663 (etoricoxib), COX-189 (lumiracoxib),<lb>
        </lb>BMS347070, RS57067, NS-398, Bextra (valdecoxib), paracoxib (paracoxib), Vioxx (rofecoxib), a SD-8381,4- methyl-2- (3, 4- dimethylphenyl)-1-(4-sulfamoyl phenyl) -1H- pyrrole,<lb>
        </lb>There exist a 2-(4-ethoxyphenyl) -4-methyl- 1-(4-sulfamoyl phenyl) -1H- pyrrole, T-614, JTE-522, S-2474, SVT-2016, CT-3, SC-58125, and Arcoxia (etoricoxib).<lb>
        </lb>Furthermore, the COX-II inhibitor is indicated by US Patent Application10/801,446, 10/801, and 429,<lb>
        </lb>As for the content, the whole is integrated for all the objective.</p>
    <p n="0209" xml:id="_2ff0351235">In preferable one Embodiment, an anti-tumor agent is a celecoxib currently indicated by US Patent 5,466,823,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of a celecoxib is shown below:</p>
    <p n="0210" xml:id="_2ff0351238">
        <formula n="0001" xml:id="_2ff0351239">
            <figure xml:id="_2ff0351240">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0211" xml:id="_2ff0351241">In preferable one Embodiment, an anti-tumor agent is the valdecoxib (valdecoxib) currently indicated by US Patent 5,633,272,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of a valdecoxib is shown below:</p>
    <p n="0212" xml:id="_2ff0351244">
        <formula n="0002" xml:id="_2ff0351245">
            <figure xml:id="_2ff0351246">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0213" xml:id="_2ff0351247">In preferable one Embodiment, an anti-tumor agent is parecoxib currently indicated by US Patent 5,932,598,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of paracoxib is shown below:</p>
    <p n="0214" xml:id="_2ff0351250">
        <formula n="0003" xml:id="_2ff0351251">
            <figure xml:id="_2ff0351252">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0215" xml:id="_2ff0351253">In preferable one Embodiment, an anti-tumor agent is deracoxib currently indicated by US Patent 5,521,207,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of deracoxib is shown below:</p>
    <p n="0216" xml:id="_2ff0351256">
        <formula n="0004" xml:id="_2ff0351257">
            <figure xml:id="_2ff0351258">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0217" xml:id="_2ff0351259">In preferable one Embodiment, an anti-tumor agent is SD-8381 currently indicated by US Patent 6,034,256,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of SD-8381 is shown below:</p>
    <p n="0218" xml:id="_2ff0351262">
        <formula n="0005" xml:id="_2ff0351263">
            <figure xml:id="_2ff0351264">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0219" xml:id="_2ff0351265">In preferable one Embodiment, an anti-tumor agent is ABT-963 currently indicated by international publication WO2002/24719,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of ABT-963 is shown below:</p>
    <p n="0220" xml:id="_2ff0351268">
        <formula n="0006" xml:id="_2ff0351269">
            <figure xml:id="_2ff0351270">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0221" xml:id="_2ff0351271">In preferable one Embodiment, an anti-tumor agent is a rofecoxib shown below:</p>
    <p n="0222" xml:id="_2ff0351272">
        <formula n="0007" xml:id="_2ff0351273">
            <figure xml:id="_2ff0351274">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0223" xml:id="_2ff0351275">In preferable one Embodiment, an anti-tumor agent is MK-663 (etoricoxib) currently indicated by international publication WO1998/03484,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of etoricoxib is shown below:</p>
    <p n="0224" xml:id="_2ff0351278">
        <formula n="0008" xml:id="_2ff0351279">
            <figure xml:id="_2ff0351280">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0225" xml:id="_2ff0351281">In preferable one Embodiment, an anti-tumor agent is COX-189 (lumiracoxib) currently indicated by international publication WO1999/11605,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of lumiracoxib is shown below:</p>
    <p n="0226" xml:id="_2ff0351284">
        <formula n="0009" xml:id="_2ff0351285">
            <figure xml:id="_2ff0351286">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0227" xml:id="_2ff0351287">In preferable one Embodiment, an anti-tumor agent is BMS-347070 currently indicated by US Patent 6,180,651,<lb>
        </lb>As for the content, the whole is integrated by the reference for all the objective.<lb>
        </lb>The structure of BMS-347070 is shown below:</p>
    <p n="0228" xml:id="_2ff0351290">
        <formula n="0010" xml:id="_2ff0351291">
            <figure xml:id="_2ff0351292">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0229" xml:id="_2ff0351293">In preferable one Embodiment, an anti-tumor agent is NS-398(CAS 123653-11-2).<lb>
        </lb>The structure of NS-398(CAS 123653-11-2) is shown below:</p>
    <p n="0230" xml:id="_2ff0351295">
        <formula n="0011" xml:id="_2ff0351296">
            <figure xml:id="_2ff0351297">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0231" xml:id="_2ff0351298">In preferable one Embodiment, an anti-tumor agent is RS57067(CAS 17932-91-3).<lb>
        </lb>The structure of RS-57067(CAS 17932-91-3) is shown below:</p>
    <p n="0232" xml:id="_2ff0351300">
        <formula n="0012" xml:id="_2ff0351301">
            <figure xml:id="_2ff0351302">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0233" xml:id="_2ff0351303">In preferable one Embodiment, an anti-tumor agent is the 4-methyl-2- (3, 4- dimethylphenyl )-1-(4-sulfamoyl phenyl) -1H- pyrrole.<lb>
        </lb>The structure of the 4-methyl-2- (3, 4- dimethylphenyl )-1-(4-sulfamoyl phenyl) -1H- pyrrole is shown below:</p>
    <p n="0234" xml:id="_2ff0351305">
        <formula n="0013" xml:id="_2ff0351306">
            <figure xml:id="_2ff0351307">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0235" xml:id="_2ff0351308">In preferable one Embodiment, an anti-tumor agent is a 2-(4-ethoxyphenyl) -4-methyl- 1-(4-sulfamoyl phenyl) -1H- pyrrole.<lb>
        </lb>The structure of a 2-(4-ethoxyphenyl) -4-methyl- 1-(4-sulfamoyl phenyl) -1H- pyrrole is shown below:</p>
    <p n="0236" xml:id="_2ff0351310">
        <formula n="0014" xml:id="_2ff0351311">
            <figure xml:id="_2ff0351312">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0237" xml:id="_2ff0351313">In preferable one Embodiment, an anti-tumor agent is a meloxicam.<lb>
        </lb>The structure of a meloxicam is shown below:</p>
    <p n="0238" xml:id="_2ff0351315">
        <formula n="0015" xml:id="_2ff0351316">
            <figure xml:id="_2ff0351317">
                <graphic url="/1">
                </graphic>
            </figure>
        </formula>
    </p>
    <p n="0239" xml:id="_2ff0351318">In another inhibitor useful as an anti-tumor agent used in combination with the antibody of this invention, and the pharmaceutical composition as described in this specification, the enzyme (cyclooxygenases I and II) which makes prostaglandin is inhibited,<lb>
        </lb>There exist the aspirin and the nonsteroidal anti-inflammatory drug (NSAID) to which the level of prostaglandin is reduced as a result,<lb>
        </lb>So, it does not restrict,<lb>
        </lb>However,<lb>
        </lb>Salsalate (Amigesic), a diflunisal (Dolobid), ibuprofen (Motrin), ketoprofen (Orudis), a nabumetone (Relafen), piroxicam (Feldene), naproxen (Aleve, Naprosyn),<lb>
        </lb>A diclofenac (Voltaren), an indomethacin (Indocin),<lb>
        </lb>Sulindac (Clinoril), the tolmetin (Tolectin), an etodolac (Lodine), a ketorolac (Toradol), an oxaprozin (Daypro), and its combination exist.<lb>
        </lb>Ibuprofen (Motrin), Nuprin, naproxen (Aleve), an indomethacin (Indocin), a nabumetone (Relafen), and its combination exist in a preferable COX-I inhibitor.</p>
    <p n="0240" xml:id="_2ff0351326">EGFr inhibitors, such as Iressa (gefitinib, AstraZeneca), Tarceva(Erlotinib or OSI-774, OSI Pharmaceuticals Inc.), Erbitux(Cetuximab, Imclone Pharmaceuticals, Inc.), EMD-7200 (Merck AG),<lb>
        </lb>ABX-EGF(Amgen Inc. and Abgenix Inc.), HR3 (Cuba government (Cuban Government)), IgA antibody (Erlangen-Nuremberg university), TP-38 (IVAX),<lb>
        </lb>An EGFR fusion protein, an EGF-vaccine, an anti- EGFr immuno liposome (Hermes Biosciences Inc.), and its combination, are among the target active substance used in combination with P-cadherin antibody as described in this specification or its antigen binding part, and its pharmaceutical composition as described in this specification.</p>
    <p n="0241" xml:id="_2ff0351329">Iressa, Erbitux, Tarceva and its combination exist in a preferable EGFr inhibitor.</p>
    <p n="0242" xml:id="_2ff0351330">This invention also CP-724,714(Pfizer,Inc.), CI-1033 (Canertinib (canertinib), Pfizer, Inc.),<lb>
        </lb>Herceptin(Tefibazumab, Genentech Inc.), Omitarg(2C4, pertuzumab, Genentech Inc.),<lb>
        </lb>TAK-165 (Takeda), GW-572016 (and) [ lonafarnib ]<lb>
        </lb>GlaxoSmithKline), GW-282974(GlaxoSmithKline), EKB-569(Wyeth), PKI-166(Novartis), dHER2 (HER2 vaccine, Corixa, and GlaxoSmithKline), APC8024 (HER2 vaccine, Dendreon), the anti- HER2/neu bispecific antibody (Decof Cancer Center),<lb>
        </lb>B7.her2.IgG3(Agensys), AS HER2(Research Institute for Rad Biology&amp;Medicine), a trifunctional bispecific antibody (Munich university),<lb>
        </lb>It is related also with the anti-tumor agent selected from  erb receptor inhibitors, such as mAB AR-209(Aronex Pharmaceuticals Inc) and mAB 2 B-1 (Chiron) and its combination, or an ErbB2 receptor inhibitor.<lb>
        </lb>Herceptin, TAK-165, CP-724,714, ABX-EGF, HER3 and its combination exist in a preferable erb selective anti-tumor agent.<lb>
        </lb>GW572016, CI-1033, EKB-569, Omitarg, and its combination exist in a preferable  erbb receptor inhibitor.</p>
    <p n="0243" xml:id="_2ff0351338">In erbB2 further inhibitor, WO98/02434 (it publish|presented to 1998/1/22),<lb>
        </lb>WO99/35146 (it publish|presented to 1999/7/15), WO99/35132 (it publish|presented to 1999/7/15),<lb>
        </lb>WO98/02437 (it publish|presented to 1998/1/22), WO97/13760 (it publish|presented to 1997/4/17),<lb>
        </lb>There exist WO95/19970 (it publish|presented to 1995/7/27), US Patent 5,587,458 (it issued to 1996/12/24), and a thing as described in US Patent 5,877,305 (it issued to 1999/3/2),<lb>
        </lb>As for these, the whole is respectively integrated in this specification by the reference.<lb>
        </lb>An ErbB2 receptor inhibitor useful at this invention is also described also in US Patent 6,465,449, 6,284,764, and international application WO2001/98277,<lb>
        </lb>As for these, the whole is respectively integrated in this specification by the reference.</p>
    <p n="0244" xml:id="_2ff0351345">Furthermore, another anti-tumor agent is the active substance BAY-43-9006(Onyx Pharmaceuticals Inc.), Genasense (and). [ augmerosen ]<lb>
        </lb>Genta, panitumumab (Abgenix/Amgen), Zevalin(Schering), Bexxar(Corixa/GlaxoSmithKline), Abarelix, Alimta, EPO906(Novartis),<lb>
        </lb>Discodermolide (XAA-296), ABT-510 (Abbott),<lb>
        </lb>Neovastat (Aeterna), enzastaurin (Eli Lilly),<lb>
        </lb>It can select from combrestatin (Combrestatin)A4P(Oxigene), ZD-6126(AstraZeneca), a flavopyridol (Aventis), CYC-202(Cyclacel), AVE-8062(Aventis), DMXAA(Roche/Antisoma), Thymitaq(Eximias), Temodar (Temozolomide, Schering Plough), Revilimd (Celegene), and its combination.</p>
    <p n="0245" xml:id="_2ff0351350">Another anti-tumor agent The active substance CyPat (cyproterone acetate) and Histerelin (histrelin acetate).<lb>
        </lb>Plenaixis (abarelix depot agent), atrasentan (ABT-627),<lb>
        </lb>Satraplatin (JM-216), Thalomid (thalidomide), Theratope,<lb>
        </lb>Tesmilifene (Temilifene)(DPPE), ABI-007 (paclitaxel),<lb>
        </lb>It can select from Evista (raloxifene), atamestane (Biomed-777), Xyotax (poly-glutamic-acid addition paclitaxel), Targetin (bexarotine (bexarotine)), and its combination.</p>
    <p n="0246" xml:id="_2ff0351355">Another anti-tumor agent Furthermore, the active substance Trizaone (tirapazamine).<lb>
        </lb>Aposyn (exisulind (exisulind)), Nevastat (AE-941),<lb>
        </lb>Ceplene (histamine dihydrochloride), Orathecin (rubitecan),<lb>
        </lb>It can select from Virulizin, Gastrimmune(G17DT), DX-8951f (exatecan mesylate), Onconase (ranpirnase), BEC2 (mitumomab (mitumoab)), Xcytrin(Motexafin gadolinium (motexafin gadolinium)), and its combination.</p>
    <p n="0247" xml:id="_2ff0351359">The further anti-tumor agent can be selected from the active substance CeaVac (CEA) and NeuTrexin (glucuronic acid trimetrexate) and the combination of those.<lb>
        </lb>The further anti-tumor agent can be selected from the active substance OvaRex (oregovomab) and Osidem (IDM-1) and the combination of those.<lb>
        </lb>The further anti-tumor agent can be selected from the active substance Advexin(ING 201), Tirazone (tirapazamine) and its combination.<lb>
        </lb>The further anti-tumor agent can be selected from active substance RSR13 (efaproxiral), Cotara(131I chTNT 1/b), NBI-3001(IL-4), and its combination.<lb>
        </lb>The further anti-tumor agent can be selected from the active substance Canvaxin, a GMK vaccine, PEG Interon A, Taxoprexin (DHA/paclitaxel), and its combination.<lb>
        </lb>In another preferable anti-tumor agent,<lb>
        </lb>PD0332991 which is BMS-387,032 and the CDK inhibitor of Pfizer which are CDK2 inhibitors of ARRY-142886, Bristol Myer which is a MEK inhibitor of PD325901, Array Biopharm which is MEK1/2 inhibitor of Pfizer.<lb>
        </lb>And AXD-5438 of AstraZeneca and its combination exist.<lb>
        </lb>Furthermore, mTOR inhibitors, such as CCI-779 (Wyeth), rapamycin derivative RAD001 (Novartis), AP-23573 (Ariad), the HDAC inhibitor SAHA(Merck Inc./Aton Pharmaceuticals), and its combination can also be utilized.<lb>
        </lb>There exist aurora2 inhibitor VX-680 (Vertex), and Chk1/2 inhibitor XL844 (Exilixis) in the further anti-tumor agent.</p>
    <p n="0248" xml:id="_2ff0351369">The following cytotoxicity effect substance, for example, 1 or several active substance selected from the group which consists of an epirubicin (Ellence), a docetaxel (Taxotere), a paclitaxel, Zinecard (dexrazoxane), rituximab (Rituxan), imatinib mesilate (Gleevec), and its combination, can be used in combination with P-cadherin antibody as described in this specification or its antigen binding part, and its pharmaceutical composition as described in this specification.</p>
    <p n="0249" xml:id="_2ff0351370">Although this invention is not also limited only to it,<lb>
        </lb>Exemestane (Aromasin, Pfizer Inc.), leuprorelin (Lupron or Leuplin, TAP/Abbott/Takeda),<lb>
        </lb>Together with anastrozole (Arimidex, Astrazeneca), goserelin (Zoladex, AstraZeneca), doxercalciferol, a fadrozole, formestane, the tamoxifen citrate (tamoxifen, Nolvadex, AstraZeneca), Casodex(AstraZeneca), Abarelix(Praecis), Trelstar, and a hormone therapy agent including the combination,<lb>
        </lb>It also intends using the antibody of this invention, and its antigen binding part.</p>
    <p n="0250" xml:id="_2ff0351374">Although this invention is not also limited only to it,<lb>
        </lb>Fulvestrant, a toremifene, a raloxifene, a lasofoxifene, the antiestrogen including letrozole (Femara, Novartis),<lb>
        </lb>Bicalutamide, a flutamide, mifepristone, nilutamide and Casodex (trademark) (4'-cyano- 3-(4-fluoro phenylsulfonyl) -2-hydroxy- 2-methyl- 3'-(trifluoromethyl) propionanilide --)<lb>
        </lb>It is related also with hormone therapy agents, such as anti-androgen, such as bicalutamide, and the combination of those.</p>
    <p n="0251" xml:id="_2ff0351378">Furthermore, this invention is independent or provides the antibody of this invention combining 1 or several product for symptomatic treatments, for example, the product selected from the group which consists of filgrastim (Neupogen), an ondansetron (Zofran), Fragmin, Procrit, Aloxi, Emend, or its combination.</p>
    <p n="0252" xml:id="_2ff0351379">Camptosar, Erbitux, Iressa, Gleevec, Taxotere and its combination exist in an especially preferable cytotoxicity effect substance.</p>
    <p n="0253" xml:id="_2ff0351380">The following topoisomerase I inhibitor can be utilized as an anti-tumor agent:<lb>
        </lb>A camptothecin, the irinotecan HCl (Camptosar), edotecarin, orathecin (orathecin) (Supergen), exatecan (Daiichi), BN-80915 (Roche), and its combination.<lb>
        </lb>There exists an epirubicin (Ellence) in an especially preferable topoisomerase II inhibitor.</p>
    <p n="0254" xml:id="_2ff0351383">The antibody of this invention can be used with an anti-tumor agent, an alkylating agent, an antimetabolite, antibiotics, a plant-derived anti-tumor agent, a camptothecin derivative|guide_body, a tyrosine kinase inhibitor, another antibody, interferon, and/or a biological response modifier.</p>
    <p n="0255" xml:id="_2ff0351384">Although not restricted to an alkylating agent so,<lb>
        </lb>There exist a nitrogen-mustard N-oxide, the cyclophosphamide, ifosfamide, melphalan, the busulfan, a mitobronitol, carboquone, thiotepa, a ranimustine, a nimustine, temozolomide, AMD-473, an altretamine, AP-5280, apaziquone (apaziquone), brostallicin (brostallicin), bendamustine, the carmustine, an estramustine, Fotemustine, glufosfamide, ifosfamide, KW-2170, mafosfamide, and mitolactol;<lb>
        </lb>Although not restricted to a platinum coordination alkylation compound so,<lb>
        </lb>A cisplatin, Paraplatin (carboplatin), eptaplatin, lobaplatin, a nedaplatin, Eloxatin (oxaliplatin, Sanofi) or satraplatin, and its combination exist.<lb>
        </lb>There exists Eloxatin (oxaliplatin) in an especially preferable alkylating agent.</p>
    <p n="0256" xml:id="_2ff0351389">Although not restricted to an antimetabolite so,<lb>
        </lb>A methotrexate, 6-mercaptopurine riboside, a mercaptopurine, 5-fluorouracil which it is individual or was combined with the leucovorin,<lb>
        </lb>A tegafur, UFT, a doxifluridine, a carmofur, cytarabine, cytarabine ocfosfate, an enocitabine, S-1, Alimta(The premetrexed (premetrexed) disodium, LY231514, MTA),<lb>
        </lb>Gemzar (a gemcitabine, Eli Lilly), a fludarabine, 5-azacytidine, capecitabine, cladribine, clofarabine, decitabine, eflornithine, ethynyl cytidine, a cytosine arabinoside,<lb>
        </lb>The hydroxyurea, TS-1, melphalan, nelarabine, nolatrexed, ocfosfate, the premetrexed disodium (disodium premetrexed), a pentostatin, pelitrexol (pelitrexol), raltitrexed, triapine, trimetrexate, a vidarabine, vincristine,<lb>
        </lb>Vinorelbine;<lb>
        </lb>Or one of the preferable antimetabolites currently indicated by the EP Patent application 239362 of N-(5-[N-(3, 4- dihydro- 2-methyl-4- oxo quinazoline 6-ylmethyl) -N- methyl amino ]-2- tenoyl)-L-glutamic acid etc., for example.<lb>
        </lb>And the combination exists.</p>
    <p n="0257" xml:id="_2ff0351397">Although not restricted to antibiotics so,<lb>
        </lb>An aclarubicin, actinomycin D, amrubicin, annamycin (annamycin),<lb>
        </lb>An adriamycin, bleomycin, the daunorubicin, a doxorubicin, elsamitrucin (elsamitrucin),<lb>
        </lb>There exist an epirubicin, glarbuicin (galarubicin), an idarubicin, mitomycin C, nemorubicin (nemorubicin), a neocarzinostatin, a peplomycin, a pirarubicin, rebeccamycin, a stimalamer, streptozocin, valrubicin, a zinostatin, and insertion antibiotics including the combination.</p>
    <p n="0258" xml:id="_2ff0351401">There exist a mitotic inhibition agent, for example, vinblastine, a docetaxel (Taxotere), a paclitaxel, and a thing selected from the combination in a plant-derived anti-tumor substance, for example.</p>
    <p n="0259" xml:id="_2ff0351402">There exists 1 or several active substance selected from the group which consists of an aclarubicin, amonafid, belotecan (belotecan), a camptothecin, the 10-hydroxy camptothecin, 9-aminocamptothecin, diflomotecan (diflomotecan), the irinotecan HCl (Camptosar),<lb>
        </lb>Edotecarin, an epirubicin (Ellence), etoposide, exatecan, gimatecan (gimatecan), lurtotecan (lurtotecan), a mitoxantrone, a pirarubicin, pixantrone (pixantrone),<lb>
        </lb>Rubitecan, a sobuzoxane, SN-38, tafluposide (tafluposide), a topotecan, and its combination in a cytotoxic topoisomerase inhibitory effect substance.</p>
    <p n="0260" xml:id="_2ff0351405">There exists 1 or several active substance selected from the group which consists of a camptothecin, the 10-hydroxy camptothecin, 9-aminocamptothecin, the irinotecan HCl (Camptosar), edotecarin, an epirubicin (Ellence), etoposide, SN-38, a topotecan,<lb>
        </lb>And the combination in a preferable cytotoxic topoisomerase inhibitory effect substance.</p>
    <p n="0261" xml:id="_2ff0351407">Immunological active substance includes interferon and much other immunostimulation active substance.<lb>
        </lb>Interferon (alpha), interferon (alpha)- 2a, interferon (alpha)- 2b, Interferon (beta), interferon (gamma)- 1a, interferon (gamma)- 1b (Actimmune) or interferon (gamma)- n1, and its combination exist in interferon.<lb>
        </lb>In other active substance, filgrastim, a lentinan, schizophyllan|sizofiran, TheraCys,<lb>
        </lb>An ubenimex, WF-10, aldesleukin, alemtuzumab, BAM-002, a dacarbazine, daclizumab, denileukin, gemtuzumab ozogamicin, ibritumomab, an imiquimod, lenograstim, a lentinan, a melanoma vaccine (Corixa),<lb>
        </lb>Molgramostim, OncoVAX-CL, sargramostim, tasonermin, tecleukin (tecleukin), thymalasin (thymalasin), tositumomab, Virulizin, Z-100, epratuzumab, mitumomab (mitumomab), oregovomab, pemtumomab (pemtumomab)(Y-muHMFG1), Provenge(Dendreon), and its combination exist.</p>
    <p n="0262" xml:id="_2ff0351412">A biological response modifier is active substance induced|guided|derived so that survival, proliferation, differentiation, etc. of a tissue cell may modify the protective mechanism of a biological body, or a biological response and it may have an anti-tumor activity.<lb>
        </lb>A Krestin, a lentinan, schizophyllan|sizofiran, a Picibanil, an ubenimex, and its combination exist in such active substance.</p>
    <p n="0263" xml:id="_2ff0351414">Alitretinoin, ampligen, atrasentan, bexarotene,<lb>
        </lb>Bortezomib, Bosentan, the calcitriol, exisulind,<lb>
        </lb>A finasteride, Fotemustine, ibandronic acid, miltefosine, a mitoxantrone, l-asparaginase, a procarbazine, a dacarbazine, hydroxycarbamide, pegaspargase, a pentostatin, tazarotene, Telcyta(TLK-286, Telik Inc.), Velcade (bortezomib, Millenium), tretinoin, and its combination exist in another anticancer agent.</p>
    <p n="0264" xml:id="_2ff0351417">To another anti-angiogenic compound, acitretin, fenretinide, thalidomide, zoledronic acid, an angiostatin, aplidine (aplidine),<lb>
        </lb>Cilengtide (cilengtide), the combretastatin A-4, an endostatin, halofuginone, rebimastat (rebimastat), removab (removab), Revlimid, squalamine, ukrain, Vitaxin, and its combination exist.</p>
    <p n="0265" xml:id="_2ff0351419">Although not restricted to a platinum coordination compound so,<lb>
        </lb>A cisplatin, a carboplatin, a nedaplatin, oxaliplatin, and its combination exist.</p>
    <p n="0266" xml:id="_2ff0351421">A camptothecin, the 10-hydroxy camptothecin, 9-aminocamptothecin, an irinotecan, SN-38, edotecarin, a topotecan, and its combination exist in a camptothecin derivative|guide_body.</p>
    <p n="0267" xml:id="_2ff0351422">A mitoxantrone, l-asparaginase, a procarbazine, a dacarbazine, hydroxycarbamide, a pentostatin, tretinoin, and its combination exist in another anti-tumor agent.</p>
    <p n="0268" xml:id="_2ff0351423">Other active substance which can interrupt|block CTLA4, such as CTLA4 compound currently indicated by the anti-tumor agent which can increase|augment anti-tumor immunity, such as CTLA4 (cytotoxic lymphocyte antigen 4) antibody, and MDX-010 (Medarex) and US Patent 6,682,736;<lb>
        </lb>And anti- proliferation agents, for example, a farnesyl protein transferase inhibitor, such as another farnesyl protein transferase inhibitor, can also be utilized.<lb>
        </lb>The thing of the USA provisional applications 60/113,647 (it applied to 1998/12/23) and US Patent 6,682,736 is among CTLA4 further specific antibodies that can be used by this invention,<lb>
        </lb>As for both of these, the whole is integrated in this specification by the reference.</p>
    <p n="0269" xml:id="_2ff0351427">The thing of International Application WO2002/053596 by which the whole is integrated in this specification by the reference is among the specific IGF1R antibodies which can be used by this invention.</p>
    <p n="0270" xml:id="_2ff0351428">The thing of International Application WO2003/040170 by which the whole is integrated in this specification by the reference is among the specific CD40 antibodies which can be used by this invention.</p>
    <p n="0271" xml:id="_2ff0351429">Gene therapy agents, such as TNFerade (GeneVec) which react with radiotherapy and makes TNF(alpha) express, can also be used as an anti-tumor agent.</p>
    <p n="0272" xml:id="_2ff0351430">In one Embodiment of this invention, a statin can be used in combination with P-cadherin antibody as described in this specification or its antigen binding part, and its pharmaceutical composition.<lb>
        </lb>A statin (HMG-CoA reductase inhibitor),<lb>
        </lb>An atrovastatin (Lipitor, Pfizer Inc.), provastatin (Provastatin)(Pravachol, Bristol-Myers Squibb),<lb>
        </lb>A lovastatin (Mevacor, Merck Inc.), a simvastatin (Zocor, Merck Inc.), a fluvastatin (Lescol, Novartis), a cerivastatin (Baycol, Bayer),<lb>
        </lb>It can select from the group which consists of rosuvastatin (Crestor, AstraZeneca), a lovostatin (Lovostatin), niacin (Advicor, Kos Pharmaceuticals), its derivative(s), and combination.</p>
    <p n="0273" xml:id="_2ff0351435">A statin is selected from the group which consists of an atrovastatin, a lovastatin, its derivative(s), and combination in preferable embodiment.</p>
    <p n="0274" xml:id="_2ff0351436">There exists Caduet in other active substance useful as an anti-tumor agent.</p>
    <p n="0275" xml:id="_2ff0351437">The combination of P-cadherin antibody or an antigen binding part, and the further at least 1 active substance for a treatment is used,<lb>
        </lb>P-cadherin antibody is couple|bonded with the further active substance for a treatment by the arbitrary methods of treating hyperproliferation disorder or abnormal cell proliferation as described in this specification,<lb>
        </lb>Or then, it can derivatize.<lb>
        </lb>The further at least 1 active substance for a treatment can also be administered separately, or it can also administer in the form which is not derivatized or is not couple|bonded.<lb>
        </lb>When not derivatizing the further at least 1 active substance for a treatment or not couple|bonding with an antibody, it can also be administered within the same pharmaceutical formulation as an antibody, or it can also administer by a separate formulation.</p>
    <p n="0276" xml:id="_2ff0351442">Gene therapy<lb>
        </lb>The nucleic acid molecule which codes the antibody and antibody part of this invention can be administered to the patient who has the need through gene therapy.<lb>
        </lb>The treatment may be performed in vivo or you may carry out by ex vivo.<lb>
        </lb>In preferable embodiment, the nucleic acid molecule which codes both of heavy chain and light chains is administered to a patient.<lb>
        </lb>In more preferable embodiment, since the B cell is specialized in production of an antibody, a nucleic acid molecule is administered so that a nucleic acid molecule may be stably integrated in the chromosome of a B cell.<lb>
        </lb>In preferable embodiment, you make it transfected or infected with a precursor B cell in ex vivo, and it transplants it again in a patient with the need.<lb>
        </lb>You make it infected with a precursor B cell or another cell in vivo in other embodiment using the virus by which being infected with the cellular type made into object is known.<lb>
        </lb>A liposome, a plasmid, and viral vector are among the typical vectors used for gene therapy.<lb>
        </lb>Illustrative viral vector is a retrovirus, adenovirus, and an adeno-associated virus.<lb>
        </lb>in After being infected in vivo or ex vivo, sample is extract|collected from patient who treated,<lb>
        </lb>The level of an antibody expression can be monitored by using arbitrary immunoassay which was known for this technical field or was discussed by this specification.</p>
    <p n="0277" xml:id="_2ff0351453">In preferable embodiment, the method of gene therapy contains the step which administers the isolated nucleic acid molecule which codes the heavy chain of P-cadherin antibody, or its antigen binding part, and the step which makes a nucleic acid molecule express.<lb>
        </lb>In other embodiment, the method of gene therapy contains the step which administers the isolated nucleic acid molecule which codes the light chain of P-cadherin antibody, or its antigen binding part, and the step which makes a nucleic acid molecule express.<lb>
        </lb>By a more preferable method, the method of gene therapy contains the step which administers the isolated nucleic acid molecule which codes the isolated nucleic acid molecule and the light chain, or its antigen binding part which codes the heavy chain of P-cadherin antibody of this invention, or its antigen binding part, and the step which makes a nucleic acid molecule express.<lb>
        </lb>The method of gene therapy can also contain the step which administers the other active substance for a treatment for either of the active substance discussed above regarding the combination therapy, etc.</p>
    <p n="0278" xml:id="_2ff0351457">The following Example is shown so that he can understand this invention better.<lb>
        </lb>These Examples are only the things of the objective of an illustration, and it should not interpret them as limiting the scope of the present invention in any forms.</p>
    <head xml:id="_2ff0351459">EXAMPLES</head>
    <p n="0279" xml:id="_2ff0351460">In the following Example and preparation, "BSA" means the bovine serum albumin,<lb>
        </lb>"EDTA" means ethylenediaminetetraacetic acid,<lb>
        </lb>"DMSO" means dimethylsulfoxide,<lb>
        </lb>"MOPS" means 3-(N-morpholino) propanesulfonic acid,<lb>
        </lb>"MES" means 2-(N-morpholino) ethanesulfonic acid,<lb>
        </lb>"PBS" means phosphoric acid buffer salt solution,<lb>
        </lb>"dPBS" means Dulbecco (Dulbecco) phosphoric acid buffer salt solution,<lb>
        </lb>"HEMA" means the 2-hydroxy ethylmethacrylate,<lb>
        </lb>"DMEM" means a Dulbecco modified eagle culture medium,<lb>
        </lb>"FBS" means fetal bovine serum,<lb>
        </lb>"NEAA" means a nonessential amino acid,<lb>
        </lb>"HEPES" means N-2-hydroxyethyl piperazine N'-2-ethanesulfonic acid and "DMF" mean a dimethylformamide.</p>
    <p n="0280" xml:id="_2ff0351472">(Example 1)<lb>
        </lb>The screening of scFv phage display library<lb>
        </lb>The recombinant human P-cadherin (R&amp;D Systems, 861-PC-100) was used as an antigen, and scFv phage display library was screened.<lb>
        </lb>The large sized scFv human antibody library cloned in the phagemid vector was used for selection (Vaughan,T.J. et al., Nat.Biotech., 14:309-314(1996)).<lb>
        </lb>In the a series of repetition selection cycle on the single|mono layer HCT116 cell of the cnfluent state which expresses a recombinant human P-cadherin and P-cadherin, scFv which has recognized P-cadherin was isolated from phage display library.<lb>
        </lb>When stated briefly, it incubated with library,<lb>
        </lb>Then, the united phages were collect|recovered from P-cadherin and the phage which was not couple|bonded was rinse-flushed.<lb>
        </lb>Subsequently, the united phage was relieved as described in Vaughan,T.J. et al., Nat.Biotech., 14:309-314(1996), and the selection process was repeated.<lb>
        </lb>The phage enzyme-linked immunosorbent assay (ELISA) was given to the clone of the typical ratio from what was fundamentally obtained as described in Vaughan, T.J. et al., and Nat.Biotech., 14:309-314(1996) as a result of the selection process, and it tested about the coupling|bonding with P-cadherin.<lb>
        </lb>A 2 different antigen called the single|mono layer A431 cell of the cnfluent state which expresses a recombinant human P-cadherin (R&amp;D Systems) and P-cadherin was used by ELISA.<lb>
        </lb>DNA-sequence determination was given to the ELISA positive clone as described in Vaughan, T.J. et al., Nat.Biotech., 14:309-314(1996), Osbourn, J.K. et al., and Immunotechnology, 3:293-302(1998).<lb>
        </lb>The distinctive ELISA positive clone was converted into all the IgG molecule|numerators, and it tested about the capability to neutralize P-cadherin by P-cadherin dependence adhesion assay described in Example 4.<lb>
        </lb>Based on the result of this screening, antibody 129-1c4 (IC50 is 1-3 micromol at A431 adhesion assay.) was selected as the further optimization as a read|lead parent line|system.</p>
    <p n="0281" xml:id="_2ff0351485">(Example 2)<lb>
        </lb>Read|lead optimization<lb>
        </lb>By the oligonucleotide specific mutagenesis of the variable heavy chain (VH) of an antibody, and variable light chain (VL) CDR3 area|region, the phage display library originating in 129-1c4 was produced.<lb>
        </lb>Library was constructed|assembled using the standard molecular-biological technique as described in Clackson and Lowman, Phage Display-A Practical Approach(Oxford University Press, 2004).<lb>
        </lb>This performed selection based on affinity;<lb>
        </lb>It incubated with library,<lb>
        </lb>Then, a recombinant human P-cadherin (R&amp;D Systems) is capture|acquired with a protein G coating|coated paramagnetic bead (Dynal, 100.03),<lb>
        </lb>Magnetic selection collect|recovers the united phage,<lb>
        </lb>On the other hand, the composite_body|complex which was not couple|bonded was rinse-flushed.<lb>
        </lb>The selection process was repeated reducing the density|concentration of the recombinant human P-cadherin which exists between selection (4 times is covered and it is from 25 nM to 10pM).<lb>
        </lb>Furthermore, what was obtained as a result of selection from VHCDR3 and VLCDR3 library is again mixed in the further phage display library,<lb>
        </lb>It selected by performing selection based on affinity of the process in which it exceeds 2 times.<lb>
        </lb>To the clone of a typical ratio, it is a 129-1c4 epitope competitive assay of Example 8 from what was obtained as a result of the selection process.<lb>
        </lb>WHEREIN:<lb>
        </lb>It screened as scFv.</p>
    <p n="0282" xml:id="_2ff0351500">(Example 3)<lb>
        </lb>P-cadherin dependence adhesion assay<lb>
        </lb>The following protocol is used,<lb>
        </lb>IC50 value was determined by P-cadherin dependence adhesion assay which was converted into IgG between the optimization steps of the antibody discovery described in said Example 2 and which uses several optimization scFv.<lb>
        </lb>Average IC50 value measured about these antibodies is shown in following Table 4.</p>
    <p n="0283" xml:id="_2ff0351505">24 hours before using the recombinant human P-cadherin Fc (R&amp;D, Cat.861-PC), it reprepares in density|concentration of 1 mg/mL which contains 2 mM CaCl2 in MilliQ water,<lb>
        </lb>It stored at 4 degreeC.<lb>
        </lb>The A431 cell was cultured and prepared as follows.<lb>
        </lb>An A431 cell (ECACC number 85090402) is put into a Nunc triple flask (an area of 3x175 cm&lt;2&gt;),<lb>
        </lb>It culture|cultivated as usual in minimum-essential-media (MEM)(Invitrogen, Cat 31095) containing 10% of fetal bovine serum (Invitrogen, Cat.10100-147), and 1% of nonessential amino acid (Invitrogen, Cat.11140-035).<lb>
        </lb>When the cultured cells were collect|recovered in order to use it by an assay, they were about 80% of cnfluent states.<lb>
        </lb>In order to protect from the influence of the subculture relation considered, they were collect|recovered, after carrying out normal use of the cell between the 8th time and culturing it from the subculture 4th time for 48 hours or 72 hours.<lb>
        </lb>It applies exactly sufficient time (7 to 10 minutes) for a cell to dissociate by trypsin /1mM EDTA(Gibco, Cat 25200-056) 0.25%, and collect|recovers A431 cells,<lb>
        </lb>Subsequently, it was immediately diluted in the density of about 2 x10&lt;8&gt; pieces of cells per mL in the culture medium for tissue culture.<lb>
        </lb>Subsequently, an A431 cell is centrifuged (1200 rpm) and it resuspends in buffer solution (The Hanks (Hanks) balanced salt solution (Mg&lt;2+&gt; and Ca&lt;2+&gt; are not included,<lb>
        </lb>A Phenol Red is not included.) to which 1 mM CaCl2 was replenished with final concentration<lb>
        </lb>(Invitrogen, Cat.14175-053)) for an assay,<lb>
        </lb>It is centrifuged again,<lb>
        </lb>It resuspended in the buffer solution for an assay again by the last density of the cell 2x10&lt;6&gt; piece per mL.</p>
    <p n="0284" xml:id="_2ff0351519">The following went through preparation of an IgG serial dilution thing and a prior incubation with an A431 cell.<lb>
        </lb>Each test IgG or 180 microliters of its part was replenished with 20 microliters of buffer solutions for an assay containing 10% of BSA (Sigma, Cat.A-9576), and the BSA density|concentration was standardized to 1%.<lb>
        </lb>The anti- mouse|rat / human P-cadherin reference|standard polyclonal antibody (R&amp;D, Cat.AF-761) was initially resuspended in MilliQ water, and a 1 mg/mL stock|stick was obtained.<lb>
        </lb>Subsequently, 40 microliters of this stock solution was put in 140 microliters of buffer solutions for an assay, and was further diluted.<lb>
        </lb>Subsequently, 20 microliters of buffer solutions for an assay containing 10% of BSA were added, and 0.2 mg/mL of antibodies and BSA0.1% of 200 microliters were obtained.<lb>
        </lb>The double serial dilution thing was prepared by adding 2x90 microliters AF-761 polyclonal antibody or test IgG to Column 1 of the plate for the product dilution made from a 96 holes|wells of Greiner(s) polypropylene (Greiner, Cat.780271) initially.<lb>
        </lb>Subsequently, 60 microliters of buffer solutions for an assay were added to Column 2 - 11.<lb>
        </lb>Subsequently, the dilution which is missing from Column 1 - 11, crosses plate from the left to the right, and puts 30 microliters in 60 microliters (1:3) was prepared.<lb>
        </lb>Subsequently, 60 microliters of buffer solution independent for an assay was added to hole 12 A-D, and the greatest adhesion|attachment was prescribed|regulated.<lb>
        </lb>By adding 25 (inside of the buffer solution for an assay) mM EDTA60microliter to hole 12 E-H prescribed|regulated the minimum adhesion|attachment.<lb>
        </lb>Subsequently, the A431 cell suspension (It prepared as the cell 2x10&lt;6&gt; piece-above described the outline per 1 mL of buffer solutions for an assay.) was added to all the holes, and plate was beforehand incubated at 37 degreeC after stirring for 1 hour.</p>
    <p n="0285" xml:id="_2ff0351530">In parallel to serial dilution of test IgG, and a prior incubation with an A431 cell, the plate for an assay coat|covered with P-cadherin was prepared as follows.<lb>
        </lb>The recombinant human P-cadherin Fc is diluted with buffer solution (PBS-Invitrogen, Cat.14190-094 which do not contain Mg&lt;2+&gt; and Ca&lt;2+&gt;) for coating|cover in density|concentration of 10 micrograms/mL,<lb>
        </lb>It was dispensed on the plate for a 96 holes|wells of Fluoronunc(s) assay (Nunc, Cat.437958) (100 microliters per hole|well).<lb>
        </lb>Subsequently, plate was incubated at room temperature for 1.5 hours.<lb>
        </lb>Subsequently, the Tecan 96-well plate cleaning instrument was used, and plate was wash|cleaned 3 times by PBS.<lb>
        </lb>200 microliters per hole|well of buffer solutions for an assay were added for the blocking process, and plate was incubated at room temperature for further 1 hour.<lb>
        </lb>Subsequently, plate was wash|cleaned 3 times by PBS as described in the above-mentioned.</p>
    <p n="0286" xml:id="_2ff0351537">Subsequently, IgG / A431 substance incubated 100 microliters per hole|well beforehand were moved from the plate for 96 holes|wells of Greiner(s) dilution to the plate for an assay coat|covered with P-cadherin.<lb>
        </lb>When moved, IgG / A431 substance was mixed by withdrawing/inserting with a pipette so that a cell may become reliably homogeneous.<lb>
        </lb>Subsequently, the adhesion process was performed by incubating the plate for an assay for 30 to 45 minutes at 37 degreeC.<lb>
        </lb>At the time of completion|finish of an incubation, the culture medium was quietly attracted|sucked from plate and the cell which was not adhere|attached was removed by satisfy|filling cell washing buffer solution (The Hanks balanced salt solution to which 1 mM CaCl2 was replenished with final concentration<lb>
        </lb>(Mg&lt;2+&gt; and Ca&lt;2+&gt; are -Invitrogen and Cat.14175-053 which do not contain and do not contain a Phenol Red.)) again in a hole.<lb>
        </lb>Subsequently, the cell which reverses plate, set|places for 15 minutes and remain|survives on the cell washing buffer solution tank and which was not adhere|attached was removed.<lb>
        </lb>At the time of completion|finish of this incubation, the contents of the hole were attracted|sucked quietly.</p>
    <p n="0287" xml:id="_2ff0351544">The following went through fixed_quantity|quantitative_assay of the adhere|attached cell.<lb>
        </lb>Melt|dissolution / mixing reagent (A diethanolamine substrate buffer solution 5x concentrate (Pierce, Cat.34064) is diluted to 1:5 with water,<lb>
        </lb>What melt|dissolved 1 dose of 15mgPNPP lock|tablet (Sigma, Cat.N-2640) per 25 mL of 1x solutions after that) for an alkaline phosphatase detection of 100 microliters per hole|well are added,<lb>
        </lb>The adhere|attached cell was detected by incubating for 30 to 60 minutes at 37 degreeC after that.<lb>
        </lb>Subsequently, 1-M NaOH (50 microliters per hole|well) was added for the purpose of acquiring the maximum OD value of about 0.8 in a state without inhibition, and reaction was stopped.<lb>
        </lb>Subsequently, the standard plate reader was used and the light absorbency in 405 nm was measured.</p>
    <p n="0288" xml:id="_2ff0351550">Subsequently, the result was analyzed as follows.<lb>
        </lb>It considered 100% that adhesion|attachment and hole E-H of Column 12 were adhesion|attachment 0%, and converted hole A-D of Column 12 into the value of % adhesion|attachment of raw data to the following passage initially:<lb>
        </lb>% Adhesion|attachment = {(the value-minimum adhesion|attachment) /(maximum-minimum adhesion|attachment)} *100<lb>
        </lb>Subsequently, % adhesion|attachment with respect to the density|concentration of an IgG inhibitor was plotted, and IC50 value was determined using the Prism software.<lb>
        </lb>When partial inhibition is observed, the value of IC50 is given as a density|concentration of IgG from which not the middle point of a curve but true 50-% inhibition is obtained.<lb>
        </lb>Table 4 reports IC50 value.</p>
    <p n="0289" xml:id="_2ff0351556">
        <figure xml:id="_2ff0351558">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0290" xml:id="_2ff0351559">Optimization IgG in which some to which 2 rotation originates in 129-1c4 lines|systems germ-line-ized separate A431 adhesion assay was investigated compared with the non-germ-line-ized equivalent.<lb>
        </lb>In these experiment, to change into P-cadherin (CFR-134041) of a new batch is required,<lb>
        </lb>This is considered to be related to slight increase of IC50 value in comparison with other data.<lb>
        </lb>The data which took the average about some germ-line-ized IgG from two experiment are shown in Table 5.<lb>
        </lb>As reference was made above, g-194-b09 and others point 194-b09 and others of a germ-line-ized type|mold out.</p>
    <p n="0291" xml:id="_2ff0351564">
        <figure xml:id="_2ff0351566">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0292" xml:id="_2ff0351567">(Example 4)<lb>
        </lb>P-cadherin dependence cell aggregation assay<lb>
        </lb>The following protocol is used,<lb>
        </lb>IC50 value was determined by P-cadherin dependence aggregation assay which was converted into IgG between the optimization steps of the antibody discovery described in said Example 2 and which uses several optimization scFv.<lb>
        </lb>Since the cell lineage which overexpresses P-cadherin forms the robust multi-cellular aggregate when it puts in a suspension proliferation thing, cell aggregation can be measured in presence of P-cadherin antibody which interferes in cell aggregation.<lb>
        </lb>Average IC50 value measured about some antibodies is shown in following Table 6.</p>
    <p n="0293" xml:id="_2ff0351573">The following went through preparation of plate.<lb>
        </lb>The plate for a 96 hole|well each assay is coat|covered with poly HEMA(It is 12 mg/mL in 90-% ethanol and 10-% methanol.) 50microliter,<lb>
        </lb>It is evaporated over 6 hours - 1 night,<lb>
        </lb>Then, it wash|cleaned by 3x100 microliters sterilization H2O before use.<lb>
        </lb>Subsequently, the cell was cultured as follows.<lb>
        </lb>(P-cadherin G418 &lt;r&gt; is expressed stably)<lb>
        </lb>The cell derived from human cell system|strain SW480 was subcultured in full proliferation culture-medium (qs DMEM (inVitrogen, 11995-065),<lb>
        </lb>10-%FBS(Omega Scientific, FB-02),<lb>
        </lb>1:100NEAA (InVitrogen, 11140-050),<lb>
        </lb>1:100 sodium-pyruvate (InVitrogen, 11360-070), 1:100 glutamine (InVitrogen, 25030-051), 1:100 penicillin / streptolysin (InVitrogen, 15070-063), 1:100 Geneticin 50mg/mL (Invitrogen, 10131-035)) +G418 (500 micrograms/mL), and was divided|segmented then to 2 times per week, and 1:3-4.<lb>
        </lb>Subsequently, the culture was frozen in +10% of proliferation culture-medium DMSO.</p>
    <p n="0294" xml:id="_2ff0351584">At the 1st day, SW480:pCLNX (a control|contrast vector is stable) of a SW480:pCAD cell and a control|contrast is diluted or less to 1:3,<lb>
        </lb>It scattered by the cell 5x10&lt;6&gt; piece per 100-mm plate.<lb>
        </lb>Subsequently, the cell was cultured for 48 hours and it was made to propagate.<lb>
        </lb>With a 100-mm each plate, the cell became about 10 x10&lt;6&gt; pieces, or it became sufficient number of objects for 2x 96-well plate.</p>
    <p n="0295" xml:id="_2ff0351588">To the 3rd day, the culture medium was removed, and it wash|cleaned by dPBS (Dulbecco PBS (InVitrogen, 14040-133)) after that, and performed the trypsinization of 3 mL per 100-mm plate into the cell after that.<lb>
        </lb>Subsequently, it neutralized after release|extrication by the full proliferation culture medium of one (6 mL) 2 time the volume of this.<lb>
        </lb>Subsequently, plate was wash|cleaned 3 times at 10 mL using the pipette, and the cluster was destroyed.<lb>
        </lb>Subsequently, the cell was counted and the pellet was obtained at 1000 rpm using the centrifuge for [ Beckman ] 5 minutes.<lb>
        </lb>Subsequently, the culture medium was attracted|sucked, the pellet was initially resuspended with the vortex with a finger|toe, and then p1000 pipette in the &lt;1mL full proliferation culture medium, and the cell density|concentration was standardized then to 1.3 M/mL.<lb>
        </lb>The state which the cell is disperse|distributing independently was confirmed by microscopy.</p>
    <p n="0296" xml:id="_2ff0351594">Subsequently, reagent plate was prepared for the 96-well plate dPBS and by carrying out a blocking process for 30 minutes by FBS 5%.<lb>
        </lb>Subsequently, plate is wash|cleaned using 1x100 microliters dPBS, and it is attracted|sucked after that, and it flipped|shed lightly and made it dry.<lb>
        </lb>The diluted series of test IgG was prepared by dPBS using density|concentration of 4x [IgG] for 3 holes|wells with process plate sufficient at 1 hole|well of a 96-well plate.<lb>
        </lb>40000 cells were dispensed in 30 microliters per hole|well at division into equal parts on the wash|cleaned 96 holes|wells plate for poly HEMA coating|coated Costar3590 non-tissue culture (Corning, 3590).<lb>
        </lb>Subsequently, 10 microliters of reagents were moved to each hole of a 96-well plate.<lb>
        </lb>A 3 links|sets per one process sample was processed using an 8 link|set pipette.<lb>
        </lb>Subsequently, a 1 night (16 to 18 hours) incubation was performed in 37 degreeC humidified in the state shaked at 250 rpm, and 5% of CO2 incubator.</p>
    <p n="0297" xml:id="_2ff0351601">40 microliters of cells shaked at the 4th day were moved to polylysine coating|coated 96-well plate (BioCoat polylysine coating|coated 96-well plate: BD 356516).<lb>
        </lb>Subsequently, it is 60 microliters of full proliferation culture media, and the hole was rinsed, by striking lightly, plate was shaked and it was moved to polylysine coating|coated plate.<lb>
        </lb>When required, the further 50 microliter washing|cleaning was implemented.<lb>
        </lb>The incubation was continued for 60 minutes in humidified 37 degreeC and 5% of CO2 incubator.<lb>
        </lb>Attention was paid|swept at this step that moves all the cells quantitatively as quietly as possible, without withdrawing/inserting with a pipette too much.<lb>
        </lb>Subsequently, by adding fixed solution (7.4-% formamide (37 % weight [/volume ]-Sigma, F15587)) 100microliter within a draft chamber, the cell was fixed and it incubated for &gt; 30 minutes at room temperature after that.</p>
    <p n="0298" xml:id="_2ff0351607">Subsequently, in order to wash|clean a cell, the liquid was decanted, it put into the collection beaker or the tray, the liquid which flips|sheds lightly and remain|survives was removed, and it struck lightly quietly on the paper towel.<lb>
        </lb>Subsequently, 100 microliters per hole|well dPBS was put and wash|cleaned, and it incubated for 15 minutes after that.<lb>
        </lb>Subsequently, it decanted as above-mentioned, 100 microliters of Hoescht(It is 1 microgram/mL Hoescht-Hoescht 10 mg/mL, Molecular Probes, and 33342 in dPBS.) was put, and the cell was dye|stained by incubating for 30 minutes after that.<lb>
        </lb>Subsequently, the cell was wash|cleaned twice and dPBS100microliter in a hole was made to remain|survive for microscopy.</p>
    <p n="0299" xml:id="_2ff0351611">Subsequently, the number of the aggregation target objects per hole|well was measured (Cellomics), and the target object count value of the average (in state with test IgG) was compared with the count value of the IgG(For example, a Gt-anti- P-cadherin, R&amp;D Systems, AF761) or culture-medium independent control|contrast.<lb>
        </lb>The target object count value with respect to the density|concentration of an IgG inhibitor was plotted, and IC50 value was determined.<lb>
        </lb>Table 6 reports IC50 value of some antibodies of this invention.</p>
    <p n="0300" xml:id="_2ff0351614">
        <figure xml:id="_2ff0351616">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0301" xml:id="_2ff0351617">(Example 5)<lb>
        </lb>P-cadherin dependence spheroid destructive assay<lb>
        </lb>The following spheroid destructive assay is a modified method of the aggregation assay (Example 4), and adds the back P-cadherin in which the cell aggregate was formed over 1 night, and the antibody of a control|contrast.<lb>
        </lb>Subsequently, it analyzes, after adding a test reagent and set|placing it for further 24 hours.</p>
    <p n="0302" xml:id="_2ff0351621">Plate was prepared as follows.<lb>
        </lb>The plate for a 96 hole|well each assay is coat|covered with poly HEMA(It is 12 mg/mL in 90-% ethanol and 10-% methanol.) 50microliter,<lb>
        </lb>It is evaporated over 6 hours - 1 night,<lb>
        </lb>Then, it wash|cleaned by 3x100 microliters sterilization H2O before use.<lb>
        </lb>Subsequently, the cell was cultured as follows.<lb>
        </lb>(P-cadherin G418 &lt;r&gt; is expressed stably)<lb>
        </lb>The cell derived from human cell system|strain SW480 was subcultured in full proliferation culture-medium (qs DMEM (InVitrogen, 11995-065),<lb>
        </lb>10-%FBS(Omega Scientific, FB-02),<lb>
        </lb>1:100NEAA (InVitrogen, 11140-050),<lb>
        </lb>1:100 sodium-pyruvate (InVitrogen, 11360-070), 1:100 glutamine (InVitrogen, 25030-051), 1:100 penicillin / streptolysin (InVitrogen, 15070-063), 1:100 Geneticin 50mg/mL (Invitrogen, 10131-035)) +G418 (500 micrograms/mL), and was divided|segmented then to 2 times per week, and 1:3-4.<lb>
        </lb>Subsequently, the culture was frozen in +10% of proliferation culture-medium DMSO.</p>
    <p n="0303" xml:id="_2ff0351632">At the 1st day, SW480:pCLNX (a control|contrast vector is stable) of a SW480:pCAD cell and a control|contrast is diluted or less to 1:3,<lb>
        </lb>It scattered by the cell 5x10&lt;6&gt; piece per 100-mm plate.<lb>
        </lb>Subsequently, the cell was cultured for 48 hours and it was made to propagate.<lb>
        </lb>With a 100-mm each plate, the cell became about 10 x10&lt;6&gt; pieces, or it became sufficient number of objects for 2x 96-well plate.</p>
    <p n="0304" xml:id="_2ff0351636">To the 3rd day, the culture medium was removed, and it wash|cleaned by dPBS (Dulbecco PBS (InVitrogen, 14040-133)) after that, and performed the trypsinization of 3 mL per 100-mm plate into the cell after that.<lb>
        </lb>Subsequently, it neutralized after release|extrication by the full proliferation culture medium of one (6 mL) 2 time the volume of this.<lb>
        </lb>Subsequently, plate was wash|cleaned 3 times at 10 mL using the pipette, and the cluster was destroyed.<lb>
        </lb>Subsequently, the cell was counted and the pellet was obtained at 1000 rpm using the centrifuge for [ Beckman ] 5 minutes.<lb>
        </lb>Subsequently, a culture medium is attracted|sucked,<lb>
        </lb>A pellet is initially resuspended with a vortex with a finger|toe, and then p1000 pipette in a &lt;1mL full proliferation culture medium,<lb>
        </lb>Subsequently, the cell density|concentration was standardized to the 1.0x10&lt;6&gt; piece per mL.<lb>
        </lb>The state which the cell is disperse|distributing independently was confirmed by microscopy.</p>
    <p n="0305" xml:id="_2ff0351644">40000 cells were dispensed in 40 microliters per hole|well at division into equal parts on the wash|cleaned 96 holes|wells plate for poly HEMA coating|coated Costar3590 non-tissue culture (Corning, 3590).<lb>
        </lb>Subsequently, a 1 night (16 to 18 hours) incubation was performed in 37 degreeC humidified in the state shaked at 250 rpm, and 5% of CO2 incubator.</p>
    <p n="0306" xml:id="_2ff0351646">Reagent plate was prepared for the 96-well plate then to the 4th day dPBS and by carrying out a blocking process for 30 minutes by FBS 5%.<lb>
        </lb>Subsequently, plate is wash|cleaned using 1x100 microliters dPBS, and it is attracted|sucked after that, and it flipped|shed lightly and made it dry.<lb>
        </lb>The diluted series of test IgG was prepared by dPBS using density|concentration of 5x [IgG] for 3 holes|wells with process plate sufficient at 1 hole|well of a 96-well plate.<lb>
        </lb>Subsequently, 10 microliters of reagents were moved to each hole of a 96-well plate.<lb>
        </lb>A 3 links|sets per one process sample was processed using an 8 link|set pipette.<lb>
        </lb>Subsequently, it incubated in 37 degreeC humidified in the state shaked at 250 rpm, and 5% of CO2 incubator (20 to 24 hours).</p>
    <p n="0307" xml:id="_2ff0351652">50 microliters of cells shaked at the 5th day were moved to polylysine coating|coated 96-well plate (BioCoat polylysine coating|coated 96-well plate: BD 356516).<lb>
        </lb>Subsequently, it is 50 microliters of full proliferation culture media, and the hole was rinsed, by striking lightly, plate was shaked and it was moved to polylysine coating|coated plate.<lb>
        </lb>When required, the further 50 microliter washing|cleaning was implemented.<lb>
        </lb>The incubation was continued for 60 minutes in humidified 37 degreeC and 5% of CO2 incubator.<lb>
        </lb>Attention was paid|swept at this step that moves all the cells quantitatively as quietly as possible, without withdrawing/inserting with a pipette too much.<lb>
        </lb>Subsequently, by adding fixed solution (7.4-% formamide (37 % weight [/volume ]-Sigma, F15587)) 100microliter within a draft chamber, the cell was fixed and it incubated for &gt; 30 minutes at room temperature after that.</p>
    <p n="0308" xml:id="_2ff0351658">Subsequently, in order to wash|clean a cell, the liquid was decanted, it put into the collection beaker or the tray, the liquid which flips|sheds lightly and remain|survives was removed, and it struck lightly quietly on the paper towel.<lb>
        </lb>Subsequently, 100 microliters per hole|well dPBS was put and wash|cleaned, and it incubated for 15 minutes after that.<lb>
        </lb>Subsequently, it decanted as above-mentioned, 100 microliters of Hoescht(It is 1 microgram/mL Hoescht-Hoescht 10 mg/mL, Molecular Probes, and 33342 in dPBS.) was put, and the cell was dye|stained by incubating for 30 minutes after that.<lb>
        </lb>Subsequently, the cell was wash|cleaned twice and dPBS100microliter in a hole was made to remain|survive for microscopy.<lb>
        </lb>Subsequently, the number of the aggregation target objects per hole|well was measured (Cellomics), and the target object count value of the average (in state with test IgG) was compared with the count value of the IgG(For example, a Gt-anti- P-cadherin, R&amp;D Systems, AF761) or culture-medium independent control|contrast.<lb>
        </lb>The target object count value with respect to the density|concentration of an IgG inhibitor can be plotted, and IC50 value can be determined.<lb>
        </lb>Instead, as shown in Table 7, the target object count value was represented as a multiple of the destruction with respect to a control|contrast at one defined density|concentration.</p>
    <p n="0309" xml:id="_2ff0351665">
        <figure xml:id="_2ff0351667">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0310" xml:id="_2ff0351668">(Example 6)<lb>
        </lb>The measurement of KD of P-cadherin antibody, and Koff<lb>
        </lb>Affinity measurement (KD and Koff) of the P-cadherin scFv single-chain antibody by surface plasmon resonance which uses BIACORE(trademark)3000 apparatus was performed using a manufacturer's protocol for the following to pass.</p>
    <p n="0311" xml:id="_2ff0351671">In order to conduct dynamic analysis, a usual amine coupling|bonding is used,<lb>
        </lb>The recombinant human P-cadherin / Fc fusion protein (hCad/Fc), and the mouse|mouth P-cadherin / Fc fusion protein (mCad/Fc) were fix|immobilized on the separate flow cell of a CM5BIACORE (trademark) sensor chip.<lb>
        </lb>The surface is prepared using the 10 mM acetate buffer containing 2.0 mM CaCl2 and pH 4.5 as a buffer solution for fixation|immobilization,<lb>
        </lb>The protein density of 5800 and 1600RU was obtained about hCad/Fc and a mCad/Fc fusion protein, respectively.<lb>
        </lb>A 1-M hydrochloric acid ethanolamine and pH 8.5 were used, and unreacted N-hydroxysuccinimide ester was deactivated.<lb>
        </lb>The blank surface which activated / deactivated was used as the control|contrast surface.<lb>
        </lb>The scFv antibody sample in the buffer solution for a flow was prepared at the density|concentration of 200-0.78 nM.<lb>
        </lb>(The 0 nM solution containing only the buffer solution for a flow was included as a zero reference|standard.).<lb>
        </lb>A sample is randomized,<lb>
        </lb>HBS-P(10 mM HEPES, pH 7.4, NaCl of 150 mM, 0.005% of Surfactant P20) containing 2.0 mM CaCl2 is used as a buffer solution for a flow,<lb>
        </lb>It inject|poured for 1 minute at 3 links|sets over the whole flow cell, respectively.<lb>
        </lb>The affinity constant was determined using 25 microliters of flow-rates /min.<lb>
        </lb>Dissociation of the antibody was monitored for 5 minutes and the surface was reproduced|regenerated by inject|pouring the 10 mM glycine- HCl and pH 1.5 for 12 second (with 25 microliter /min).<lb>
        </lb>Raw data were processed using the Scrubber((C)BioLogic Software) software package, and were analyzed using the CLAMP((C)BioLogic Software) software package.<lb>
        </lb>Data were entirely fitted to the simple Langmuir (Langmuir) coupled models of 1:1.</p>
    <p n="0312" xml:id="_2ff0351686">In Table 8, the affinity constants of the single-chain anti- P-cadherin antibody of this invention are enumerated.</p>
    <p n="0313" xml:id="_2ff0351687">
        <figure xml:id="_2ff0351689">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0314" xml:id="_2ff0351690">(Example 7)<lb>
        </lb>Determination of the selectivity of P-cadherin antibody<lb>
        </lb>The following protocol was used and the selectivity of various antibodies with respect to P-cadherin in comparison with E-cadherin was determined.</p>
    <p n="0315" xml:id="_2ff0351693">In PBS+0.5mM CaCl2, by the 1 microgram/mL recombinant human P-cadherin (R&amp;D Systems, 861-PC-100) and a recombinant human E-cadherin (R&amp;D Systems, 648-EC-100),<lb>
        </lb>The hole top of Exiqon protein immobilization plate (VWR International) was coat|covered.<lb>
        </lb>It is titrated from 50 nM (7.5 micrograms/mL) after performing the blocking process of sample IgG in 3%Marvel/PBS+0.5mM CaCl2 for 1 hour to 0.64 nM (0.096 microgram/mL),<lb>
        </lb>It added to the hole coat|covered with the 2 different antigen at 2 links|sets.<lb>
        </lb>1 night was equilibrated at 4 degreeC,<lb>
        </lb>Then, CaCl2 (3 times and then 1xPBS+0.5mM) wash|cleaned plate 3 times by 1xPBS/0.1%Tween+0.5mM CaCl2.<lb>
        </lb>Subsequently, 50 microliters of the antihuman Fab peroxidase binding bodies diluted to 1:5000 in 3%Marvel/PBS+0.5mM CaCl2 are added to each hole,<lb>
        </lb>It was equilibrated at room temperature for 1 hour.<lb>
        </lb>1xPBS+0.5mM CaCl2 wash|cleans plate 3 times 3 times by 1xPBS/0.1%Tween+0.5mM CaCl2,<lb>
        </lb>3,3', 5, 5'- tetramethyl benzidine (TMB;Sigma) 50microliter is added to each hole,<lb>
        </lb>After raise|generating a coloring reaction for 20 minutes, it was stopped by adding 25 microliters per hole|well of 0.5-M H2SO4.<lb>
        </lb>After reading the value of a light absorbency at 450 nm, data are analyzed using a Graphpad Prism software,<lb>
        </lb>The relative KD value of each antibody about a coupling|bonding with P-cadherin and E-cadherin was calculated.<lb>
        </lb>The outline|summary of the obtained data is shown in Table 9.</p>
    <p n="0316" xml:id="_2ff0351707">
        <figure xml:id="_2ff0351709">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0317" xml:id="_2ff0351710">(Example 8)<lb>
        </lb>Epitope competitive assay<lb>
        </lb>IC50 value is measured by an epitope competitive assay using the following protocol,<lb>
        </lb>The capability of variation|mutation scFv within the parent line|system which removes parent IgG from the natural P-cadherin on the surface of an A431 cell was measured.<lb>
        </lb>The quantity of biotinylation parent IgG united in presence of inhibiting scFv is detected using europium streptavidine and a DELFIA assay method.<lb>
        </lb>IC50 value measured about some scFv is shown in Table 10.</p>
    <p n="0318" xml:id="_2ff0351716">It culture|cultivates in accordance with a standard method,<lb>
        </lb>The A431 cell (ECACC number 85090402) collect|recovered in about 80% of cnfluent state was scattered by the cell 2.5x10&lt;4&gt; piece per hole|well in 96 hole|well Beckton Dickenson collagen coating plate (BD, Cat.6407) on the previous day when it is used.<lb>
        </lb>Subsequently, it wash|cleaned 3 times by immersing in a PBS buffer solution (Gibco, Cat.14190-094, calcium, magnesium, and sodium hydrogencarbonate are not included.) storage tank,<lb>
        </lb>Then, 200 microliters per hole|well of buffer solutions (PBS(Gibco, Cat.14190-094)+3%Marvel(Premier International Foods Ltd.)) for blocking were added, and it was incubated at room temperature for 2 hours.<lb>
        </lb>Subsequently, plate was wash|cleaned 3 times by PBS as above-mentioned.</p>
    <p n="0319" xml:id="_2ff0351721">A high-throughput ability screening or IC50 profile creation also prepared initially the scFv/IgG substance in the buffer solution for an assay with a sum total volume of 60 microliters in plate (96 holes|wells of Greiner(s) polypropylene plate (Greiner, Cat.780271)) for Greiner dilution.<lb>
        </lb>Subsequently, 50 microliters was moved from subordinate Greiner plate on the plate for a direct assay, and joint reaction was advanced at room temperature for 2 hours and 30 minutes.<lb>
        </lb>Plate was wash|cleaned 3 times by PBS at the time of completion|finish of joint reaction,<lb>
        </lb>Then, streptavidine (Perkin Elmer, Cat.1244-360, 1:1000 dilutions in the buffer solution (Perkin Elmer, Cat.4002-0010) for a DELFIA assay) label|marked with the europium was added and it was incubated at room temperature for further 1 hour.</p>
    <p n="0320" xml:id="_2ff0351725">Subsequently, the buffer solution (Perkin Elmer, Cat.4010-0010) for DELFIA washing|cleaning wash|cleaned plate 7 times by repeating and immersing plate in a buffer solution storage tank.<lb>
        </lb>Finally, DELFIA enhancer (enhancer)(Perkin Elmer, 100 microliters per Cat.4001 -0010,1 hole) was added,<lb>
        </lb>Then, the protocol of standard DELFIA is used,<lb>
        </lb>Plate was read on compatible reader|leader (For example, Wallac or Envision).</p>
    <p n="0321" xml:id="_2ff0351729">Preparation-HTS of the plate for Greiner dilution<lb>
        </lb>According to the step of an optimization, the conditions of the high-throughput ability screening (HTS) were comprised separately.<lb>
        </lb>In HTS of what was obtained from the optimization of each VH and VL chain|strand, last [peri prep] was fixed at 12.5 %, and, as a result, parent scFv showed partial inhibition.<lb>
        </lb>In HTS of what was obtained from next VH:VL recombinant library, the last peri prep density|concentration is reduced to 1.7%,<lb>
        </lb>On this condition, reference|standard scFv (TOP-108 -C01) which optimized VH showed partial inhibition.<lb>
        </lb>Room to identify the improved clone by the optimization of a peri prep density|concentration as related reference|standard scFv shows partial inhibition remained.</p>
    <p n="0322" xml:id="_2ff0351735">The following procedure was employ|adopted in order to implement|achieve these last scFv peri prep density|concentrations:<lb>
        </lb>i) The peri prep sample substance of the volume (refer the following) which uses and requires a Cybiwell apparatus was moved from the sample plate of the deep hole in Column 1 - 11 to the plate for Greiner dilution.<lb>
        </lb>The [last peri prep] Volume to move<lb>
        </lb>[12.5%]=7.5uL<lb>
        </lb>[1.7 %]=(peri prep diluted 1:10 times)10.0uL<lb>
        </lb>(The peri prep which diluted peri prep 10microliter previously to 1:10 as it was by moving sample plate to the buffer solution for an assay in the plate for Greiner dilution included 90 microliters (using Cybiwell) was prepared.)<lb>
        </lb>ii) Subsequently, Column 1 - the volume of 11 were 30 microliters by adding the buffer solution for an assay of a suitable volume.<lb>
        </lb>iii) Subsequently, 30 microliters of buffer solutions for an assay were added to Column 12 (A-D) (hole of all the coupling|bondings).<lb>
        </lb>iv) Excessive quantity unlabel parent IgG(129-1c4)30microliter in the buffer solution for assay was added to Column 12 (E-H), and the nonspecific coupling|bonding was prescribed|regulated.<lb>
        </lb>This was added at the density|concentration of 1000 nM and it was made final concentration of 500 nM.<lb>
        </lb>v) 129-1c4 IgG was biotinylated using water-soluble reagent EZ-link-NHS-LC-Biotin(Perbio/Pierce, product number 21336).<lb>
        </lb>The IgG solution was replenished by adding 1/10 volume 1M NaHCO3 and a 1/10 volume dimethylformamide.<lb>
        </lb>An EZ-link-NHS-LC-Biotin reagent is melt|dissolved in DMF, then, from IgG, it was added with mole concentration with 5 excess time, and reaction was advanced for 20 minutes at room temperature.<lb>
        </lb>Subsequently, biotinylation IgG was stabilized by adding BSA (0.1 %).<lb>
        </lb>Biotinylation parent 129-1c4 IgG30microliter in the buffer solution for an assay was added to all the holes, and it was made final concentration of 1.5 nM in a last volume of 60 microliters.<lb>
        </lb>(That is, europium label|marker IgG was added with 2x final concentration.).<lb>
        </lb>vi) Contents of Greiner plate were mixed by stirring,<lb>
        </lb>Then, 50 microliters was moved to the plate for a direct assay, and joint reaction was advanced at room temperature for 2 hours and 30 minutes (as described in the above-mentioned).</p>
    <p n="0323" xml:id="_2ff0351753">Preparation-IC50 profile creation of the plate for Greiner dilution<lb>
        </lb>i) The 30 microliters per hole|well buffer solution for an assay was added to Column 2 [ of the standard plate for Greiner dilution ] -11, and hole 12A-12D.<lb>
        </lb>ii) Excessive quantity unlabel 129-1c4 parent IgG30microliter in the buffer solution for assay was added to Column 12 (E-H), and the nonspecific coupling|bonding was prescribed|regulated.<lb>
        </lb>This should be added at the density|concentration of 1000 nM and should be made final concentration of 500 nM.<lb>
        </lb>iii) 2x45 microliters of scFv His-preps which have not been diluted, respectively were added to Column 1 so that four 2 links|sets IC50 titration things which exist 11 points|pieces per plate for a 96 hole|well assay could be prepared.<lb>
        </lb>Subsequently, what (below substantially) 15 microliters is taken from Column 1, it mixes in Column 2, 15 microliters is taken from Column 2 after that, and is mixed in Column 3 performed 1:3 2 links|sets serial dilution.<lb>
        </lb>15 microliters was removed after mixing in Column 11.<lb>
        </lb>(That is, it removed and left a last volume of 30 microliters.).<lb>
        </lb>iv) Biotinylation 129-1c4 parent IgG30microliter in buffer solution for assay was added to all the holes, and it was made final concentration of 1.5 nM in a last volume of 60 microliters.<lb>
        </lb>(That is, europium label|marker IgG was added with 2x final concentration.).<lb>
        </lb>v) Contents of Greiner plate were mixed by stirring,<lb>
        </lb>Then, 50 microliters was moved to the plate for a direct assay, and joint reaction was advanced at room temperature as described in the above-mentioned for 2 hours and 30 minutes.</p>
    <p n="0324" xml:id="_2ff0351765">scFv was made to express in a 96 holes|wells format at HTS as a crude extract (scFv peri prep) of the bacteria periplasm in MOPS/EDTA/sorbitol, and the basic buffer solution containing pH 7.4 (MES, pH 7.4).<lb>
        </lb>scFv was made to express in IC50 profile creation with the refinement|purification forms of the low process ability which uses the His-tag of scFv for the affinity purification in the basic buffer solution of PBS.</p>
    <p n="0325" xml:id="_2ff0351767">HTS or IC50 analysis also converted raw data into the data of % coupling|bonding initially according to the following equation:<lb>
        </lb>% Joint = {(value-nonspecific coupling|bonding) /(all the joint-nonspecific coupling|bondings)} *100</p>
    <p n="0326" xml:id="_2ff0351769">Subsequently, the hit which further analyzes HTS data using a standard Excel template, and shows more serious inhibition (low % coupling|bonding) than related reference|standard scFv was identified.<lb>
        </lb>In IC50 analysis, the data of % coupling|bonding were analyzed using the Prism 4.0th edition curve fitting software.<lb>
        </lb>Like Example 2, scFv is a variant of 129-1c4 parent IgG, and CDR3 area|region of VH and VL has mutated at random.<lb>
        </lb>A VHCDR3 variation|mutation arrangement|sequence is shown as sequence number 91 - 256 in FIG. 1.<lb>
        </lb>A VLCDR3 variation|mutation arrangement|sequence is shown as sequence number 257 - 319 in FIG. 1.<lb>
        </lb>IC50 value of several scFv which showed the binding improvement which exceeds parent 129-1c4 IgG is shown in Table 10.<lb>
        </lb>129-1c4 parents' scFv variant is respectively specified by two sequence number: VHCDR3 and VLCDR3.<lb>
        </lb>As reference, IC50 of parent 129-1c4 IgG was 108.3 nM.</p>
    <p n="0327" xml:id="_2ff0351777">
        <figure xml:id="_2ff0351779">
            <graphic url="/1">
            </graphic>
        </figure>
    </p>
    <p n="0328" xml:id="_2ff0351780">All the publications referred by this specification, the patent, and the patent application are integrated in this specification by the reference similarly to, when it is shown concretely and each independently that each each publication or patent application is integrated by reference.<lb>
        </lb>Illustration and an example aiming at understanding clearly have demonstrated said invention to some extent or more in detail,<lb>
        </lb>However,<lb>
        </lb>That a specific change and modification|change can be added to it illuminates with teaching of this invention, without deviating from the attached meaning or the range of a claim,<lb>
        </lb>It will become clear easily at the expert.</p>
    <head xml:id="_2ff0351785">BRIEF DESCRIPTION OF THE DRAWINGS</head>
    <p n="0329" xml:id="_2ff0351786">
        <lb>
        </lb>FIG. 1 :It is a figure which shows the amino acid and nucleic acid sequence of sequence number 1 - 347.<lb>
        </lb>FIG. 1A<lb>
        </lb>FIG. 1B<lb>
        </lb>FIG. 1C<lb>
        </lb>FIG. 1D<lb>
        </lb>FIG. 1E<lb>
        </lb>FIG. 1F<lb>
        </lb>FIG. 1G<lb>
        </lb>FIG. 1H<lb>
        </lb>FIG. 1I<lb>
        </lb>FIG. 1J<lb>
        </lb>FIG. 1K<lb>
        </lb>FIG. 1L<lb>
        </lb>FIG. 1M<lb>
        </lb>FIG. 1N<lb>
        </lb>FIG. 1O<lb>
        </lb>FIG. 1P<lb>
        </lb>FIG. 1Q<lb>
        </lb>FIG. 1R<lb>
        </lb>FIG. 1S<lb>
        </lb>FIG. 1T<lb>
        </lb>FIG. 1U<lb>
        </lb>FIG. 1V<lb>
        </lb>FIG. 1W<lb>
        </lb>FIG. 1X<lb>
        </lb>FIG. 1Y<lb>
        </lb>FIG. 1Z</p>
</description>